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Abstract 
 
Amino acid transport is controlled by a system of transporter proteins whose function 
remains poorly defined in CHO cells. In this thesis, the relationship between amino acid 
transporter activity and culture performance parameters was investigated and used as a 
basis to explore new opportunities for improving cell line productivity. Transcriptomic 
analysis of transporter expression was first performed in two non-producing CHO cell 
lines and one antibody-producing CHO cell line during fed-batch cultures. Seven 
transporters were highly expressed across the three cell lines (ASCT1, CAT-1, GLAST, 
LAT1, SNAT2, xCT and y+LAT2). For all cell lines, the cystine-glutamate xCT 
transporter was significantly upregulated at stationary phase and formed part of a larger 
adaptive response to support the cellular availability of glutathione. The antibody-
producing cell line also upregulated ASCT1 and LAT1 transporter expression during 
stationary phase, which allowed the cells to maintain a high consumption rate of amino 
acids abundant in the antibody. Cells were next treated with inhibitors that block amino 
acid transport through individual or groups of transporters. Inhibition results confirmed 
that xCT transport activity is a key determinant of culture viability in all cell lines, and 
along with LAT1, also supports specific productivity during late-stage culture in the 
antibody-producing cell line. A directed evolution strategy was subsequently developed 
to increase xCT transport capability in the host. Evolved host cells demonstrated an 
increased capacity for GSH synthesis, increased resistance to a ROS insult, and a 
heritable improvement in cell growth but were not able to outperform the unevolved 
host in the transient production of an IgG. Finally, a mechanistic model to describe 
essential amino acid transport processes in CHO cells was constructed from 
transcriptomic and inhibitor data. This model can be used to direct future optimisation 
of amino acid concentrations in culture media to maximise cell growth and antibody 
production. 
! iv 
Contents 
 
List of Figures .............................................................................................................. 1 
List of Tables ............................................................................................................... 5 
Amino Acid Abbreviations ......................................................................................... 7 
Acronyms and Abbreviations ..................................................................................... 8 
 
Chapter 1: Manufacturing Recombinant Therapeutic Monoclonal Antibodies ... 9 
     1.1 Biologics Market ................................................................................................ 9 
     1.2 Expression Systems ............................................................................................ 9 
     1.3 Chinese Hamster Ovary (CHO) Expression System ........................................ 11 
     1.4 Manufacturing Antibodies ............................................................................... 11 
     1.5 Upstream Process Development ...................................................................... 11 
          1.5.1 Cell Line Development (CLD) ................................................................. 11 
          1.5.2 Cell Culture Process Development .......................................................... 13 
     1.6 Summary .......................................................................................................... 14 
 
Chapter 2: Amino Acid Metabolism and Transport ............................................. 15 
     2.1 Mammalian Cell Metabolism ........................................................................... 15 
          2.1.1 Aerobic Glycolysis and Glutaminolysis Support Cell Proliferation ........ 17 
          2.1.2 Stationary Phase is Associated With Oxidative Metabolism and PPP      
          Activity .............................................................................................................. 19 
          2.1.3 CHO Cell Metabolism is Cell Line Dependent ........................................ 19 
     2.2 Amino Acids and Signaling Pathways ............................................................. 21 
          2.2.1 Leucine and Glutamine Stimulate mTORC1 Signaling ........................... 21 
          2.2.2 Amino Acid Response (AAR) Pathway ................................................... 22 
     2.3 Mammalian Amino Acid Transporters ............................................................ 22 
     2.4 Amino Acid Transporters in Cancer ................................................................ 30 
     2.5 Amino Acid Transporters as Potential Cell Engineering Targets .................... 32 
     2.6 Summary .......................................................................................................... 33 
     2.7 Thesis Overview ............................................................................................... 34 
 
Chapter 3: Materials and Methods ......................................................................... 36 
     3.1 Cell Lines and Culture ..................................................................................... 36 
          3.1.1 Cell lines ................................................................................................... 36 
! v 
          3.1.2 Routine Sub-Culture ................................................................................. 36 
          3.1.3 Cell Growth Parameters ........................................................................... 36 
               3.1.3.1 Cell Specific Growth Rate ............................................................... 37 
               3.1.3.2 Integral of Viable Cell Density ........................................................ 37 
               3.1.3.3 Generation Number .......................................................................... 37 
     3.2 Extracellular Amino Acid Analysis ................................................................. 37 
     3.3 Antibody Quantification ................................................................................... 38 
 
Chapter 4: Amino Acid Transporter Gene Expression Analysis in CHO Cells 
Using RNA-Sequencing ............................................................................................ 39 
     4.1 Introduction ...................................................................................................... 39 
     4.2 Materials and Methods ..................................................................................... 43 
          4.2.1 Cell Culture .............................................................................................. 43 
          4.2.2 Sample Collection .................................................................................... 43 
          4.2.3 RNA Extraction ........................................................................................ 43 
          4.2.4 RNA Assessment ..................................................................................... 44 
          4.2.5 Library Preparation and Sequencing ........................................................ 44 
          4.2.6 Read Mapping and Transcriptome Assembly .......................................... 44 
     4.3 Results .............................................................................................................. 45 
          4.3.1 Growth Profiles and RNA-Sequencing Sample Selection ....................... 45 
          4.3.2 Transcriptome Data Sets .......................................................................... 46 
          4.3.3 Amino Acid Transporter Expression Analysis ........................................ 47 
               4.3.3.1 Proteinogenic Transporter Expression at Exponential Growth  
               Phase ............................................................................................................ 49 
               4.3.3.2 Proteinogenic Transporter Expression at Stationary Growth  
               Phase ............................................................................................................ 51 
               4.3.3.3 Expression of Genes Involved in Regulating Cellular GSH  
               Levels ........................................................................................................... 55 
               4.3.3.4 Expression of Target Genes of the AAR Pathway ........................... 57 
               4.3.3.5 Expression of Non-Proteinogenic Transporters ............................... 58 
          4.3.4 Amino Acid Transport Rate Analysis ...................................................... 59 
          4.3.5 Amino Acid Analysis of Two Additional IgG-Producing Cell Lines ...... 63 
     4.4 Discussion ........................................................................................................ 67 
          4.4.1 LAT1, ASCT1 and SNAT2 Transport Neutral Amino Acids .................. 67 
          4.4.2 GLAST, CAT-1 and y+LAT2 Transport Charged Amino Acids ............. 69 
! vi 
          4.4.3 ASCT1, LAT1 and xCT Are Potential Markers for Antibody  
          Production ......................................................................................................... 70 
          4.4.4 Increased xCT Expression During Stationary Growth Forms Part of An  
          Adaptive Response That Supports Cellular Availability of GSH ..................... 71 
          4.4.5 Changes in ASCT1, LAT1 and xCT Expression Could be an Adaptive  
          Response to Support Antibody Production ....................................................... 72 
          4.4.6 Summary .................................................................................................. 74 
 
Chapter 5: Inhibition of Amino Acid Transport and its Effects on Cell Growth and 
Antibody Production ................................................................................................. 76 
     5.1 Introduction ...................................................................................................... 76 
     5.2 Materials and Methods ..................................................................................... 77 
          5.2.1 Inhibitor Treatment at Exponential Growth ............................................. 77 
          5.2.2 Inhibitor Treatment at Stationary Growth ................................................ 78 
          5.2.3 Analysis of Factorial Experimental Data ................................................. 78 
     5.3 Results .............................................................................................................. 79 
          5.3.1 System L Transport Inhibition ................................................................. 82 
          5.3.2 System A Transport Inhibition ................................................................. 87 
          5.3.3 System XC- Transport Inhibition .............................................................. 92 
          5.3.4 System ASC Transport Inhibition ............................................................ 98 
          5.3.5 GlyT1 Transport Inhibition .................................................................... 104 
          5.3.6 Multi-Transporter Inhibition in T127 Cells During Exponential  
          Growth ............................................................................................................. 109 
               5.3.6.1 Multi-Transporter Inhibition and Growth Rate .............................. 111 
               5.3.6.2 Multi-Transporter Inhibition and Culture Viability ....................... 112 
               5.3.6.3 Multi-Transporter Inhibition and Specific Productivity ................ 112 
     5.4 Discussion ...................................................................................................... 113 
          5.4.1 System L Inhibition Blocks Essential Amino Acid Uptake, Suppresses 
          Cell Growth and Inhibits Antibody Production .............................................. 113 
          5.4.2 Dependence Upon System A and ASC Transport for Cell Growth Differs  
          Between Cell Lines ......................................................................................... 114 
          5.4.3 The xCT Transporter Supports Cell Viability in all Cell Lines and 
          Antibody Production During Late-Stage Culture ........................................... 116 
          5.4.4 The GlyT1 Transporter Supports Antibody Production During Late-Stage 
          Culture ............................................................................................................. 117 
! vii 
          5.4.5 Conclusions and Future Perspectives ..................................................... 117 
 
Chapter 6: Evolving Resistance to Amino Acid Transport Inhibition for Improved 
Cell Line Performance ............................................................................................ 119 
     6.1 Introduction .................................................................................................... 119 
     6.2 Materials and Methods ................................................................................... 122 
          6.2.1 Transient Transfection ........................................................................... 122 
               6.2.1.1 Expression Vectors ......................................................................... 122 
               6.2.1.2 Lipofection ..................................................................................... 122 
          6.2.2 Flow Cytometry ..................................................................................... 123 
          6.2.3 Cellular Glutathione Quantification ....................................................... 124 
          6.2.4 Inhibitor Treatment ................................................................................ 124 
          6.2.5 Batch Overgrow Shake Flask Cultures .................................................. 124 
          6.2.6 Fed-Batch Overgrow Shake Flask Cultures ........................................... 125 
     6.3 Results ............................................................................................................ 125 
          6.3.1 Creation of a SAS-Resistant CAT-S Cell Line (CAT-R-S700) ............. 125 
               6.3.1.1 Growth Profile of the CAT-R-S700 Cell Line ............................... 126 
               6.3.1.2 Intracellular Glutathione Content and Cell Line Responses to 
               Reactive Oxygen Species Exposure ........................................................... 129 
               6.3.1.3 Heritability of the CAT-R-S700 Phenotype ................................... 130 
          6.3.2 Creation of a GPNA-Resistant CAT-S Cell Line (CAT-R-G200) ......... 132 
               6.3.2.1 Growth Profile of the CAT-R-G200 Cell Line .............................. 134 
               6.3.2.2 Heritability of the CAT-R-G200 Phenotype .................................. 136 
          6.3.3 Transfection Efficiency and Transient Production of a Recombinant 
          IgG Antibody in Parental and Resistant Cell Lines ........................................ 137 
          6.3.4 Creation of SAS-Resistant T127 Cell Lines .......................................... 139 
               6.3.4.1 Growth and Antibody Production Characteristics for Non-Evolved 
               and Resistant T127 Cell Lines ................................................................... 140 
     6.4 Discussion ...................................................................................................... 144 
 
Chapter 7: Rational Design of Culture Media From an Understanding of Amino 
Acid Transport Mechanisms .................................................................................. 149 
     7.1 Introduction .................................................................................................... 149 
     7.2 Materials and Methods ................................................................................... 150 
          7.2.1 Generation of Amino Acid Transport Profile Data ................................ 150 
! viii 
               7.2.1.1 CAT-S Transport Profiles .............................................................. 151 
               7.2.1.2 GS-Null Transport Profiles ............................................................ 151 
               7.2.1.3 T127 Transport Profiles ................................................................. 151 
          7.2.3 Statistical Analysis ................................................................................. 151 
     7.3 Results ............................................................................................................ 151 
          7.3.1 Essential Amino Acid Correlations ........................................................ 155 
          7.3.2 Non-Essential Amino Acid Correlations ............................................... 159 
     7.4 Discussion ...................................................................................................... 160 
 
Chapter 8: Conclusions and Future Work ........................................................... 163 
     8.1 Conclusion ...................................................................................................... 163 
          8.1.1 Characterisation of Amino Acid Transport Processes ........................... 163 
          8.1.2 Improving Cell Growth and Productivity .............................................. 165 
     8.2 Future Work ................................................................................................... 166 
 
Appendix A .............................................................................................................. 168 
Appendix B .............................................................................................................. 183 
Appendix C .............................................................................................................. 189 
 
References ................................................................................................................ 194 
 
 
! 1 
List of Figures 
 
Figure 2.1 Central metabolism in mammalian cells ................................................... 16 
Figure 2.2 Comparison of flux through CHO central metabolic pathways at exponential 
growth and stationary phase ........................................................................................ 20 
Figure 2.3 Amino acid transporters are functionally coupled to metabolic and signaling 
pathways that promote cell proliferation ..................................................................... 32 
 
Figure 4.1 Production characteristics of CAT-S, GS-Null, and T127 cells grown in a 
14-day fed-batch operation ......................................................................................... 46 
Figure 4.2 Differential expression of amino acid transporter genes between CAT- S, 
GS-Null, and T127 cells at exponential growth phase ................................................ 50 
Figure 4.3 Differential expression of amino acid transporter genes within culture ... 52 
Figure 4.4 Differential expression of amino acid transporter genes between CAT- S, 
GS-Null, and T127 cells at stationary growth phase ................................................... 53 
Figure 4.5 Comparison of proteinogenic amino acid transporter expression in CAT-S, 
GS-Null, and T127 cells at exponential and stationary growth phase ........................ 55 
Figure 4.6 Comparison of specific amino acid transport rates throughout culture for 
CAT-S, GS-Null, and T127 cells ................................................................................ 60 
Figure 4.7 Production characteristics of T29, T48, and T127 cells grown in a 14- day 
fed-batch operation ...................................................................................................... 64 
Figure 4.8 Comparison of specific amino acid transport rates throughout culture for 
T29, T48, and T127 cells ............................................................................................ 65 
 
Figure 5.1 Inhibitors used to block amino acid transporter activity at exponential and 
stationary growth phases of batch cultures. ................................................................ 81 
Figure 5.2 The effect of BCH treatment on cell proliferation during exponential growth 
phase ............................................................................................................................ 83 
Figure 5.3 The effect of BCH treatment on culture viability and amino transport rates 
during exponential growth phase ................................................................................ 84 
Figure 5.4 The effect of BCH treatment on antibody production during exponential 
growth phase ............................................................................................................... 85 
Figure 5.5 The effect of BCH treatment on CAT-S and T127 cells at stationary phase of 
batch culture ................................................................................................................ 87 
! 2 
Figure 5.6 The effect of MeAIB treatment on cell proliferation during exponential 
growth phase ............................................................................................................... 88 
Figure 5.7 The effect of MeAIB treatment on culture viability and amino transport rates 
during exponential growth phase ................................................................................ 89 
Figure 5.8 The effect of MeAIB treatment on antibody production during exponential 
growth phase ............................................................................................................... 91 
Figure 5.9 The effect of MeAIB treatment on CAT-S, GS-Null, and T127 cells at 
stationary phase of batch culture ................................................................................. 92 
Figure 5.10 The effect of SAS treatment on cell proliferation during exponential growth 
phase ............................................................................................................................ 94 
Figure 5.11 The effect of SAS treatment on culture viability and amino transport rates 
during exponential growth phase ................................................................................ 95 
Figure 5.12 The effect of SAS treatment on antibody production during exponential 
growth phase ............................................................................................................... 97 
Figure 5.13 The effect of SAS treatment on CAT-S, GS-Null, and T127 cells at 
stationary phase of batch culture ................................................................................. 98 
Figure 5.14 The effect of GPNA treatment on cell proliferation during exponential 
growth phase ............................................................................................................. 100 
Figure 5.15 The effect of GPNA treatment on culture viability and amino transport 
rates during exponential growth phase ...................................................................... 101 
Figure 5.16 The effect of GPNA treatment on antibody production during exponential 
growth phase ............................................................................................................. 103 
Figure 5.17 The effect of GPNA treatment on CAT-S, GS-Null, and T127 cells at 
stationary phase of batch culture ............................................................................... 104 
Figure 5.18 The effect of ALX 5407 HCl treatment on CAT-S, GS-Null, and T127 
cells during exponential growth phase ...................................................................... 106 
Figure 5.19 The effect of ALX 5407 HCl treatment on CAT-S, GS-Null, and T127 
cells at stationary phase of batch culture ................................................................... 108 
Figure 5.20 The effect of multi-transporter inhibition on T127 cells during exponential 
growth phase ............................................................................................................. 110 
 
Figure 6.1 Gated population of viable cells ............................................................. 123 
Figure 6.2 Example daughter plot for GFP expression ............................................ 124 
Figure 6.3 Creation of a SAS-resistant CAT-S cell line .......................................... 126 
! 3 
Figure 6.4 Batch and fed-batch culture growth curves for parental, CAT-CTRL and 
CAT-R-S700 cells ..................................................................................................... 128 
Figure 6.5 Glutathione content and effect of H2O2 treatment on parental and CAT- R-
S700 cells during exponential growth phase ............................................................. 130 
Figure 6.6 Heritability of the CAT-R-S700 phenotype ............................................ 131 
Figure 6.7 Creation of the GPNA-resistant CAT-S cell line .................................... 133 
Figure 6.8 Batch and fed-batch culture growth curves for parental, CAT-CTRL and 
CAT-R-G200 cells .................................................................................................... 135 
Figure 6.9 Heritability of the CAT-R-G200 phenotype ........................................... 136 
Figure 6.10 Growth characteristics of parental and resistant CAT-S cells transiently 
expressing GFP and an IgG monoclonal antibody .................................................... 138 
Figure 6.11 Transient production of an IgG monoclonal antibody in parental and 
resistant CAT-S cells ................................................................................................. 139 
Figure 6.12 Creation of SAS-resistant T127 cell lines ............................................. 140 
Figure 6.13 Batch culture growth curves for non-evolved T127, T127-CTRL, T127-R-
S500 and T127-R-S700 cells .................................................................................... 142 
Figure 6.14 Comparison of growth and production characteristics for non-evolved 
T127, T127-CTRL, T127-R-S500 and T127-R-S700 cells as assessed in batch cultures
 ................................................................................................................................... 143 
 
Figure 7.1 Relationships between total specific amino acid transport rates and growth 
rates in CAT-S, GS-Null and T127 cells .................................................................. 152 
Figure 7.2 Correlations between the 20 proteinogenic amino acids in CAT-S, GS- Null 
and T127 cells ........................................................................................................... 154 
Figure 7.3 Proposed mechanistic model of essential amino acid transport in CAT- S, 
GS-Null and T127 cells ............................................................................................. 156 
 
Figure A1 Extracellular amino acid concentrations for CAT-S, GS-Null, and T127 cells 
throughout culture ..................................................................................................... 181 
 
Figure B1 Half-normal probability plot of absolute effects for growth response .... 184 
Figure B2 Normal probability plot of residuals for growth rate .............................. 184 
Figure B3 Half-normal probability plot of absolute effects for culture viability ..... 185 
Figure B4 Normal probability plot of residuals for culture viability ....................... 185 
Figure B5 Interactions between systems ASC, L, and XC- for culture viability ...... 186 
! 4 
Figure B6 Half-normal probability plot of absolute effects for specific productivity 
 ................................................................................................................................... 187 
Figure B7 Normal probability plot of residuals for specific productivity ................ 188 
 
Figure C1 Relationships between transport rates of individual amino acids and growth 
rates in CAT-S, GS-Null and T127 cells .................................................................. 189 
! 5 
List of Tables 
 
Table 1.1 Expression systems commonly used to express recombinant proteins ...... 10 
 
Table 2.1 Mammalian amino acid transporters and their transport properties ........... 24 
 
Table 4.1 Proteinogenic amino acid transporters with medium or high expression at 
exponential and stationary growth phase .................................................................... 48 
Table 4.2 Differential expression of enzymes involved in regulating cellular GSH levels 
in response to transition from exponential to stationary growth phase of culture 
 ..................................................................................................................................... 56 
Table 4.3 Differential expression of genes regulated by the AAR pathway in response 
to transition from exponential to stationary growth phase of culture ......................... 57 
Table 4.4 Non-proteinogenic amino acid transporters with medium or high expression 
at exponential and stationary growth phase ................................................................ 58 
Table 4.5 Total specific amino acid transport rates throughout culture for CAT- S, GS-
Null, and T127 cells .................................................................................................... 61 
Table 4.6 Total specific amino acid transport rates throughout culture for T29, T48, and 
T127 cells .................................................................................................................... 66 
Table 4.7 Amino acid composition of a mammalian cell and an IgG antibody ......... 74 
 
Table 5.1 Summary of growth and production characteristics of five CHO cell lines as 
assessed in 14-day fed-batch operations ..................................................................... 80 
 
Table 7.1 Specific transport rates of amino acids in CAT-S, GS-Null and T127 cells 
grown under control conditions ................................................................................ 158 
 
Table A1 CHO amino acid transporters identified in genome, transcriptome, and 
proteome studies ........................................................................................................ 168 
Table A2 Transcript abundance of CAT-S amino acid transporter genes at exponential 
and stationary growth phase of culture  .................................................................... 171 
Table A3 Transcript abundance of GS-Null amino acid transporter genes at exponential 
and stationary growth phase of culture  .................................................................... 174 
Table A4 Transcript abundance of T127 amino acid transporter genes at exponential 
and stationary growth phase of culture  .................................................................... 177 
! 6 
Table A5 FPKM boundaries for low, medium, and high gene expression in CAT-S, GS-
Null, and T127 cells at exponential and stationary growth phase ............................. 180 
 
Table B1 Design matrix for the two-level factorial experiment showing factor 
interactions, response variable data, and calculated effects ...................................... 183 
 
Table C1 Spearman’s rank correlation coefficient values for CAT-S cells ............. 192 
Table C2 Spearman’s rank correlation coefficient values for GS-Null cells ........... 192 
Table C3 Spearman’s rank correlation coefficient values for T127 cells ................ 193 
! 7 
Amino Acid Abbreviations 
 
Amino acid  Three-letter code  One-letter code 
 
Alanine   Ala    A 
Arginine   Arg    R 
Asparagine   Asn    N 
Aspartate   Asp    D 
Cysteine   Cys    C 
Cystine   Cys2    C-C 
Glutamate   Glu    E 
Glutamine   Gln    Q 
Glycine   Gly    G 
Histidine   His    H 
Isoleucine   Ile    I 
Leucine   Leu    L 
Lysine    Lys    K 
Methionine   Met    M 
Phenylalanine   Phe    F 
Proline    Pro    P 
Serine    Ser    S 
Threonine   Thr    T 
Tryptophan   Trp    W 
Tyrosine   Tyr    Y 
Valine    Val    V 
 
! 8 
Acronyms and Abbreviations 
 
AAA  Aromatic amino acids 
AAR  Amino acid response  
ATP  Adenosine triphosphate 
BCAA  Branched-chain amino acids 
BCH  2-amino-2-norbornanecarboxylic acid 
CHO  Chinese hamster ovary 
DMSO Dimethyl sulfoxide 
DoE  Design of experiments 
FPKM Fragments per kilobase of transcript per million fragments mapped 
GFP  Green fluorescent protein 
GPNA  L-γ-glutamyl-p-nitroanilide 
GS  Glutamine synthetase 
GSH  Reduced glutathione 
GSSG  Oxidised glutathione 
IgG  Immunoglobulin G  
MeAIB α-(methylamino)isobutyric acid  
MFA  Metabolic flux analysis 
mTORC1 Mammalian target of rapamycin (mTOR) complex 1 
NADPH Nicotinamide adenine dinucleotide phosphate 
PPP  Pentose phosphate pathway 
ROS  Reactive oxygen species 
SAS  Sulfasalazine  
SLC  Solute carrier  
TCA  Tricarboxylic acid 
! 9!
Chapter 1 
Manufacturing Recombinant Therapeutic 
Monoclonal Antibodies 
 
This chapter provides an overview of the manufacturing of monoclonal antibodies in 
CHO cells with a focus on upstream process development. Industrial drivers are 
discussed such as high product titres, product quality attributes and speed to market, 
and how this has influenced the development of current industrial manufacturing 
processes.  
 
 
1.1 Biologics Market 
Recombinant therapeutic proteins are a class of biologics that are produced using 
recombinant DNA technology. Products within this group include blood factors, 
cytokines, fusion proteins, growth factors, hormones, monoclonal antibodies (mAbs), 
therapeutic enzymes, and vaccines (Aggarwal, 2014). Of these, mAbs dominate the 
biologics market, accounting for around 38.7% of total sales in 2012 (Aggarwal, 2014) 
and for six of the top ten selling biologics in 2013 (Walsh, 2014). Nearly all marketed 
mAbs are treatments for cancers and autoimmune diseases such as Crohn’s disease, 
psoriasis, rheumatoid arthritis and ulcerative colitis, all of which are chronic conditions 
that typically require high treatment doses (≥100 mg; Jain and Kumar, 2008). The 
development of cost-effective manufacturing processes that yield high mAb titres is 
therefore a major industrial challenge to meet current and future patient demands 
(Kelley et al., 2001; Shukla and Thomas, 2010). 
 
 
1.2 Expression Systems 
A variety of cell-based systems exist that can be used to express recombinant proteins, 
including Escherichia coli, yeast cells, insect cells, and mammalian cells (Table 1.1). 
The choice of expression system is largely dictated by any post-translational 
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modification (PTM) requirements the protein may have for folding, assembly and in 
vivo activity in patients. All therapeutic mAbs are of the IgG (immunoglobulin G) 
isotype (Walsh, 2014), which are composed of two heavy and two light polypeptide 
chains that are assembled into a Y-shaped monomer (Schroeder and Cavacini, 2010). 
Correct assembly requires disulphide bond formation between polypeptide chains, while 
glycosylation affects the stability, function, half-life and immunogenicity of mAbs in 
patients (Schroeder and Cavacini, 2010; Walsh and Jefferis, 2006). These two PTM 
requirements necessitate the use of a mammalian expression system, as E. coli are 
unable to glycosylate and generate inclusion bodies, while lower eukaryotes such as 
yeast and insect cells can produce incorrect glycosylation patterns (reviewed in Demain 
and Vaishnav, 2009). Around 56% of all recombinant therapeutic proteins approved 
between 1982 and 2014 are manufactured using a mammalian expression system, of 
which approximately 63% are produced using Chinese hamster ovary (CHO) systems 
(Walsh, 2014). 
 
Table 1.1 Expression systems commonly used to express recombinant proteins 
 
 
Expression systems
Prokaryotic
Escherichia coli
Yeast
Saccharomyces cerevisiae
Pichia pastoris
Mammalian
Chinese hamster ovary (CHO)
Baby hamster kidney (BHK)
Mouse myeloma (NS0)
Mouse B cell hybridoma (SP2/0)
Human embryonic kidney (HEK-293)
Human retinoblast (PER.C6)
Insect
Drosophila melanogaster (S2)
Spodoptera frugiperda (SF9 and SF21)
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1.3 Chinese Hamster Ovary (CHO) Expression System 
The CHO cell line (CHO-K1) was first isolated in 1958 from a population of 
immortalised ovarian fibroblasts taken from a Chinese hamster (Cricetulus griseus; 
Puck et al., 1958). Mutagenesis of the CHO-K1 cell line over subsequent years resulted 
in the creation of cell line variants (DG44 and DXB11) that are currently in use within 
the biotechnology industry (Wurm and Hacker, 2011). CHO cell lines offer a number of 
industrial advantages, in addition to their ability to glycosylate, that have made them a 
popular expression system. They can be easily genetically manipulated, adapted into 
scalable single cell suspension cultures, and adapted to grow in serum-free chemically 
defined media (Jayapal et al., 2007). The first CHO recombinant product, tissue 
plasminogen activator (tPA), was marketed by Genentech in 1987 (Activase®) and 
manufactured using suspension-adapted cells cultured in bioreactors (De Jesus and 
Wurm, 2011). Since 1987, the establishment of productive and efficient CHO cell 
manufacturing processes that have a proven track record with regulatory authorities has 
helped secure CHO cells as the dominant mammalian expression system. 
 
 
1.4 Manufacturing Antibodies 
A typical manufacturing process begins with the culture of recombinant CHO cell lines 
in stirred-tank bioreactors for antibody production. At the end of the production process 
the culture is harvested, centrifuged and filtered to remove cells and cell debris (Shukla 
and Thomas, 2010). Purification of the antibody is achieved through a series of capture 
(protein A) and polishing (anion/cation exchange) chromatography steps that remove 
impurities such as host cell proteins and DNA (Shukla and Thomas, 2010). Platform 
approaches to manufacturing have helped develop processes that are efficient (reduced 
costs and fast), reproducible, well characterised, and adaptable to new products (Shukla 
and Thomas, 2010). Specifically, developments to upstream processing have resulted in 
cell cultures capable of achieving antibody yields of up to 5 g/L (De Jesus and Wurm, 
2011) with multiple grams per litre titres also being reported (Jiang et al., 2012).  
 
 
1.5 Upstream Process Development 
1.5.1 Cell Line Development (CLD) 
The construction of a recombinant CHO cell line with a high specific antibody 
production rate (pg/cell/day) is the first step in the development of a productive cell 
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culture process. Specific productivities (QP) are reported to be in the range of 50–60 
pg/cell/day (De Jesus and Wurm, 2011). These values have largely been achieved 
through the development of improved expression vectors and screening platforms to 
select for rare cells with a high QP.  
Expression vectors are DNA molecules encoding genes for both the heavy and 
light antibody chains in addition to a selection marker for positive transfectants. To 
maximise specific productivity the coding sequences are optimised for expression (e.g. 
codon optimisation and removal of cryptic splice sites). Additionally the vector 
backbone contains elements that enhance transcription, translation and secretion such as 
viral promoters (e.g. CMV), poly(A) tails, Kozak sequences and signal peptides 
(reviewed in Birch and Racher, 2006). The two leading platform vector systems for 
recombinant gene expression in CHO cells are the dihydrofolate reductase (DHFR) and 
Lonza’s proprietary glutamine synthetase (GS) selection systems. The DHFR system 
introduces a functional copy of the DHFR gene into DHFR-deficient CHO-K1 variants 
(DG44 and DXB11). Transfectants are selected by growth in glycine, hypoxanthine and 
thymidine free media (GHT-), and the DHFR inhibitor methotrexate (MTX) is used to 
increase expression of both DHFR and the recombinant gene over multiple 
amplification rounds (Jayapal et al., 2007). The GS system introduces a recombinant 
GS gene and transfectants are grown in glutamine free media. Methionine sulfoximine 
(MSX) is used to inhibit endogenous CHO GS and to select for high producers in a 
single amplification round. The GS system is preferentially used as the single 
amplification round can reduce the cell line development period to ~3 months compared 
to ~6 months with the DHFR system (Barnes et al., 2000). 
Transfected CHO cells typically demonstrate significant variation in 
recombinant antibody expression. Cells exhibiting a high Qp are rare and must be 
selected for. Automated high-throughput screening platforms such as fluorescence-
activated cell sorting (FACS) and ClonePix can help screen 100-1000s of individual 
cells (reviewed in De Jesus and Wurm, 2011). In addition to a high Qp, selected cells 
must have a growth rate suitable to meet large-scale production process times, and 
produce antibodies with the correct quality attributes (e.g. glycosylation profile) to 
ensure they are safe and efficacious in patients. Regulatory authorities require the cell 
line to be clonal, and stability testing is performed to ensure that clonal cell growth, Qp 
and product quality is heritable over multiple generations (typically 60–80). 
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1.5.2 Cell Culture Process Development  
Despite improvements to expression vectors, specific productivities have not changed 
significantly over the last 25 years and a biological limit of 100 pg/cell/day has been put 
forward (De Jesus and Wurm, 2011). Improvements in antibody titres have instead been 
reached mostly by the development of scalable fed-batch stirred-tank bioreactor 
processes, capable of achieving very high cell densities. A fed-batch process involves 
an initial growth period with a basal medium followed by the addition of a concentrated 
feed medium at set intervals throughout the culture (Whitford, 2006; Jiang et al., 2012). 
As the majority of antibody synthesis is uncoupled from cell growth, a fed-batch 
process must be designed to rapidly generate high cell densities that can be maintained 
for extended periods at high viabilities.  
The design of a fed-batch process typically involves optimisation of either (or 
both) the basal and feed media composition, as well as process control parameters such 
as temperature, pH, dissolved oxygen, and feeding schedule. Design of experiments 
(DoE) is a statistical method frequently used in media development to identify optimal 
concentrations of media components for improved cell line productivity (reviewed in 
Chapter 7; Section 7.1). The feed primarily replenishes depleted nutrients, particularly 
amino acids, however it can also contain other components to extend culture longevity 
(e.g. antioxidants), or increase specific productivity (e.g. butyrate) late in culture 
(reviewed in Whitford, 2006). For optimisation of process control, temperature 
reduction during late culture is widely used to extend the stationary phase and boost 
specific IgG productivity (Sou et al., 2015). Although this can have a negative effect on 
IgG glycosylation (Sou et al., 2015), which must be characterised to ensure product 
safety and efficacy is unaffected. Jiang et al. (2012) demonstrated that DoE could be 
used to optimise the basal medium, feed medium, and process control (temperature 
shift, feeding schedule and seeding density) in a single workflow. This integrated 
approach to fed-batch design resulted in faster growth rates and cell densities in excess 
of 25 million cells/mL for an antibody-producing CHO cell line. More recently the 
development of scaled-down micro bioreactors such as the ambr™ (TAP Biosystems, 
UK) have been widely adopted by the industry to speed up cell line selection, fed-batch 
process optimisation, and process characterisation. The ambr™ system comprises of 24 
or 48 parallel disposable vessels of 10-15 mL working volumes in which agitation, 
temperature, pH, DO, and automated sampling and feeding can be controlled with each 
vessel. Importantly, the system has been demonstrated to be capable of simulating cell 
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culture performances in traditional stirred-tank bioreactors up to 200 L with a high level 
of reproducibility (Rameez et al., 2014). 
 
 
1.6 Summary 
CHO cells are the dominant expression system in the biotechnology industry as they 
can deliver on the major industrial drivers such as production of high product titres, 
required quality attributes, speed to market, and are compatible with cost-effective 
manufacturing processes. The introduction of high-throughput technology for screening 
cell lines and the development of fed-batch cell culture processes has helped to 
significantly improve product titres since the approval of Activase® in 1987. However, 
it is considered that antibody titres can be improved further by further increasing cell 
densities and maintaining them for longer (De Jesus and Wurm, 2011). To help with 
this, a significant level of research has been directed at trying to further understand 
CHO cell metabolism. The aim being to identify cell line engineering targets, or rational 
methods of optimising feed compositions and feeding regimes to improve cell growth 
and productivity. Much of this research has focused on understanding and altering flux 
rates through central metabolic pathways involved in glucose, glutamine, lactate and 
ammonia metabolism (discussed further in Chapter 2). Yet, the intracellular availability 
of nutrients is controlled by systems of membrane transporter proteins, whose function 
remains largely unknown in CHO cells. Chapter 2 explores how further investigation of 
CHO amino acid transport is of importance to upstream process development and sets 
the context for the work in this thesis. 
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Chapter 2 
Amino Acid Metabolism and Transport 
 
This chapter reviews amino acid metabolism and transport to help contextualise the 
subsequent work within this thesis. An overview of how biomass synthesis in 
transformed cell lines is supported by amino acids is first provided. The chapter then 
reviews mammalian amino acid transporters and how their activity is functionally 
coupled to metabolic and signaling pathways critical to cell growth. A short discussion 
on the potential of amino acid transporters as cell engineering targets is then given. 
Finally, the aims and objectives of this thesis are discussed, including a brief synopsis 
for each of the subsequent results chapters. 
 
  
2.1 Mammalian Cell Metabolism 
Cultured cells import small nutrients (e.g. amino acids, glucose, and fatty acids) from 
their extracellular environment to build the macromolecules (e.g. nucleic acids, 
proteins, and lipids) required for cell division. Many anabolic processes are supported 
by ATP and enzyme cofactors such as NADPH, which must be regenerated through the 
metabolism of assimilated nutrients (Lunt and Vander Heiden, 2011). For example, 
synthesis of the fatty acid palmitate requires 7 molecules of ATP and 14 molecules of 
NADPH in addition to 16 carbons (Vander Heiden et al., 2009). Three metabolic 
pathways can meet the majority of anabolic demands: glycolysis, the tricarboxylic acid 
(TCA) cycle, and the pentose phosphate pathway (PPP) (Figure 2.1).  
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Figure 2.1 Central metabolism in mammalian cells. Amino acids and glucose are 
directed through glycolysis, the PPP, and the TCA cycle to support ATP and biomass 
production. Pathways have been simplified to demonstrate the important fluxes 
described in the main text as well as the interconnectivity of the three pathways. Key 
metabolic enzymes are provided in parentheses. ACL, ATP citrate lyase; ALT, Alanine 
transaminase; CS, Citrate synthase; LDH, Lactate dehydrogenase; ME, Malic enzyme; 
PC, Pyruvate carboxylase; PDH, Pyruvate dehydrogenase. 
 
 
Glucose is the primary carbon source consumed by mammalian cells (Lunt and 
Vander Heiden, 2011). Glucose is first metabolised through glycolysis to generate 
pyruvate and 2 net molecules of ATP (Berg et al., 2007). Subsequent decarboxylation 
and oxidation of pyruvate to acetyl-CoA by pyruvate dehydrogenase (PDH) allows it to 
enter the mitochondrial TCA cycle as citrate by condensing with oxaloacetate. As 
citrate moves through the TCA cycle it undergoes both decarboxylation and oxidation 
reactions with released electrons being donated to the electron transport chain. This 
metabolism, known as oxidative phosphorylation, allows the cell to generate a further 
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28 molecules of ATP per molecule of glucose (Berg et al., 2007). Under hypoxic 
conditions this process is inhibited and pyruvate must instead be converted to lactate 
and secreted from the cell, a process known as anaerobic glycolysis. Mammalian cells 
can redirect glycolytic intermediates to support the biosynthesis of nucleotides, amino 
acids, and lipids (Lunt and Vander Heiden, 2011). TCA cycle intermediates can also 
exit the mitochondria, a process known as cataplerosis, and be used for amino acid or 
lipid synthesis (Figure 2.1). 
Amino acids are required by mammalian cells for protein synthesis and as a 
source of nitrogen, primarily for nucleotide synthesis. However, removal of the amine 
group leaves a carbon skeleton that can also be used to support biosynthesis processes, 
replace TCA cycle intermediates lost through cataplerotic reactions (anaplerosis), or be 
used as an energy source (Berg et al., 2007) (Figure 2.1). Glutamine is the highest 
consumed amino acid by mammalian cells and provides a second major carbon source 
(Lunt and Vander Heiden, 2011). 
 
2.1.1 Aerobic Glycolysis and Glutaminolysis Support Cell Proliferation 
Antibody-producing CHO cells growing in a fed-batch process transition through three 
growth phases: exponential, stationary, and decline. Exponential growth is characterised 
by rapid cell division and minimal antibody production. During the stationary phase 
cells cease division but remain viable and maximise their antibody production. 
Significant cell death towards the end of culture causes the decline phase. CHO cells 
exhibit high consumption rates for glucose and glutamine together with high secretion 
rates of alanine, ammonia, and lactate during exponential growth (Altamirano et al., 
2004). Ammonia and lactate are toxic to cell growth and antibody production. The 
metabolism of glucose to lactate proceeds even in the presence of oxygen, a metabolic 
characteristic of cancer cells termed Warburg metabolism or aerobic glycolysis 
(Warburg, 1956).  
An increasing number of studies have used metabolic flux analysis (MFA) to 
better understand the altered metabolism of cultured mammalian cells. MFA uses 
mathematical models of simplified metabolic networks in combination with 
experimentally measured transport rates of culture metabolites to estimate the flux 
through intracellular pathways (technique reviewed by Quek et al., 2010). Replacing 
nutrients such as glucose with 13C tracers and then measuring their distribution within 
metabolites have significantly improved MFA estimates (13C-MFA)(Ahn and 
Antoniewicz, 2012). 
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Aerobic glycolysis was investigated in a human glioblastoma cell line using 13C-
labeled glucose and glutamine (DeBerardinis et al., 2007). Over 90% of glucose was 
metabolised to lactate and alanine through glycolysis. However, TCA cycle activity was 
detected with pyruvate entering only as acetyl-CoA and citrate being exported for fatty 
acid synthesis. Glutamine was found to act as an anaplerotic substrate, replacing lost 
oxaloacetate. The study also found that 60% of glutamine was converted to lactate 
(glutaminolysis) via efflux of malate from the TCA cycle, generating NADPH. It has 
been hypothesised that high rates of aerobic glycolysis and glutaminolysis in cancer 
cells supports cell proliferation by sustaining a rapid supply of ATP, NADPH, and 
biosynthetic precursors for biomass synthesis (Vander Heiden et al., 2009).  
13C-MFA studies with CHO cells provide evidence that the TCA cycle functions 
in a similar manner to glioblastoma cells during exponential growth phase (Ahn and 
Antoniewicz, 2011; Dean and Reddy, 2013; Templeton et al., 2013). Feeding 13C-
labelled glucose to a non-producing adherent CHO-K1 cell line, Ahn and Antoniewicz 
(2011) found the majority of pyruvate produced by glycolysis metabolism was secreted 
as lactate. Most of the remaining pyruvate entered the TCA cycle as acetyl-CoA via 
PDH. Flux through the malic enzyme (ME) represented a significant cataplerotic 
reaction but negligible citrate export was observed. TCA cycle replenishment was 
mediated by pyruvate and glutamine through the anaplerosis reactions catalysed by 
pyruvate carboxylase (PC) and glutamate dehydrogenase (GDH) respectively. 
Templeton et al. (2013) found significant cataplerotic flux through ATP citrate lyase 
(ACL) in addition to ME in an antibody-producing CHO cell line. Pyruvate flux 
through PC helped replace oxaloacetate, however a parallel study found glutamine and 
asparagine also significantly contributed to TCA cycle replenishment (Dean and Reddy, 
2013). Furthermore, 25% of secreted lactate was derived from glutamine but none from 
asparagine. However, asparagine majorly contributed to the production of the fatty acid 
palmitate whereas minimal glutamine carbon was detected in this macromolecule. In 
support of the importance of asparagine and glutamine consumption to exponential 
growth, Sellick et al. (2011) found that depletion of asparagine, aspartate and glutamate 
coincided with the end of exponential growth for an antibody-producing GS-CHO cell 
line. Feeding back these amino acids in addition to pyruvate extended exponential 
growth and increased antibody titre by 75%. 
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2.1.2 Stationary Phase is Associated With Oxidative Metabolism and PPP Activity 
Transition into stationary phase has been found to coincide with lactate uptake, a drop 
in cataplerosis and anaplerosis rates, and an increased flux of pyruvate towards acetyl-
CoA, which collectively indicate a shift in TCA cycle function towards oxidative 
metabolism (Ahn and Antoniewicz, 2011; Dean and Reddy, 2013; Templeton et al., 
2013). Zagari et al. (2013) found lactate consumption during stationary phase correlated 
with increased mitochondrial membrane potential and oxygen consumption, two key 
indicators of oxidative metabolism. 
Stationary phase has also been found to coincide with increase flux through the 
PPP whose activity is minimal during exponential growth phase (Ahn and Antoniewicz, 
2011; Templeton et al., 2013). Sengupta et al. (2011) found nearly all 13C-glucose was 
metabolised to pyruvate via the PPP before entering the TCA cycle for an antibody-
producing GS-CHO cell line at stationary phase. Increased activity of the PPP cannot be 
due to an increased requirement of ribose-5-phosphate for nucleotide synthesis as all the 
glucose was cycled back to glycolysis. Increased flux through the PPP is therefore 
likely to promote NADPH production (Figure 2.1). In addition to supporting anabolic 
reactions, NADPH is required by glutathione reductase for catalysing the reduction of 
oxidised glutathione (GSSG) back to glutathione (GSH). GSH – a tripeptide (glutamate, 
cysteine, and glycine) – is a major cellular antioxidant that helps remove reactive 
oxygen species (ROS). Sengupta et al. (2011) hypothesised that high NADPH 
production may help to protect the cell from oxidative stress since minimal cellular 
biomass production takes place at stationary phase. In support of this Templeton et al. 
(2013) found that both the GSH/GSSG and NADPH/NADP+ ratios decreased as cells 
transition into late exponential growth and stationary phases. However, this also 
indicates that increased flux through the PPP is still not enough to maintain NADPH at 
levels equivalent to early exponential growth phase and to fully regenerate GSH.  
 
2.1.3 CHO Cell Metabolism is Cell Line Dependent 
The above studies demonstrate that transition from exponential to stationary growth 
phase is accompanied by a significant shift in CHO cell metabolism. Figure 2.2 
summarises how fluxes through glycolysis, the TCA cycle, and the PPP are redirected 
to support the biomass objectives of both growth phases.  
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Figure 2.2 Comparison of flux through CHO central metabolic pathways at 
exponential growth and stationary phase. (A.) Aerobic glycolysis and glutaminolysis 
support biomass production during exponential growth phase. (B.) Increased oxidative 
metabolism and flux through the PPP takes place during stationary phase. Arrow weight 
indicates the magnitude of flux through a pathway with thick arrows representing high 
flux rates. 
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Cell metabolism can however also be very heterogeneous within a cell line. Zagari et al. 
(2013) found lactate metabolism to differ between a parental CHO-S cell line and a 
subclone. The parental cell line exhibited a shift to lactate consumption at stationary 
phase while the subclone continued to be a lactate producer. Furthermore, changing the 
media composition was shown to shift lactate metabolism in both cell lines. Such a cell-
media interaction is in agreement with a study by Dietmair et al. (2012a), which showed 
that growing a single cell line in three different commercial media resulted in three 
distinct growth profiles, each with their own unique metabolic profile. Luo et al. (2011) 
found that changing just the copper concentration in media could significantly alter 
CHO cell metabolism, demonstrating that cell-media interactions are not just dependent 
on the nutrient composition of the media. 
 
 
2.2 Amino Acids and Signaling Pathways 
Availability of intracellular amino acids also plays an essential role in regulating global 
protein synthesis. Amino acid sufficiency stimulates the mammalian target of 
rapamycin (mTOR) complex 1 (mTORC1) signaling pathway whose activation 
promotes cell growth (Kim and Guan, 2011; Wullschleger et al., 2006). Amino acid 
depletion however stimulates the amino acid response (AAR) signaling pathway whose 
activation inhibits growth (Kilberg et al., 2009). 
 
2.2.1 Leucine and Glutamine Stimulate mTORC1 Signaling 
mTOR is a serine-threonine protein kinase that associates with several secondary 
proteins to form mTORC1 whose structure, upstream regulators, and downstream 
targets have been extensively reviewed (Kim and Guan, 2011; Wullschleger et al., 
2006). Activation of mTORC1 promotes ribosome biogenesis in addition to global 
protein synthesis while also inhibiting autophagy. Leucine is a potent activator of 
mTORC1 mediated phosphorylation of both the 70 kDa ribosomal protein S6 kinase 
(S6K) and the eukaryotic translation initiation factor 4E (eIF4E) binding protein (4E-
BP1) (Christie et al., 2002; Hara et al., 1998). Phosphorylation of both S6K and 4E-BP1 
activates cellular mechanisms that mediate an increase in protein translation 
(Wullschleger et al., 2006). Increasing intracellular leucine by 7% in Xenopus laevis 
oocytes was shown to induce a 50% maximal increase in S6K phosphorylation, 
suggesting a highly sensitive leucine sensing mechanism (Christie et al., 2002). More 
recently, glutamine has been shown to activate mTORC1 signaling but through a 
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mechanism distinct from leucine (Jewell et al., 2015). Constitutive expression of human 
mTOR in CHO cells was shown to increase growth rate, maximal cell density, cell size, 
total protein content, specific antibody productivity, and culture viability (Dreesen and 
Fussenegger, 2011). Furthermore, mTOR expression minimised the negative impact 
that oxygen and nutrient depletion stress conditions had on process productivity. 
 
2.2.2 Amino Acid Response (AAR) Pathway 
Depletion of intracellular amino acid levels reduces mTORC1 activity and stimulates 
autophagy (Kim and Guan, 2011) but also activates the AAR pathway, which acts to 
decrease global protein synthesis. Kilberg et al. (2009) provide a detailed review of 
AAR signaling. In brief, a decrease in any amino acid leads to an increase of uncharged 
tRNA molecules. Their accumulation permits the binding of the general control non-
depressible 2 (GCN2) protein kinase, which subsequently phosphorylates the translation 
initiation factor eIF2α. This inhibits global protein synthesis, but permits an increase in 
translation of a small subset of genes that includes activating transcription factor 4 
(ATF4). ATF4 increases transcription of a number of genes that contain amino acid 
response elements (AARE), which include a number involved in amino acid transport 
(xCT/SLC7A11; SNAT2/SLC38A2; CAT-1/SLC7A1) and amino acid biosynthesis 
(ASNS, asparagine synthetase). Mammalian cells therefore use a combination of 
autophagy and transport to restore intracellular amino acid levels during nutrient 
starvation stress. 
 
 
2.3 Mammalian Amino Acid transporters 
Membrane transporters control the movement of amino acids across mammalian cell 
membranes. These are large proteins containing multi transmembrane domains that 
create a hydrophilic passage spanning the phospholipid bilayer. Early research on 
mammalian amino acid transport identified distinct transport systems defined by 
characteristics such as substrate specificity, ion dependency, transport mechanisms, and 
sensitivity to substrate analogs (Christensen et al., 1967; Oxender and Christensen, 
1963). Many of the individual transporters belonging to these systems were 
subsequently identified and named during the 90s using molecular cloning and 
functional characterisation in X. laevis oocytes. Amino acid transporters are now 
grouped into 9 solute carrier (SLC) families based upon amino acid sequence homology 
to other family members (Bodoy et al., 2013; Fotiadis et al., 2013; Hediger et al., 2004; 
 ! 23!
Kanai et al., 2013; Pramod et al., 2013; Schiöth et al., 2013; Smith et al., 2013). Genes 
are named using the SLC symbol, followed by a number to indicate the family it 
belongs to, then the letter A and a second number to indicate an individual transporter 
(Hediger et al., 2004). Both the traditional and SLC naming systems are however 
commonly used within the literature. 
To date, 61 mammalian genes encoding proteins with amino acid transport 
activity at the plasma membrane have been identified (see Table 2.1). These genes can 
be grouped into four categories: 43 proteinogenic amino acid transporters (those that 
transport the 20 proteinogenic amino acids), 9 orphan transporters (those with an 
unknown amino acid transport function), 4 di/tripeptide transporters (those that 
transport a range of di/tripeptides), and 5 other amino acid transporters (those that 
transport molecules with an amino acid like structure such as taurine and GABA).  
Table 2.1 demonstrates that individual proteinogenic amino acid transporters 
facilitate the movement of multiple amino acids. Neutral amino acids are mostly 
transported through transporters belonging to systems A, ASC, B0, B0,+, Gly, L and N. 
Anionic transport is predominately through systems XAG- and XC-, and cationic transport 
is predominately through systems y+ and y+L. The two proteins belonging to SLC3 have 
no transport function but multiple SLC7 family transporters must form disulphide 
bridges with a SLC3 protein for cell surface expression. 
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Table 2.1 Mammalian amino acid transporters and their transport properties 
!!
Gene name    
(SLC ID)
Protein name Associated 
transport system
Amino acid 
substrates*
Transport 
mechanism
Ion dependency References
Proteinogenic amino acid transporters:
SLC1A1 EAAC1, EAAT3 X-AG D, E S Na+, H+ (S) | K+ (A) Kanai et al., 2013
SLC1A2 GLT-1, EAAT2 X-AG D, E S Na+, H+ (S) | K+ (A) Kanai et al., 2013
SLC1A3 GLAST, EAAT1 X-AG D, E S Na+, H+ (S) | K+ (A) Kanai et al., 2013
SLC1A4 ASCT1, SATT ASC A, S, C, T, (V) A Na+ Arriza et al., 1993; Kanai et al., 2013
SLC1A5 ASCT2, AAAT ASC
A, S, C, T, Q, N, (M, 
L, G, V, E) A Na
+ Kanai et al., 2013; Utsunomiya-Tate et 
al., 1996
SLC1A6 EATT4 X-AG D, E S Na+, H+ (S) | K+ (A) Kanai et al., 2013
SLC1A7 EATT5 X-AG D, E S Na+, H+ (S) | K+ (A) Kanai et al., 2013
SLC3A1 rBAT Fotiadis et al., 2013
SLC3A2 4F2hc Fotiadis et al., 2013
SLC6A5 GlyT2 G S Na+, Cl- Pramod et al., 2013
SLC6A7 PROT P S Na+, Cl- Pramod et al., 2013
SLC6A9 GlyT1 G S Na+, Cl- Pramod et al., 2013
Heterodimerizes with SLC7A9
Heterodimerizes with SLC7 members
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Gene name    
(SLC ID)
Protein name Associated 
transport system
Amino acid 
substrates*
Transport 
mechanism
Ion dependency References
SLC6A14 ATB0,+ B
0,+, beta-alanine 
carrier system
All AA except: D, E S Na+, Cl- Pramod et al., 2013; Ugawa et al., 2001
SLC6A15 B0AT2 B0 L, I, V, M, P (A, Q, F) S Na+ Bröer et al., 2006; Pramod et al., 2013
SLC6A17 XT1, NTT4 P, L, M, (C, A, Q, S) S Na+
Pramod et al., 2013; Zaia and Reimer, 
2009
SLC6A18 B0AT3, XT2 Gly L, I, V, M, A, G, S, C S Na+, Cl- Pramod et al., 2013; Singer et al., 2009
SLC6A19 B0AT1, HND B0 L, I, V, M S Na+ Böhmer et al., 2005; Pramod et al., 2013
SLC6A20 XT3, Xtrp3 IMINO P S Na+, Cl- Pramod et al., 2013
SLC7A1 CAT-1, ATRC1 y+ R, K, H, O U - Closs et al., 2006; Fotiadis et al., 2013
SLC7A2 CAT-2 y+ R, K, O U - Closs et al., 2006; Fotiadis et al., 2013
SLC7A3 CAT-3, ATRC3 y+ R, K, O U - Fotiadis et al., 2013; Vekony et al., 2001
SLC7A5/SLC3A2 LAT1/4F2hc L
L, I, F, M, Y, H, W, V, 
(Q) A - Kanai et al., 1998; Yanagida et al., 2001
SLC7A6/SLC3A2 y+LAT2/4F2hc y+L R, K, H, O, Q, L, M
A (CAA out 
& NAA in) Na
+ (S with NAA) Bröer et al., 2000; Fotiadis et al., 2013
SLC7A7/SLC3A2 y+LAT1/4F2hc y+L R, K, H, O, Q, L, M
A (CAA out 
& NAA in) Na
+ (S with NAA) Kanai et al., 2000; Torrents et al., 1998
SLC7A8/SLC3A2 LAT2/4F2hc L
L, I, F, M, Y, H, W, V, 
G, A, S, T, C, N, (Q) A - Pineda et al., 1999; Segawa et al., 1999
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Gene name    
(SLC ID)
Protein name Associated 
transport system
Amino acid 
substrates*
Transport 
mechanism
Ion dependency References
SLC7A9/SLC3A1 b0,+AT/rBAT b0,+ R, K, H, L, F, C-C
A (NAA out 
& CAA in) - Chillarón et al., 1996
SLC7A10/SLC3A2 Asc-1/4F2hc asc A, C, G, S, T A -
Fukasawa et al., 2000; Nakauchi et al., 
2000
SLC7A11/SLC3A2 xCT/4F2hc X-C E, C-C
A (E out &       
C-C in) - Sato et al., 1999
SLC7A12 Asc-2 asc A, C, G, S, T U - Chairoungdua et al., 2001
SLC7A13 AGT-1, XAT2 D, E A - Matsuo et al., 2002
SLC7A15 ArpAT Y, W, F, A, S, Q A - Fernández et al., 2005
SLC16A10 TAT1, MCT10 T F, W, Y U - Kim et al., 2001
SLC36A1 PAT1 PAT A, G, P S H+ Schiöth et al., 2013
SLC36A2 PAT2 PAT A, G, P S H+ Schiöth et al., 2013
SLC36A4 PAT4 P, W S H+ Schiöth et al., 2013
SLC38A1 SNAT1 A Q, N, H, A, M, S S Na+ Schiöth et al., 2013
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Gene name    
(SLC ID)
Protein name Associated 
transport system
Amino acid 
substrates*
Transport 
mechanism
Ion dependency References
SLC38A2 SNAT2 A
Q, N, H, A, M, S, C, 
P, G S Na
+ Schiöth et al., 2013
SLC38A3 SNAT3 N Q, N, H, A S Na+ (S) | H+ (A) Schiöth et al., 2013
SLC38A4 SNAT4 A N, A, S, C, G, T S Na+ Schiöth et al., 2013
SLC38A5 SNAT5 N Q, N, H, A, G, S S Na+ (S) | H+ (A) Schiöth et al., 2013
SLC38A7 SNAT7 A/N Q, N, H, A, S unknown unknown Schiöth et al., 2013
SLC43A1 LAT3 L L, I, V, F, M U - Babu et al., 2003
SLC43A2 LAT4 L L, I, V, F, M U - Bodoy et al., 2005
Orphan transporters:
SLC7A4 CAT-4 - Fotiadis et al., 2013
SLC7A14 - Fotiadis et al., 2013
SLC36A3 PAT3 - Schiöth et al., 2013
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Gene name    
(SLC ID)
Protein name Associated 
transport system
Amino acid 
substrates*
Transport 
mechanism
Ion dependency References
SLC38A6 SNAT6 - Schiöth et al., 2013
SLC38A8 - Schiöth et al., 2013
SLC38A9 - Schiöth et al., 2013
SLC38A10 - Schiöth et al., 2013
SLC38A11 - Schiöth et al., 2013
SLC43A3 EEG1 - Bodoy et al., 2013
Di/Tripeptide transporters:
SLC15A1 PepT1 di- and tripeptides S H+ Smith et al., 2013
SLC15A2 PepT2 di- and tripeptides S H+ Smith et al., 2013
SLC15A3 PhT2 di- and tripeptides S H+ Smith et al., 2013
SLC15A4 PhT1 di- and tripeptides S H+ Smith et al., 2013
Other amino acid transporters:
SLC6A1 GAT1 GABA Pramod et al., 2013
SLC6A6 TauT b Taurine Pramod et al., 2013
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Amino acids are given by their one-letter codes. *Substrates with a low transport affinity are given in parentheses. AA, amino acids; CAA, cationic 
amino acids; NAA, neutral amino acids; O, ornithine; C-C, cystine; A, antiport; S, symport; U, uniport. Protein names and associated transport systems 
represent the traditional naming system for amino acid transporters. 
 
Gene name    
(SLC ID)
Protein name Associated 
transport system
Amino acid 
substrates*
Transport 
mechanism
Ion dependency References
SLC6A11 GAT-B, GAT-3 GABA Pramod et al., 2013
SLC6A12 BGT1 GABA, Betaine Pramod et al., 2013
SLC6A13 GAT2 GABA Pramod et al., 2013
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2.4 Amino Acid Transporters in Cancer 
Cancer cell lines support their increased demand for nutrients by upregulating the 
expression of nutrient transporters (Ganapathy et al., 2009). Amino acid transporters 
reported to be upregulated in many cancer cell lines include four neutral transporters: 
ASCT2 (SLC1A5), LAT1/4F2hc (SLC7A5/SLC3A2), SNAT5 (SLC38A5), and ATB0,+ 
(SLC6A14), plus the anionic transporter xCT/4F2hc (SLC7A11/SLC3A2) (Fuchs and 
Bode, 2004; Ganapathy et al., 2009; Karunakaran et al., 2011). 
A detailed review of neutral amino acid transport in cancer concluded that the 
majority of cancers preferentially increase their expression of ASCT2 and LAT1 over 
other neutral amino acid transporters, though ATB0,+ expression was not considered in 
this analysis (Fuchs and Bode, 2004). ASCT2 is a Na+-dependent obligatory amino acid 
antiporter that transports a broad range of small neutral amino acids (Utsunomiya-Tate 
et al., 1996). Because of its high affinity for glutamine (Table 2.1), upregulation of 
ASCT2 expression has been hypothesised to support mitochondrial glutaminolysis 
during cell proliferation (Wise and Thompson, 2010). LAT1 is a Na+-independent 
obligatory amino acid antiporter that transports neutral amino acids with large, branched 
or aromatic side-chains, which includes the mTORC1 activating leucine (Kanai et al., 
1998; Mastroberardino et al., 1998). In contrast to ASCT2 and LAT1, ATB0,+ can 
transport all neutral and cationic amino acids but not aspartate and glutamate 
(Karunakaran et al., 2011). The transport of 18 amino acids through a single transporter 
may however not be beneficial to a proliferating cell as important amino acids such as 
glutamine and leucine will compete with each other for cell entry.  
Nicklin et al. (2009) identified a two-step transport mechanism in HeLa cells by 
which ASCT2 and LAT1 are functionally coupled to regulate mTORC1 activation. 
Glutamine is first transported into the cell through ASCT2 and then serves as an efflux 
substrate through LAT1 for leucine uptake, which subsequently activates mTORC1. 
The transport of glutamine was found to be rate limiting for mTORC1 activation. This 
is consistent with the finding that LAT1 has an intracellular affinity for amino acids that 
is around 100-fold lower than on the extracellular side (Meier et al., 2002), meaning a 
high intracellular concentration of glutamine is first required to stimulate leucine influx. 
Interestingly, MCF7 cells have a high basal intracellular concentration of glutamine and 
are therefore not dependent on glutamine influx through ASCT2 for leucine uptake and 
mTORC1 activation (Nicklin et al., 2009). This study demonstrates the existence of 
functional relationships between transporters and how metabolic processes can regulate 
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transport activity. This could have some important implications for recombinant CHO 
cells using the glutamine synthetase system when compared to the parental host cells. 
Mammalian cells require the activity of uniporters to net accumulate amino 
acids. In the transport mechanism described above, ASCT2 and LAT1 antiporter 
activity function together to modify the relative composition of the existing intracellular 
pool in favor of leucine. Boer (2002) proposed that intracellular glutamine accumulated 
through uniport transporters from systems A and N may act as an efflux substrate for 
antiporters belonging to systems ASC and L. In support of this model, coexpression of 
the system A uniporter SNAT2 (SLC38A2) with LAT1 enhanced leucine uptake in X. 
laevis oocytes (Baird et al., 2009). The expression of the system N SNAT5 in some 
cancer cell lines (Fuchs & Bode, 2004; Wise et al., 2008) may therefore be supporting 
antiporter function in addition to glutamine uptake. The efflux of alanine (a ASCT2 
substrate) as a waste product during cell proliferation may however be enabling ASCT2 
to effectively act as a uniporter and accumulate glutamine in place of a system A or N 
transporter. 
Just one transporter mediates system XC- activity – the xCT antiporter. xCT 
provides the primary import route for cystine (oxidative product of two cysteine 
molecules) in exchange for exporting intracellular glutamate (Fotiadis et al., 2013; Sato 
et al., 1999). Cysteine is oxidised to cystine in culture medium and the xCT transporter 
is commonly expressed in cultured cell lines to support its uptake (Ganapathy et al., 
2009). Within the cell, cystine is reduced back to cysteine and can be directed towards 
the biosynthesis of GSH. Incorporation of cysteine into GSH is the rate-limiting step in 
its synthesis (Griffith, 1999). The relationship between system XC- activity and GSH 
synthesis has been examined (Chung et al., 2005; Shih et al., 2006). System XC- 
inhibition in human glioma cell lines exhibiting high expression of xCT resulted in 
rapid depletion of total intracellular GSH and caspase-mediated apoptotic cell death 
(Chung et al., 2005). Whereas ectopic overexpression of xCT was shown to increase 
GSH content and offer increased protection from oxidative stress conditions in neuronal 
rat cells (Shih et al., 2006). Activity of high-affinity glutamate uniporters belonging to 
system XAG- can support GSH synthesis by accumulating intracellular glutamate, which 
is subsequently exported through xCT for cystine import (Lewerenz et al., 2006). This 
is an example of the functional coupling between uniporters and antiporters as proposed 
by Boer (2002). 
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Figure 2.3 summarises the transport activities of the transporters described 
above and how they function to support the metabolic and signaling pathways that 
promote cell proliferation. 
 
Figure 2.3 Amino acid transporters are functionally coupled to metabolic and 
signaling pathways that promote cell proliferation. 
 
 
2.5 Amino Acid Transporters as Potential Cell Engineering Targets 
Metabolic engineering can significantly improve the productivity of mammalian cell 
lines. Most strategies have targeted genes involved in pyruvate metabolism with the aim 
of decreasing lactate accumulation during culture. For example, overexpression of 
pyruvate carboxylase (PC) in BHK-21 or CHO cells has been shown to significantly 
decrease lactate production, improve culture viability, increase product titres, and 
elevate the ATP content of cells by increasing carbon flux into the TCA cycle  (Fogolin 
et al., 2004; Irani et al., 1999; Kim and Lee, 2007). An alternative engineering strategy 
has been to knock down gene expression. Zhou et al. (2011) stably expressed small 
inhibitory RNAs (siRNA) against lactate dehydrogenase (LDH) and three pyruvate 
dehydrogenase (PDH) kinases (PDHK) whose function is to phosphorylate PDH, which 
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inhibits PDH activity. Simultaneously reducing LDH and PDHK expression decreased 
lactate levels and increased antibody production in CHO cells. 
Amino acid transporters represent a novel metabolic engineering target because 
their substrates often feed into several cellular processes that promote growth (Figure 
2.3). Similar to overexpression of mTOR discussed above (section 2.2.1), increased 
expression of amino acid transporters have the potential to simultaneously improve 
growth, viability, and productivity. A limited number of studies have attempted to 
engineer mammalian metabolism by targeting transporters. Paredes et al. (1999) used 
siRNA against GLUT1 (SLC2A1), a high-affinity glucose transporter, to reduce glucose 
consumption. Wlaschin and Hu (2007) demonstrated that stable expression of GLUT5 
(SLC2A5), a fructose-specific transporter, could improve cell growth and reduce lactate 
production when the main carbon source was switched to fructose. Recently, Tabuchi et 
al. (2010) demonstrated that overexpression of TauT (SLC6A6), a taurine transporter, 
can increase culture viability and productivity. TauT helps osmoregulates cells by 
transporting taurine (Pramod et al., 2013). However, TauT overxpression stimulated 
increased glutamine consumption and an upregulation of genes involved in GSH 
metabolism compared to the parental cell line (Tabuchi et al., 2010). 
 
  
2.6 Summary 
The growth of transformed cell lines including CHO cells is supported by amino acids. 
They can be used directly for macromolecule synthesis (proteins and nucleic acids) and 
protection against oxidative stress (GSH production), however removal of the amine 
group leaves a carbon skeleton that can be used for biomass synthesis or anaplerosis of 
the TCA cycle to support ATP and NADPH production. Amino acids also have a 
critical role in signaling to pathways that regulate global protein synthesis (mTORC1 
and AAR). Cancer cells, as examples of transformed cell lines, support proliferation at 
high cell densities by upregulating the expression of certain amino acid transporters. 
These proteins are unique in that they interface with both the extra- and intracellular 
environment, coupling amino acid influx to metabolic and signaling pathways that 
promote cell growth. Amino acid transporters therefore represent an attractive group of 
proteins to investigate further in CHO cells as an understanding of their activity could 
support media design or open up new cell engineering strategies to improve biomass 
synthesis. Preliminary evidence in the literature suggests that manipulating amino acid 
transporter expression in CHO cells can improve productivity.  
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2.7 Thesis Overview 
CHO cells meet the major industrial manufacturing requirements for bringing a 
recombinant therapeutic mAb to market, securing them as the dominant mammalian 
expression system. However, the biotechnology industry is continually looking at ways 
to reduce process development timelines and further increase mAb titres to meet current 
and future patient demands. A significant level of research has been directed towards 
understanding CHO cell metabolism, including amino acids, with the aim of identifying 
cell line engineering targets or rational methods of optimising media compositions to 
improve cell line productivity. Yet, the intracellular availability of amino acids is 
controlled by a system of transporter proteins whose function remains largely unknown 
in CHO cells. The first aim of this thesis is to address this knowledge gap by 
characterising amino acid transport processes in CHO cells and to understand how they 
might support culture performance (Chapters 4 & 5). The second aim is to use this 
knowledge as a basis for exploring ways to improve cell growth and antibody 
production. Both a cell engineering strategy (Chapter 6) and media design strategy 
(Chapter 7) is explored. 
The first objective in characterising amino acid transport processes was to 
understand how transporter expression correlates with growth rate, cell viability, and 
IgG antibody titre. In Chapter 4, Illumina next-generation sequencing was used to 
measure the expression of amino acid transporter genes in a parental host and two 
recombinant cell lines throughout a fed-batch process. The data was analysed to identify 
key transporters and investigate expression differences between the three cell lines at 
exponential and stationary growth phases. The results indicated that GLAST (SLC1A3, 
system X-AG) expression acted as a marker for GS expression, while ASCT1 (SLC1A4, 
system ASC), LAT1 (SLC7A5, system L), and xCT (SLC7A11, system XC-) expression 
acted as potential markers for production of a recombinant IgG antibody. Furthermore, 
the xCT transporter was significantly upregulated in all cell lines at stationary phase and 
formed part of a larger adaptive response to support cellular availability of GSH. 
Despite xCT upregulation, cystine influx is identified as a bottleneck in GSH synthesis.  
Chapter 5 builds upon Chapter 4 by disrupting the activity of amino acid 
transporters and evaluating the impact this has on culture performance parameters. Cells 
were treated with inhibitors that block amino acid movement through specific 
transporter(s). The results confirmed that LAT1 and xCT transport activity supports 
recombinant antibody production, while xCT transport was also confirmed as a key 
determinant of culture viability throughout culture for all cell lines. The glycine 
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transporter GlyT1 (SLC6A9) was also found to support antibody production during late 
culture. Inhibition of branched-chain and aromatic amino acid transport was found to 
inhibit cell growth in all cell lines. For non-essential amino acids, the primary entry 
route for glutamine in parental CHO cells is through system ASC transporters, 
inhibition of which results in cell death. In contrast, recombinant GS cells were found to 
be highly dependent on SNAT2 (SLC38A2, system A) activity for cell growth. 
In Chapter 6, a directed evolution method was established to isolate sub-
populations of the parental host and an antibody-producing cell line resistant to xCT 
transport inhibition. It was hypothesised that these cells would have increased xCT 
transport activity and provide the cells with a greater capacity for cystine import to 
support GSH and antibody synthesis. The evolved host demonstrated increased rates of 
GSH synthesis, a better ability to deal with an oxidative stress insult, and a heritable 
improvement in cell growth compared to the non-evolved host. Results regarding 
specific productivity with the evolved antibody-producing cell line were inconclusive 
and require further investigation. A sub-population of host cells resistant to system ASC 
inhibition was also isolated. Neither these cells, nor the host cells with evolved 
resistance to xCT inhibition were able to outperform the non-evolved parental host in 
the transient production of a recombinant IgG antibody. The work in this chapter 
demonstrates that it is possible to isolate cell lines with desirable characteristics for 
biomanufacturing through manipulation of amino acid transport processes. It however 
also requires further chracterisation work, which is discussed. 
Chapter 7 explores how knowledge of CHO transport processes can be used to 
rationally direct the optimisation of amino acid concentrations in basal and feed media. 
In this chapter a mechanistic model for essential amino acid transport is constructed 
from data generated in Chapters 4 and 5. This model, validated with a subset of data 
from Chapter 5, demonstrates a hypothetical approach to controlling amino acid 
consumption rates through modulation of extracellular concentrations. A discussion is 
provided on how this can then be exploited to maximise the changing biomass 
objectives throughout cell culture. 
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Chapter 3 
Materials and Methods 
 
This chapter describes general experimental techniques used throughout the subsequent 
results chapters. Experiments requiring specialised techniques are described in the 
relevant results chapters.  
 
 
3.1 Cell Lines and Culture 
3.1.1 Cell Lines 
MedImmune kindly provided their proprietary suspension-adapted parental CHO host 
cell line (CAT-S) and four stable recombinant cell lines (GS-Null, T29, T48 and T127). 
The GS-Null cell line was transfected with an empty glutamine synthetase (GS) vector. 
The T29, T48 and T127 cell lines were transfected with a vector containing genes for 
GS, and the heavy and light chains of a human IgG monoclonal antibody (mAb-109). 
 
3.1.2 Routine Sub-Culture 
All cell lines were sub-cultured every 3–4 days at a seeding density of 2 x 105 cells.mL-1 
in 25 mL of CD-CHO medium (Life Technologies, Paisley, UK) in 125 mL vented 
Erlenmeyer flasks (Corning, Surrey, UK) shaking at 140 rpm in 37oC and 5% CO2 air 
(Infors UK, Reigate, UK). CAT-S and recombinant cells were supplemented with 8 mM 
L-glutamine (Life Technologies) and 50 µM L-methionine sulfoximine (Sigma-Aldrich, 
Dorset, UK) respectively. Routine assessment of cell concentration and viability was 
performed by automated trypan blue exclusion using a Vi-CELL Cell Viability 
Analyzer (Beckham Coulter, High Wycombe, UK). 
 
3.1.3 Cell Growth Parameters 
Three parameters were used to describe cell growth: i) Growth rate (µ), ii) Integral of 
viable cell density (IVCD), and iii) Generation number (GN). 
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3.1.3.1 Cell Specific Growth Rate 
The cell specific growth rate (µ) represents the rate of cell biomass accumulation and 
was calculated with equation 2.1: 
 !!(hr!!) != ln VCD!VCD! ∗ ! 1t! − t!  
 
Where, VCD1 and VCD2 is the viable cell density (x106 cells.mL-1) at the first and 
second time point t (hr-1) respectively. 
 
3.1.3.2 Integral of Viable Cell Density 
The integral of viable cell density (IVCD) is the area under the growth curve. It 
quantifies the number of working cell hours per unit volume of culture and was used to 
calculate specific transport rates of amino acids (section 3.2) and antibody production 
(section 3.3). IVCD was calculated with equation 2.2: 
 IVCD!(10!cell. hr.mL!!) != ! VCD! + VCD!2 ∗ (!t! − t!) 
 
3.1.3.3 Generation Number 
The generation number (GN) is a measure of cell age and was calculated with equation 
2.3: 
 GN! = ln VCD!VCD! ∗ ! 1ln(2) 
 
 
3.2 Extracellular Amino Acid Analysis  
Culture samples were centrifuged at 200g for 5 min. The supernatant was removed and 
frozen at -80oC until analysis. Quantification of amino acids was performed at 
MedImmune by Dr Chris Sellick using the Waters Acquity UPLC® Amino Acid 
Analysis (AAA) Solution (Waters, Hertfordshire, UK). Specific amino acid transport 
rates were calculated with equation 2.4: 
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Specific!amino!acid!transport!rate!(nmol. 10!cell!!. hr!!) = ! AA! − AA!IVCD! − IVCD! 
 
Where, AA1 and AA2 is the amino acid concentration (nmol.mL-1) at the first and 
second time point respectively. 
 
 
3.3 Antibody Quantification  
Culture samples were centrifuged at 200g for 5 min. The supernatant was removed and 
frozen at -80oC until analysis. Quantification of antibody was performed using either a 
FastELYSA Human Immunoglobulin G Quantification Kit (RD Biotech, Besançon, 
France), or at MedImmune by Dr Chris Sellick using either an in-house Protein A 
chromatography method or the Octet® System (Pall Life Sciences, Portsmouth, UK). 
Specific monoclonal antibody productivity (QmAb) rates were calculated with equation 
2.5: 
  Q!"#!(mg!mAb. 10!cell!!. hr!!) = ! mAb! −mAb!IVCD! − IVCD! 
 
Where, mAb1 and mAb2 is the IgG antibody concentration (mg.mL-1) at the first and 
second time point respectively. 
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Chapter 4 
Amino Acid Transporter Gene Expression 
Analysis in CHO Cells Using RNA-Sequencing 
 
This chapter characterises the expression of amino acid transporter genes in a parental 
CHO host and two recombinant cell lines throughout a fed-batch process. Illumina 
next-generation sequencing data in combination with measured amino acid transport 
rates were analysed to identify seven key CHO transporters required to support culture 
performance. The expression of three transporters: SLC1A4, SLC7A5, and SLC7A11, 
correlated well with productivity and warrant further investigation as potential targets 
for cell engineering strategies to improve cell line productivity.  
 
 
4.1 Introduction 
As discussed in Chapters 1 and 2, amino acids support the growth of mammalian cells 
in a plethora of ways and optimisation of their concentrations in culture medium has 
helped to significantly improve cell line productivity in fed-batch processes. However, 
intracellular availability of amino acids is controlled by a system of membrane transport 
proteins whose function remains largely unknown in CHO cells. Understanding how the 
expression and activity of these transporters correlates with critical culture performance 
parameters such as growth rate, cell viability, and product titre could help identify 
potential bottlenecks in amino acid transport and/or offer new opportunities for 
improving cell line productivity.  
The identity of amino acid transporters in CHO cells is just emerging. Early 
research found transport systems for neutral amino acids (A, ASC, and L), cationic 
amino acids (y+), and anionic amino acids (XAG- and XC-) in CHO cells (Ash et al., 
1993; Bass et al., 1981; Igo and Ash, 1998; Rotoli et al., 1989; Shotwell et al., 1981). 
But it was not until the development of CHO-specific DNA microarrays (Melville et al., 
2011; Wlaschin et al., 2005) that expression of individual transporters began to be 
identified in industrial cell lines (Birzele et al., 2010; Clarke et al., 2011; Doolan et al., 
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2010; Shen et al., 2010). However, only a fraction of all mammalian transporters were 
found using microarrays due to incomplete coverage of the CHO transcriptome. 
Subsequent studies using next-generation sequencing (NGS) platforms expanded 
transcriptome coverage and identified the expression of additional CHO amino acid 
transporters (Becker et al., 2011; Birzele et al., 2010). Recent CHO genome sequencing 
projects have now predicted the existence of almost all amino acid transporter genes 
(Lewis et al., 2013; Xu et al., 2011) and has been used to help identify further 
transporters at both the transcriptomic (Kyriakopoulos et al., 2013) and proteomic level 
(Baycin-Hizal et al., 2012). To date, of the 61 mammalian genes known to encode 
proteins with amino acid transport activity at the plasma membrane, 56 have been 
identified in the CHO genome and 46 have been found expressed at either the 
transcriptomic or proteomic level. A full list can be found in Appendix Table A1. Of the 
amino acid transporters reported to be upregulated in cancer cell lines (see Chapter 2; 
Section 2.4), all but ATB0,+ (SLC6A14) have had their expression identified in CHO 
cells.  
Comparative CHO transcriptomic studies have also been used to help identify 
genes whose expression are associated with desirable cellular biomanufacturing 
characteristics such as Qp (Harreither et al., 2005) or high growth rate (Doolan et al., 
2010), and to understand the biological mechanisms by which process control strategies 
such as temperature shift (Kantardjieff et al. 2010) and the inclusion of media 
components such as copper (Yuk et al., 2014) or sodium butyrate (Yee et al., 2008; 
Kantardjieff et al. 2010) can enhance cell line productivity. In these studies, the authors 
analyse the transcriptional response to a treatment compared to control conditions to 
identify differentially expressed genes (upregulated or downregulated) that are then 
mapped back to biological pathways. Such studies have helped to identify genes, 
cellular pathways or processes that are amenable to engineering approaches to increase 
cell line productivity. For example, Doolan et al. (2010) investigated differences in the 
transcriptome and proteome of four CHO cells with either a fast or slow growth rate. 
The authors identified 21 genes associated with a high cell proliferation rate phenotype, 
5 of which were investigated further by manipulating their expression with siRNA or 
overexpression. Interestingly, overexpression of valosin-containing protein (VCP), a 
gene not obviously identified as having a growth-related function, could increase cell 
densities by 2.1-fold. The authors concluded that transcriptomic approaches in CHO 
cells offer a non-hypothesis-limited approach to cell engineering strategies. Other 
studies have also used transcript profiling to focus on specific cellular pathways. Wong 
! 41 
et al. (2006a) used a CHO-specific DNA microarray to compare the transcriptomes of a 
CHO cell line producing a recombinant human interferon gamma (IFN-γ) at different 
growth phases of batch and fed-batch cultures. The authors focused their analysis on 
apoptosis-related genes and identified 2 anti-apoptotic genes (Fadd and Faim) and 2 
pro-apoptotic genes (Alg-2 and Requiem) that were overexpressed and knocked down 
respectively in a subsequent cell line engineering study (Wong et al., 2006b). All four 
approaches were able to delay the onset of apoptosis in batch and fed-batch cultures, 
which increased IFN-γ titres up to 2.5-fold due to extended periods of high culture 
viabilities. Kyriakopoulos et al. (2013) is the only transcriptomic study to purposely 
investigate amino acid transporter expression in CHO cells. By performing qRT-PCR, 
they identified the expression of 22 amino acid transporter genes in three CHO cell lines 
grown in batch culture: a non-producer expressing the glutamine synthetase vector, and 
two antibody-producing cell lines differing in their specific productivity. Of this subset, 
21 were proteinogenic amino acid transporters, all of which were upregulated at 
stationary phase for all cell lines with the largest change observed for the SLC7A11 
(xCT, system XC-) transporter (up to 16-fold). As discussed in Chapter 2, GSH synthesis 
is critically dependent upon xCT activity for cystine uptake (Chung et al., 2005; Shih et 
al., 2006). In addition to SLC7A11, Kyriakopoulos et al. (2013) found transporters for 
glycine and glutamate, also required for GSH synthesis, to be significantly upregulated 
for all cell lines at stationary phase. This is suggestive that CHO cells, independent of 
recombinant protein production, may be modifying their transporter expression at 
stationary phase to support GSH synthesis. 
Kyriakopoulos et al. (2013) focused their data analysis on significant fold-
changes in expression and did not take into account transcript abundance. However, a 
reanalysis of their data revealed some interesting biological conclusions that were 
missed by the authors. For example, similar to observations in cancer cell lines, there 
was high expression of SLC7A5 (LAT1, system L), SLC7A11, and their heterodimeric 
partner SLC3A2 (4F2hc) for all three cell lines. But unlike cancer cells, expression of 
SLC1A5 (ASCT2, system ASC) was low and SLC38A2 (SNAT2, system A) was very 
high, suggesting a difference in transport mechanism of small neutral amino acids such 
as asparagine and serine in CHO cells. There was also equally high expression of the 
aspartate/glutamate SLC1A3 (GLAST, system XAG-) transporter, indicating a possible 
adaptation of cells expressing glutamine synthetase to glutamine free media. The 
parental host cell line was not analysed however, which could have confirmed this. A 
comparison of gene expression between the three cell lines found SLC43A1 (LAT4, 
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system L) and SLC1A2 (GLT-1, system XAG-) to be significantly upregulated at all time 
points in culture for antibody-producing cells. The authors suggested that these two 
transporters could be used as possible biomarkers for productivity. However, the 
biological significance of these markers is unclear. For example, transcript abundance 
of SLC1A2 was just a fraction of the abundance of SLC1A3 and both transporters share 
identical transport kinetics (Danbolt, 2001), suggesting the biological function of GLT-
1 is insignificant. A similar comparison can be made with LAT4 and LAT1. 
In this chapter, a proprietary parental CHO host cell line (CAT-S) and two 
recombinant cell lines transfected with either an empty glutamine synthetase (GS) 
vector (GS-Null) or a human IgG mAb (T127) were grown in a fed-batch process. 
Illumina next-generation sequencing was used to sequence the transcriptome of the 
three cell lines at exponential and stationary growth phases. Data on amino acid 
transporter expression were extracted from the data sets to identify key transporters and 
investigate possible expression differences between the three cell lines throughout 
culture. Seven transporters were highly expressed in all three cell lines which 
collectively account for the transport of all 20 proteinogenic amino acids: SLC1A4 
(ASCT1, system ASC), SLC7A1 (CAT-1, system y+), SLC1A3, SLC7A5, SLC38A2, 
SLC7A11, and y+LAT2 (SLC7A6, system y+L). Of these, SLC1A3 expression acted as 
a marker for glutamine synthetase expression. While SLC1A4, SLC7A5, and SLC7A11 
were identified as potential markers for antibody production in the T127 cell line. 
Similar to observations reported by Kyriakopoulos et al. (2013), SLC7A11 expression 
was significantly upregulated at stationary phase in all cell lines. This was found to 
form part of a larger adaptive response to support cellular availability of GSH. 
However, measurements of cystine transport rates indicate that despite the upregulation 
of SLC7A11, cystine transport represents a bottleneck. Together these data 
demonstrated that ASCT1, LAT1, and xCT warrant further investigation as potential 
targets for cell engineering or selection strategies to improve cell line productivity. 
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4.2 Materials and Methods 
This section describes the materials and methods used for RNA sample preparation, 
sequencing, and transcriptome assembly only. The reader is referred to Chapter 3 for 
details on all other experimental techniques performed in this chapter. 
 
4.2.1 Cell Culture 
Fed-batch cultures were performed in parallel duplicate 1-L DASGIP® benchtop 
stirred-tank bioreactors (Eppendorf, Stevenage, UK). Bioreactors were inoculated at 
approximately 5 x 105 viable cells.mL-1 in 800 mL of CD-CHO medium (Life 
Technologies, Paisley, UK). The bioreactor environment was controlled using DASGIP 
Control 4.0 software (Eppendorf, Stevenage, UK) with the following set points: 
agitation 175 rpm; temperature 36.5oC; dissolved oxygen (DO) 50%; pH range 6.8 ± 
0.1. Temperature was controlled using a heater blanket; DO by sparging with a blend of 
air and oxygen; pH using CO2 or 1 M NaHCO3. Cultures were maintained for 14 days 
by feeding 10% of the initial culture volume of a proprietary chemically defined 
nutrient feed every 48 hr from day 2 onwards. Glucose was measured daily offline using 
a NOVA 100 Bioprofile Analyzer (Nova Biomedical, Cheshire, UK) and maintained at 
8 g.L-1 using a separate feed. CAT-S cells were supplemented with 8 mM L-glutamine 
(Life Technologies) at day 0. 
 
4.2.2 Sample Collection 
Duplicate samples of 5 x 106 viable cells were collected daily from each bioreactor. 
Samples were centrifuged at 300g for 5 min, washed once in room temperature PBS, 
and recentrifuged to remove the supernatant. Cell pellets were snap frozen on dry ice 
before storing at -80oC until RNA extraction. 
 
4.2.3 RNA Extraction 
Total RNA was extracted from samples using the RNeasy® Mini Kit (QIAGEN, 
Manchester, UK). In brief, samples were lysed and homogenised in the presence of 
guanidine salt buffers and passed through a silica membrane within a spin column. The 
membrane selectively binds RNA molecules longer than 200 nucleotides, which 
enriched the extracted samples for mRNA molecules. An on-column DNase I digestion 
using the RNase-Free DNase Set (QIAGEN, Manchester, UK) was performed to 
remove contaminating genomic DNA. 
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4.2.4 RNA Assessment 
RNA integrity was assessed using a 2100 Bioanalyzer (Agilent Technologies, Cheshire, 
UK). This is an automated microfluidic device that offers a standardised method of 
assessing RNA integrity (reviewed in Schroeder et al., 2006). The device separates 
RNA samples according to their molecular weight and examines multiple features 
associated with 28S and 18S ribosomal RNA (rRNA) peaks, which then get analysed by 
an algorithm to generate a RNA Integrity Number (RIN). RIN is graded on a scale of 1 
(totally degraded RNA) to 10 (intact). All samples had a RIN > 9.  
RNA purity was assessed using a NanoDrop 2000 Spectrophotometer (Thermo 
Scientific, Loughborough, UK). The ratio of absorbance at 260 nm and 280 nm 
(A260/280), and at 260 nm and 230 nm (A260/230) was used to check for carry-over of 
guanidine salts or other contaminants from the RNA extraction step. All samples were 
free of contaminants.  
 
4.2.5 Library Preparation and Sequencing 
Library preparation and sequencing was outsourced to The Genome Analysis Centre 
(Norwich, UK). Indexed cDNA libraries were constructed using the TruSeq® RNA 
Sample Prep Kit (Illumina, Little Chesterford, UK). In brief, poly(A) containing mRNA 
molecules were extracted from total RNA using poly(T) oligo-attached magnetic beads 
through two rounds of selection. During the second poly(A) purification round, the 
RNA was fragmented to help minimise secondary structure formations (Zeng and 
Mortazavi, 2012). First strand cDNA synthesis was performed on the fragmented RNA 
molecules using reverse transcriptase and random primers. Following second strand 
synthesis, 3’ and 5’ overhangs were removed, and a single A nucleotide was added to 
the 3’ end for subsequent adaptor ligation. Index adaptor oligos were then ligated to 
both ends of the cDNA and fragments were amplified by PCR to create the final cDNA 
libraries. 
 Indexed cDNA libraries were sequenced using the Illumina HiSeq 2000 System 
(Illumina, Little Chesterford, UK). 12 libraries were loaded over 4 flow cell lanes (3 
libraries per lane) and sequenced using 100 bp paired-end reads. Across the 12 libraries 
66,085,235 ± 3,954,267 (mean ± SD; n = 12) sequence reads were obtained. 
 
4.2.6 Read Mapping and Transcriptome Assembly 
Read mapping and transcriptome assembly was outsourced to The Genome Analysis 
Centre (Norwich, UK) and performed using the Tuxedo analysis package (Trapnell et 
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al., 2012). In brief, sequence reads were first mapped to the Bioprocessing Research 
Industry Club (BRIC) sequenced reference CHO-K1 (ECACC catalogue number 
85051005) genome with TopHat. Mapped reads were then provided to Cufflinks to 
assemble transcripts and estimate their abundance. Transcript abundance within each 
library was normalised by transcript length and the total number of sequence reads 
obtained to generate FPKM (fragments per kilobase of transcript per million fragments 
mapped) values (reviewed in Trapnell et al., 2012). Cuffdiff was subsequently used to 
compare experimental conditions to identify differentially expressed genes. This 
analysis package tested the observed log2 fold change in gene expression against the 
null hypothesis of no change (Trapnell et al., 2012). Significance was determined by 
assessing the false discovery rate (FDR) adjusted P-values (Q-values), which was used 
to reduce the number of false-positives.  
 
 
4.3 Results 
4.3.1 Growth Profiles and RNA-Sequencing Sample Selection 
The parental host cell line (CAT-S), a stable transfectant pool expressing the empty 
glutamine synthetase vector (GS-Null) and a non-clonal cell line expressing an IgG 
antibody (T127) were grown in fed-batch operations. Growth profiles of the CAT-S, 
GS-Null, and T127 cell lines are shown in Figure 4.1. The three cell lines were grown in 
parallel duplicate fed-batch operations but the T127 cell line failed to grow in the 
second bioreactor. Both CAT-S and T127 cells had an extended exponential growth 
period and reached stationary phase on day 8 compared to day 6 for the GS-Null cell 
line. During stationary phase CAT-S and T127 cells diverged in growth with the latter 
able to maintain higher culture viability until day 14. 
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Figure 4.1 Production characteristics of CAT-S, GS-Null, and T127 cells grown in 
a 14-day fed-batch operation. CAT-S (blue) and GS-Null (green) cells were grown in 
parallel duplicate 1-L bioreactors (mean ± SEM, n = 2). T127 (red) cells were grown in 
a single bioreactor. (A.) Viable cell density (VCD). (B.) Daily growth rates. (C.) 
Culture viability. (D.) IgG titre and specific productivity (QmAb) across the culture 
period for T127 cells only. 
 
 
Duplicate samples were taken from a single representative bioreactor at days 4 
(mid-exponential) and 8 (stationary) for each cell line and used for RNA-sequencing. 
The growth rate (d-1) at day 4 was approximately equivalent for the three cell lines (0.44 
± 0.03; mean ± SEM) and cell specific productivity for the T127 cell line was 11.0 pg 
mAb.cell-1.d-1. At day 8 all cell lines had culture viabilities greater than 80% and the 
growth rate became negligible (0.05 ± 0.01; mean ± SEM) but cell specific productivity 
increased approximately 3-fold to 28.9 pg mAb.cell-1.d-1.  
 
4.3.2 Transcriptome Data Sets 
The mRNA species from the 12 samples described above was sequenced by synthesis 
using the Illumina HiSeq 2000 System. From each sample, 66 ± 4 million 100-bp reads 
(mean ± SD) was obtained and mapped to the Bioprocessing Research Industry Club 
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(BRIC) sequenced reference CHO-K1 genome (see 4.2 Materials and Methods). Gene 
expression levels are reported as normalised FPKM values, enabling direct comparisons 
of expression within and between biological samples.  
 
4.3.3 Amino Acid Transporter Expression Analysis 
The transcriptome data sets were mined to obtain average FPKM values for all amino 
acid transporters for each cell line at both exponential and stationary growth phases 
(Appendix Table A2–4). Of the 61 known mammalian transporters, 17 were missing 
from the transcriptome data sets. The remaining 44 transporters were grouped by their 
FPKM values into low, medium, and high expression. Expression boundaries were 
determined by dividing the FPKM values for all genes in each transcriptome data set 
into quartiles (Appendix Table A5) (method adapted from Toung et al., 2011). 
Proteinogenic transporters were then filtered for those whose expression is either 
medium or high (top 75% percentile) relative to the global transcriptome (Table 4.1). 
Applying a FPKM cut-off risks missing biologically important transporters with low 
expression. However, the transporters identified in Table 4.1 can account for the 
transport of all 20 amino acids. Furthermore, many of these transporters have high 
substrate affinities and some have biological significance in cancer cell lines (see 
Chapter 2). 
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Table 4.1 Proteinogenic amino acid transporters with medium or high expression 
at exponential and stationary growth phase 
 
All FPKM values are the average of two independently sequenced samples. aIndicates 
that expression was in the bottom 25th percentile at the given time point but has been 
included in the table for comparison purposes. 
 
 
SLC ID Protein name CAT-S GS-Null T127 CAT-S GS-Null T127
Transporters of small neutral amino acids (broad specificity):
SLC38A2 SNAT2 89.87 127.22 93.19 107.48 149.09 129.40
SLC1A4 ASCT1, SATT 39.08 39.76 76.81 70.68 80.95 243.63
SLC38A7 SNAT7 19.29 20.14 19.62 22.08 16.74 22.06
SLC38A4 SNAT4 3.38a 5.01 7.68 5.92 8.40 7.57
Transporters of small neutral amino acids (narrow specificity):
SLC36A4 PAT4 14.06 17.43 10.89 19.67 23.72 19.91
SLC6A9 GlyT1 4.65 10.31 7.07 8.40 12.25 13.14
SLC36A1 PAT1 7.57 9.53 5.70 9.97 12.40 10.30
Transporters of branch-chained and aromatic amino acids:
SLC7A5 LAT1 58.57 81.76 30.85 77.31 82.27 91.26
SLC43A2 LAT4 28.42 18.41 18.87 26.07 14.62 19.74
SLC6A15 B0AT2, v7-3, NTT7-3 21.29 27.38 16.66 28.16 31.66 20.06
SLC7A15 ArpAT 11.64 9.65 12.76 12.54 12.31 14.12
Transporters of cationic amino acids:
SLC7A1 CAT-1, ATRC1 23.07 25.71 26.09 24.65 26.00 28.31
SLC7A6 y+LAT2 23.98 23.54 23.25 23.86 21.69 20.53
SLC7A7 y+LAT1 7.88 12.05 11.77 9.48 12.73 13.70
Transporters of anionic amino acids:
SLC1A3 GLAST, EAAT1 26.91 46.64 39.35 32.74 50.99 59.95
SLC7A11 xCT 2.89a 9.45 5.99 15.36 22.58 49.86
SLC1A2 GLT-1, EAAT2 0.99a 2.25a 0.90a 2.22a 4.01 2.55a
Heterodimeric/heavy subunit partner:
SLC3A2 4F2hc 113.23 136.64 161.58 128.09 138.43 215.08
FPKM
Exponential Stationary
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4.3.3.1 Proteinogenic Transporter Expression at Exponential Growth Phase 
The 18 transporters in Table 4.1 were first examined to identify transporters with a high 
expression during exponential growth and to detect possible expression differences 
between the three cell lines at this point in culture. 
When ranked in order of increasing expression, four transporters were found to 
be highly expressed in all three cell lines: SLC3A2 (4F2hc, heavy subunit partner of 
multiple SLC7 family transporters), SLC38A2 (SNAT2, system A), SLC1A4 (ASCT1, 
system ASC), and SLC7A5 (LAT1, system L). Both SNAT2 and ASCT1 transport 
small non-essential neutral amino acids such as alanine, asparagine, glutamine, and 
serine. Whereas LAT1 transports both branched-chained and aromatic essential amino 
acids such as leucine and phenylalanine respectively (see Chapter 2; Table 2.1). For the 
two cell lines expressing glutamine synthetase (GS-Null and T127), SLC1A3 (GLAST, 
system XAG-) – a glutamate and aspartate transporter, was also highly expressed. 
Moderate expression of SLC7A1 (CAT-1, system y+) and SLC7A6 (y+LAT2, system 
y+L) in all three cell lines suggests that these transporters facilitate the transport of 
arginine and lysine (the cationic amino acids). 
Differences between the three cell lines were investigated by identifying 
transporters differentially expressed with a statistical significance of Q-value < 0.05 
(Figure 4.2). The effect of recombinant glutamine synthetase on transporter expression 
was first explored by comparing the CAT-S and GS-Null cell lines (Figure 4.2 A). Both 
SLC7A11 (xCT, system XC-) – a cystine and glutamate transporter, and SLC6A9 
(GlyT1) – a glycine transporter, were found to be significantly upregulated by over 2-
fold (log2 value of 1.0) in GS-Null cells. The SLC1A3 transporter was also found to be 
significantly upregulated but just short of a 2-fold increase.   
The effect of antibody expression on transporter expression was then explored 
by comparing the CAT-S and T127 cell lines (Figure 4.2 B). As with GS-Null cells, 
SLC7A11 was again found to be significantly upregulated by over 2-fold in T127 cells. 
Both SLC1A3 and SLC6A9 were also again significantly upregulated but the 
magnitude of increase was lower in the antibody producing cells compared to GS-Null 
cells. Differences in expression unique to antibody producing cells were found with two 
transporters described above as having high FPKM values in all three cell lines: 
SLC1A4 and SLC7A5. The SLC1A4 transporter was found to be significantly 
upregulated by over 2-fold, while the SLC7A5 transporter was found to be significantly 
downregulated by approximately 2-fold in T127 cells. Interestingly, SLC43A2 (LAT4) 
– a second system L transporter with similar selectivity for branched-chain amino acids, 
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was also found to be significantly downregulated in T127 cells during exponential 
growth. Lastly, SLC38A4 (SNAT4) – a second system A transporter with similar amino 
acid selectivity and transport kinetics to SNAT2, was found to be significantly 
upregulated by 2-fold in T127 cells. However, SLC38A4 has a very low FPKM value 
compared to SLC38A2 suggesting that despite the large change in expression, this 
transporter makes a small contribution to the movement of small non-essential neutral 
amino acids in T127 cells during exponential growth. 
 
 
Figure 4.2 Differential expression of amino acid transporter genes between CAT-S, 
GS-Null, and T127 cells at exponential growth phase. (A.) Comparison of CAT-S 
and GS-Null cells. (B.) Comparison of CAT-S and T127 cells. Average (n = 2) log2 
fold change in gene expression was provided by Cuffdiff (see 4.2 Materials and 
Methods). Closed bars represent significant changes in expression (Q-value < 0.05). 
Broken red line at 1.0 indicates a 2-fold change in expression.  
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4.3.3.2 Proteinogenic Transporter Expression at Stationary Growth Phase 
Stationary growth phase is characterised by the arrest of cell proliferation and 
maintenance of high cell viability. For antibody producing cells it is also associated 
with an increase in antibody production compared to exponential growth. Expression of 
the 18 transporters from Table 4.1 was examined to identify any significant differences 
in gene expression that may support these changes in biomass objectives. Two 
comparisons were performed: within culture for a given cell line (Figure 4.3) and 
between cell lines at stationary phase (Figure 4.4), the latter identical to the previous 
analysis for exponential growth. 
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Figure 4.3 Differential expression of amino acid transporter genes within culture. (A.) CAT-S, (B.) GS-Null, and (C.) T127 cells had their 
expression compared at exponential and stationary growth phase. Average (n = 2) log2 fold change in gene expression was provided by Cuffdiff. 
Closed bars represent significant changes in expression (Q-value < 0.05). Broken red line at 1.0 indicates a 2-fold change in expression.  
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Figure 4.4 Differential expression of amino acid transporter genes between CAT-S, 
GS-Null, and T127 cells at stationary growth phase. (A.) Comparison of CAT-S and 
GS-Null cells. (B.) Comparison of CAT-S and T127 cells. Average (n = 2) log2 fold 
change in gene expression was provided by Cuffdiff (see 4.2 Materials and Methods). 
Closed bars represent significant changes in expression (Q-value < 0.05). Broken red 
line at 1.0 indicates a 2-fold change in expression. 
 
 
Transition into stationary growth phase was associated with a significant 
upregulation of SLC7A11 in all three cell lines (Figure 4.3). The magnitude of increase 
was largest in the T127 cells (8-fold) such that its expression is now 3-fold higher than 
the host cell line and one of the most abundantly expressed transporters in T127 cells 
(Figure 4.4 B and Table 4.1). Expression of SLC7A11 is associated with GSH synthesis 
and resistance to ROS (Chung et al., 2005; Shih et al., 2006). Interestingly, CAT-S and 
T127 cells, which demonstrated the largest upregulation of SLC7A11, also demonstrate 
a large significant upregulation of the glutamate and glycine transporters SLC1A2 
(GLT-1, system XAG-) and SLC6A9 respectively (Figure 4.3). The same observation 
was made by Kyriakopoulos et al. (2013). Increased expression of SLC7A11 was found 
to correlate with increased cell viability in T127 cells compared to the host and GS-Null 
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cell line (Figure 4.1 C). In addition to SLC7A11 the SLC1A4 transporter was also 
found to be significantly upregulated in all three cell lines (Figure 4.3). SLC1A4 
expression is now the most abundant transporter in T127 cells with an expression 3-fold 
higher than the host cell line (Figure 4.4 B and Table 4.1). A change unique to the 
antibody expressing cell line is the significant upregulation (3-fold) of the SLC7A5 
transporter. Whilst found to be downregulated compared to the host and GS-Null cell 
lines during exponential growth, the transporter is now expressed equivalently across 
the three cell lines (Figure 4.4). 
Ranking the 18 transporters in order of increasing expression again shows that 
SLC3A2 and SLC38A2 remain amongst the most abundant transporters during 
stationary growth in all cell lines with no considerable change in expression from 
exponential growth (Table 4.1 and Figure 4.3). SLC1A3 expression also remains high 
in the two glutamine synthetase expressing cell lines (GS-Null and T127), whereas 
SLC7A1 and SLC7A6 remain moderately expressed in all cell lines and do not change 
throughout culture. 
Figure 4.5 provides a graphical summary of proteinogenic amino acid 
transporter expression differences between cell lines and within culture. 
 
! 55 
 
Figure 4.5 Comparison of proteinogenic amino acid transporter expression in 
CAT-S, GS-Null, and T127 cells at exponential and stationary growth phase. 
Arrow thickness is weighted to represent relative differences in abundance (FPKM 
values) with the broken arrow indicating low expression. Blue, green, and red arrows 
represent CAT-S, GS-Null, and T127 cell lines respectively. Single and double arrows 
signify uniport and antiport transport respectively. An asterisk denotes a significant 
upregulation of transporter expression by 2-fold at stationary phase compared to 
exponential phase (Q-value < 0.05). 
 
 
4.3.3.3 Expression of Genes Involved in Regulating Cellular GSH Levels  
To investigate if increased SLC7A11 expression at stationary phase is part of an 
adaptive response to support GSH synthesis, the expression of enzymes involved in 
regulating cellular GSH levels was examined in the three cell lines (Table 4.2). De novo 
synthesis of GSH is mediated by the sequential action of γ-glutamylcysteine synthetase 
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intermediate of these reactions, L-γ-glutamyl-L-cysteine, can be degraded byჼγ-
glutamylcyclotransferase (GGCT), which limits GSH synthesis via GSS (Griffith, 
1999). Finally, glutathione reductase (GSR) activity increases cellular availability of 
GSH by catalysing the reduction of GSSG back to GSH (discussed in Chapter 2). Both 
the recombinant glutamine synthetase expressing cell lines exhibited a significant 
downregulation (~2-fold) of GGCT. The T127 cell line also exhibited a significant 
upregulation (~1.5-fold) of GSR. In contrast, the CAT-S cells showed a significant 
upregulation of GCLM but the fold-change was relatively small. In summary, T127 and 
GS-Null cells modulate the expression of three and two genes respectively to increase 
GSH availability, while CAT-S cells modulate a single gene. The total number of 
changes correlates well with observed culture viabilities during late culture: T127 > GS-
Null > CAT-S (Figure 4.1 C). 
 
Table 4.2 Differential expression of enzymes involved in regulating cellular GSH 
levels in response to transition from exponential to stationary growth phase of 
culture 
 
Average (n = 2) log2 fold change in gene expression was provided by Cuffdiff (see 4.2 
Materials and Methods). Significant fold changes are in bold (Q-value < 0.05). 
*Indicates genes with multiple transcriptomic gene entries, which had their FPKM 
values summed to calculate total fold change and designated significant if at least one 
gene entry exhibited a significant fold change. 
 
 
 
 
Gene symbol Gene name CAT-S GS-Null T127
Genes that promote cellular GSH levels:
SLC3A2
Solute carrier family 3 (amino acid transporter heavy chain), member 
2; 4F2hc 0.18 0.02 0.41
SLC7A11*
Solute carrier family 7 (anionic amino acid transporter light chain, xc- 
system), member 11 2.41 1.26 3.06
GSR* Glutathione reductase 0.04 -0.04 0.72
GCLM Glutamate-cysteine ligase, modifier subunit 0.39 0.07 0.15
GCLC Glutamate-cysteine ligase, catalytic subunit -0.09 -0.03 0.14
GSS Glutathione synthetase -0.34 -0.31 0.16
Genes that limit cellular GSH levels:
GGCT Gamma-glutamyl cyclotransferase -0.26 -0.87 -0.97
Log2 (fold change)
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4.3.3.4 Expression of Target Genes of the AAR Pathway 
Activation of the amino acid response (AAR) pathway will also lead to increased 
expression of the xCT transporter (discussed in Chapter 2). The AAR pathway has been 
shown to be stimulated by amino acid depletion in multiple CHO cell lines (Fomina-
Yadlin et al., 2013). To investigate if increased xCT expression at stationary phase is a 
consequence of AAR activation the expression of additional genes known to be 
regulated via this pathway was examined (Table 4.3). Of the 12 AAR target genes 
identified from the literature (Fomina-Yadlin et al., 2013; Kilberg et al., 2009; Lee et 
al., 2008), 3 were missing from the transcriptome data sets. Of the remaining 9 genes, 
ASNS, ATF3, and TRIB3 were significantly upregulated in addition to SLC7A11 in all 
cell lines. DDIT3 was upregulated in CAT-S and GS-Null cells only. There was no 
change in the 4 remaining genes for any cell line. In summary, of the AAR pathway 
target genes examined, increased expression was observed in only half of them in 
response to transition into stationary phase. 
 
Table 4.3 Differential expression of genes regulated by the AAR pathway in 
response to transition from exponential to stationary growth phase of culture 
 
Average (n = 2) log2 fold change in gene expression was provided by Cuffdiff (see 4.2 
Materials and Methods). Significant fold changes are in bold (Q-value < 0.05). 
*Indicates genes with multiple transcriptomic gene entries, which had their FPKM 
values summed to calculate total fold change and designated significant if at least one 
gene entry exhibited a significant fold change. 
 
 
Gene symbol Gene description CAT-S GS-Null T127
ASNS Asparagine synthetase 0.46 0.76 0.56
ATF3 Activating transcription factor 3 1.00 0.98 0.77
DDIT3 DNA-damage-inducible transcript 3 1.12 1.43 0.18
SLC7A1
Solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 1; CAT-1 0.10 0.02 0.12
TRIB3 Tribbles homolog 3 0.82 1.00 1.21
VEGFA Vascular endothelial growth factor A 0.26 0.08 -0.01
ATF4* Activating transcription factor 4 0.20 -0.04 0.12
SLC7A11*
Solute carrier family 7 (anionic amino acid transporter light chain, xc- 
system), member 11 2.41 1.26 3.06
SLC38A2* Solute carrier family 38, member 2; SNAT2 0.26 0.23 0.47
CEBPB CCAAT/enhancer binding protein (C/EBP), beta - - -
EIF4EBP1 Eukaryotic translation initiation factor 4E binding protein 1 - - -
HERPUD1
Homocysteine-inducible, endoplasmic reticulum stress-inducible, 
ubiquitin-like domain member 1 - - -
Log2 (fold change)
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4.3.3.5 Expression of Non-Proteinogenic Transporters 
Expression of transporters belonging to the three groups of non-proteinogenic 
transporters (orphan, di/tripeptide, and other) were also filtered to identify transporters 
whose expression is in the top 75% percentile (Table 4.4). Three transporters were 
found to be highly expressed in all three cell lines at both growth phases: SLC38A10 
(orphan transporter), SLC15A3 (PhT2, di/tripeptide transporter), and SLC6A6 (TauT, 
taurine transporter). The substrate profile and biological function of SLC38A10 is 
unknown, however it shares a high degree of protein homology to SLC38 family 
transporters that includes the highly expressed SLC38A2 transporter (Schiöth et al., 
2013). PhT2 transports dipeptides, tripeptides, and histidine (Smith et al., 2013). 
Interestingly, feeding histidine- and tyrosine-dipeptides to antibody-producing CHO 
cells in fed-batch processes has been shown to enhance productivity and culture 
viability by ~40% and ~70% respectively (Kang et al., 2012). Also, TauT 
overexpression has been shown to enhance the viability and productivity of CHO cells 
(Tabuchi et al., 2010).  
 
Table 4.4 Non-proteinogenic amino acid transporters with medium or high 
expression at exponential and stationary growth phase 
 
All FPKM values are the average of two independently sequenced samples. 
 
 
 
 
SLC ID Protein name CAT-S GS-Null T127 CAT-S GS-Null T127
Orphan transporters:
SLC38A10 103.11 91.86 62.90 130.61 146.91 93.22
SLC38A6 SNAT6 15.38 18.60 20.65 15.55 14.76 17.19
SLC38A9 7.41 9.27 6.47 9.84 9.99 9.46
Di/Tripeptide transporters:
SLC15A3 PhT2 36.95 44.78 44.34 43.88 58.50 26.97
SLC15A4 PhT1 12.50 11.45 12.04 20.46 17.04 14.36
Other amino acid transporters:
SLC6A6 TauT 82.25 41.07 57.82 87.67 32.55 77.54
FPKM
Exponential Stationary
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4.3.4 Amino Acid Transport Rate Analysis 
Extracellular amino acid concentrations were measured for the three cell lines 
(Appendix Figure A1) and net transport rates were calculated at days 4, 6, 8, and 10 to 
see if they reflect observations in transporter expression (Figure 4.6 and Table 4.5). 
Transport rates were grouped by amino acid charge and size as transporters typically 
facilitate the movement of multiple amino acids based upon these two properties. This 
was done to help maximise biological interpretation from the data sets.  
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Figure 4.6 Comparison of specific amino acid transport rates throughout culture 
for CAT-S, GS-Null, and T127 cells. CAT-S (blue) and GS-Null (green) rates are 
measured from parallel duplicate 1-L bioreactors (mean + SEM, n = 2). T127 (red) rates 
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are from a single bioreactor. Negative and positive rates represent consumption and 
production respectively. Amino acids are grouped by charge and size. *Cystine is 
included with the anionic group due its transport dependence upon glutamate via the 
xCT transporter. 
 
 
Table 4.5 Total specific amino acid transport rates throughout culture for CAT-S, 
GS-Null, and T127 cells  
 
The absolute value is taken of negative consumption rates in calculating total transport 
rates (nmol 10-5 cells-1 day-1). Amino acids are grouped by charge and size. BCAA, 
branched-chain amino acids; AAA, aromatic amino acids. *Anionic group includes 
cystine due its transport dependence upon glutamate via the xCT transporter. 
 
 
 
 
Total amino acid transport rates were approximately equivalent in the CAT-S 
and T127 cell lines at day 4 (168.0 ± 0.1 versus 155.5 x10-5 nmol.cell-1.d-1; Table 4.5). 
The GS-Null cell line had a higher transport rate (200.4 ± 20.9 x10-5 nmol.cell-1.d-1) 
Day High transport Low transport BCAA and AAA Cationic Anionic* Total
CAT-S:
4 103.2 ± 0.4 16 ± 0.0 32.1 ± 0.1 12.4 ± 0.4 4.2 ± 0.3 168.0 ± 0.1
6 67.0 ± 1.8 15.4 ± 1.6 31.6 ± 3.1 11.9 ± 1.1 4.6 ± 0.5 130.4 ± 7.1
8 34.4 ± 1.9 10.9 ± 1.4 24.0 ± 2.6 7.7 ± 0.9 9.9 ± 1.4 87.0 ± 8.2
10 28.6 ± 0.3 4.7 ± 0.1 6.0 ± 2.4 2.2 ± 0.0 3.2 ± 1.5 44.8 ± 4.1
GS-Null:
4 83.9 ± 4.0 23.9 ± 1.4 57.8 ± 8.3 19.8 ± 3.1 15.0 ± 4.0 200.4 ± 20.9
6 56.7 ± 4.4 11.1 ± 1.8 24.9 ± 0.7 6.1 ± 1.1 5.8 ± 1.9 104.5 ± 1.1
8 49.1 ± 9.2 5.5 ± 0.6 15.1 ± 2.8 1.8 ± 1.5 3.6 ± 2.1 75.1 ± 2.2
10 45.6 ± 6.8 8.5 ± 1.6 18.5 ± 6.1 2.8 ± 1.4 4.6 ± 1.7 80.0 ± 14.2
T127:
4 86.7 16.6 33.1 8.5 10.5 155.5
6 83.2 14.1 33.5 9.4 17.4 157.6
8 36.5 14.0 30.7 6.8 15.2 103.2
10 32.9 9.3 26.1 5.8 19.4 93.4
Total specific amino acid transport rate
Small neutral amino acids Charged amino acids
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despite achieving comparable growth rates, suggesting poor amino acid utilisation 
efficiency in these cells. Kyriakopoulos et al. (2013) reported a similar obsevation in 
their GS-Null cell line. A breakdown analysis of total transport revealed GS-Null cells 
to be consuming branched-chain, aromatic, and cationic amino acids at rates 
approximately twice that of the CAT-S and T127 cell lines (Table 4.5). Both GS-Null 
and T127 cells were found to have increased transport of aspartate and glutamate 
compared to CAT-S cells, correlating well with a higher expression of GLAST in these 
cell lines (Figure 4.2). At day 6 CAT-S and T127 cells remained in exponential growth. 
Total amino acid transport stayed constant in T127 cells but dropped slightly for CAT-S 
cells as glutamine availability became limited (Appendix Figure A1). 
Total amino acid transport rates decrease as cells transition into stationary phase: 
87.0 ± 8.2 for CAT-S cells at day 8, 103.2 for T127 cells at day 8, and 104.5 ± 1.1 for 
GS-Null cells at day 6 (Table 4.5). A drop in asparagine consumption largely caused the 
reduction in total transport for CAT-S and T127 cells at day 8 compared to day 4 as its 
availability became limited (Appendix Figure A1). Total transport rates are 
approximately equivalent across the three cell lines at stationary phase despite T127 
cells producing an antibody with a high specific productivity, suggesting amino acid 
consumption is in excess of protein synthesis requirements. However, breakdown 
analysis of total transport also reveals that T127 cells were best able to maintain their 
consumption rate of certain small neutral amino acids (histidine, methionine, proline, 
serine, and threonine) as well as the branched-chain and aromatic amino acids at day 8. 
At day 10, the consumption rate of these amino acids continued to remain high in T127 
cells but dropped drastically in CAT-S cells. This observation correlates with the 
previously described significant upregulation of SLC7A5 (branched-chain/aromatic 
amino acid transporter) and SLC1A4 (high affinity transporter of threonine) expression 
at day 8 for T127 cells. The SLC1A4 transporter also has a high affinity for serine, 
whose transport rate is greatest in T127 cells at all culture time points. 
Transcriptomic data found the xCT transporter to be significantly upregulated in 
all three cell lines during stationary phase. This antiporter imports extracellular cystine 
in exchange for intracellular glutamate with a 1:1 stoichiometry, suggesting an 
increased cellular requirement for cystine during stationary growth. Cystine 
consumption was however found to decrease during stationary phase in all three cell 
lines (Figure 4.6).  
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4.3.5 Amino Acid Analysis of Two Additional IgG-Producing Cell Lines 
Two further cell lines producing the same human IgG mAb (T29 and T48) were grown 
in duplicate fed-batch operations independently of the three cell lines already described 
(Figure 4.7). The three IgG producing cells lines vary in productivity. Average cell 
specific productivity (pg mAb.cell-1.d-1) of T127 cells is approximately double that of 
T29 cells (17.7 versus 7.5 ± 0.7, mean ± SEM) but approximately equal to T48 cells 
(17.7 versus 15.0 ± 1.1, mean ± SEM). Extracellular amino acid concentrations were 
measured for both cell lines to calculate net transport rates that were then compared to 
those in T127 cells (Figure 4.8 and Table 4.6). 
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Figure 4.7 Production characteristics of T29, T48, and T127 cells grown in a 14-
day fed-batch operation. T29 (yellow) and T48 (orange) cells were grown in parallel 
duplicate 1-L bioreactors (mean ± SEM, n = 2). T127 cells (red) were grown in a single 
bioreactor. (A.) Viable cell density (VCD). (B.) Culture viability. (C.) IgG titre across 
the culture period.  
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Figure 4.8 Comparison of specific amino acid transport rates throughout culture 
for T29, T48, and T127 cells. T29 (yellow) and T48 (orange) rates are measured from 
parallel duplicate 1-L bioreactors (mean + SEM, n = 2). T127 (red) rates are from a 
single bioreactor. Negative and positive rates represent consumption and production 
respectively. Amino acids are grouped by charge and size. *Cystine is included with the 
anionic group due its transport dependence upon glutamate via the xCT transporter. 
 
 
 
Table 4.6 Total specific amino acid transport rates throughout culture for T29, 
T48, and T127 cells  
 
The absolute value is taken of negative consumption rates in calculating total transport 
rates (nmol 10-5 cells-1 day-1). Amino acids are grouped by charge and size. BCAA, 
branched-chain amino acids; AAA, aromatic amino acids. *Anionic group includes 
cystine due its transport dependence upon glutamate via the xCT transporter. 
  
Day High transport Low transport BCAA and AAA Cationic Anionic* Total
T29:
4 62.7 ± 0.6 16.2 ± 0.9 22.1 ± 0.6 2.4 ± 0.3 4.1 ± 0.2 107.5 ± 0.4
6 63.7 ± 0.4 14.6 ± 0.2 37.4 ± 0.1 9.1 ± 0.1 9.1 ± 0.4 134.0 ± 0.2
8 53.5 ± 1.2 9.0 ± 0.4 23.9 ± 0.8 5.1 ± 0.5 6.6 ± 0.8 98.1 ± 1.3
10 49.3 ± 2.7 8.5 ± 0.3 23.0 ± 1.5 3.4 ± 1.0 8.6 ± 2.0 92.9 ± 2.1
T48:
4 99.3 ± 4.4 23.9 ± 1.9 34.0 ± 4.5 8.0 ± 2.0 7.4 ± 1.0 172.5 ± 13.7
6 89.9 ± 1.9 14.9 ± 1.1 31.3 ± 4.6 5.3 ± 2.2 8.9 ± 1.9 150.4 ± 7.9
8 66.4 ± 8.1 13.6 ± 0.6 34.4 ± 1.4 7.3 ± 1.3 14.4 ± 1.6 136.1 ± 3.2
10 46.1 ± 8.4 10.7 ± 1.2 24.7 ± 7.6 4.3 ± 2.5 14.3 ± 2.9 100.1 ± 5.8
T127:
4 86.7 16.6 33.1 8.5 10.5 155.5
6 83.2 14.1 33.5 9.4 17.4 157.6
8 36.5 14.0 30.7 6.8 15.2 103.2
10 32.9 9.3 26.1 5.8 19.4 93.4
Total specific amino acid transport rate
Small neutral amino acids Charged amino acids
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Total amino acid transport rates were higher in the two high producers (T48 and 
T127) during exponential growth (days 4 and 6; Table 4.6). This was a result of 
increased asparagine consumption and glutamine production in these cell lines 
compared to the low producer (T29). Amino acid transport profiles were otherwise very 
similar between the three producing cell lines. Total transport rates were approximately 
equivalent at stationary phase (days 8 and 10) across the three cell lines despite T29 
cells having a lower QmAb, again suggesting that amino acid consumption may be in 
excess of protein synthesis requirements. Of noticeable difference is that the two high 
producers were consuming anionic amino acids at rates approximately twice that of the 
T29 cell line during stationary growth. As with T127 cells, both T29 and T48 cells are 
able to maintain their consumption rate of histidine, methionine, proline, and threonine 
as well as the branched-chain and aromatic amino acids during stationary growth. 
 
 
4.4 Discussion  
CHO membrane transporters control the availability of intracellular amino acids and are 
expected to have an essential role in supporting cell growth and high product titres. 
However, an analysis of transporter function during fed-batch CHO cultures has never 
been performed. The work presented here is the first chapter of two whose objective is 
to explore the first aim of this thesis: to characterise amino acid transport processes in 
CHO cells and understand how they might support culture performance. In this first 
characterisation chapter, Illumina next-generation sequencing was used to measure 
transporter expression in three CHO cell lines at exponential and stationary growth of a 
fed-batch process. Data on amino acid transporter expression were extracted from 
transcriptomic data sets and analysed by assessment of (i) transcript abundance (FPKM 
value), and (ii) fold-change (log2 value) in expression between cell lines and culture 
phase. Extracellular amino acid concentrations were measured and converted to 
transport rates that were then mapped to expression data. A number of transporters have 
been identified as having a key role in supporting culture performance and are discussed 
below. Three transporters: ASCT1, LAT1, and xCT are identified as potential targets 
for cell engineering strategies to improve cell line productivity. 
 
4.4.1 LAT1, ASCT1 and SNAT2 Transport Neutral Amino Acids 
An analysis of transcript abundance identified seven highly expressed transporters that 
collectively can facilitate the transport of all 20 proteinogenic amino acids (Figure 4.5). 
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The results show that LAT1 is the main transporter of the previously identified system 
L transport in CHO cells (Bass et al., 1981; Shotwell et al., 1981). Four transporters 
(LAT1–4) belong to system L and exhibit comparable selectivity for branched-chain 
amino acids (isoleucine, leucine, and valine), although LAT1–2 have a wider substrate 
specificity that also includes the aromatic amino acids (see Chapter 2; Section 2.3). 
Expression was detected for SLC7A8 and SLC43A2 but this was markedly reduced 
compared to SLC7A5 throughout culture (Appendix Table A2–4), consistent with 
observations reported by Kyriakopoulos et al. (2013) who also reported low expression 
for SLC43A1. It is therefore assumed that LAT1 is mediating the majority of system L 
transport. In support of this, LAT1 is the only CHO system L transporter to be 
identified in a proteomic study (Baycin-Hizal et al., 2012). LAT1 is the primary entry 
route for essential amino acids in most transformed cell lines (Fuchs and Bode, 2004), 
and regulates leucine-mediated mTORC1 signaling (Nicklin et al., 2009). Activation of 
mTORC1 in CHO cells is therefore likely to also be dependent upon LAT1 activity. 
 LAT1 antiport activity can be functionally coupled to the system ASC antiporter 
ASCT2 (Nicklin et al., 2009) and possibly coupled to system A and N uniporters (Baird 
et al., 2009; Boer et al., 2002) (Figure 2.3). System A and ASC transport has been 
previously demonstrated in CHO cells (Bass et al., 1981; Shotwell et al., 1981). 
SLC1A5 was missing from the transcriptomic data sets but the second system ASC 
transporter SLC1A4 (see Chapter 2; Table 2.1) was present and highly expressed (Table 
4.1). The expression of both transporters has however been reported at the transcript 
(Kyriakopoulos et al. 2013) and protein level (Baycin-Hizal et al., 2012). Five 
transporters make up systems A and N (see Chapter 2; Section 2.3). The results show 
that expression of SLC38A2 (system A) was markedly higher than the other four 
transporters throughout culture (Appendix Table A2–4), making it the primary entry 
route for small neutral amino acids such as asparagine and glutamine through these two 
systems. This is consistent with transcript measurements reported by Kyriakopoulos et 
al. (2013). Furthermore, SLC38A2 is the only transporter of systems A and N whose 
expression has been confirmed at the protein level (Baycin-Hizal et al., 2012). A 
striking conclusion from this assessment of neutral transporters is that CHO cells 
heavily rely on a single transporter for the uptake of all branched-chain and aromatic 
amino acids, i.e. those amino acids that cannot be synthesised de novo and are 
designated as essential within multicellular organisms. Whereas for smaller neutral 
amino acids (e.g. asparagine, glutamine and serine) - the cellular requirement of which 
typically exceeds the cells capability for de novo synthesis making them conditionally 
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essential amino acids in CHO cell line manufacturing platforms - is divided over two 
transporters with distinct transport mechanisms. This redundancy in transport of smaller 
neutral amino acids suggests their intracellular availability is of a greater importance to 
cell growth than larger branched-chain and aromatic amino acids. As discussed in 
Chapter 2, glutaminolysis and asparagine metabolism have been shown to provide CHO 
cells with a carbon source that gets directed towards the TCA cycle to support 
macromolecule synthesis (e.g. fatty acids) and energy production. It is therefore 
hypothesised that expression of multiple transporters for smaller neutral amino acids in 
CHO cells is an adaptive response to support this metabolism which was reflected by a 
2-3 fold increased consumption rate of these amino acids compared to essential amino 
acids (Table 4.5 and 4.6). The flux of amino acid derived carbon into the TCA cycle is 
associated with the production of ammonia as a byproduct while glutaminolysis is 
closely associated with aerobic glycolysis and associated lactate production (see 
Chapter 2). In addition to measurements of amino acid concentrations, glucose, lactate 
and ammonia were also measured throughout the fed-batch cultures described in this 
chapter. Glucose measurements were used to feed back glucose to ensure that it was 
never growth limiting while the pH was controlled to minimise the negative effects of 
lactate and ammonia on growth (see 4.2 Materials and Methods). No analysis was 
performed on glucose/lactate consumption/production rates due to the unknown 
contribution that other carbon sources expected to be found in the undisclosed media 
such as pyruvate may make to aerobic glycolysis. 
 
4.4.2 GLAST, CAT-1 and y+LAT2 Transport Charged Amino Acids 
Anionic transport (aspartate and glutamate) is predominantly through system XAG-, and 
cationic transport (arginine and lysine) is predominantly through systems y+ and y+L in 
mammalian cells (see Chapter 2; Section 2.3). Five transporters belong to system XAG- 
and have near identical transport kinetics (Danbolt, 2001). All transporters were 
expressed but expression of SLC1A3 markedly exceeded expression of the other four 
transporters throughout culture (Appendix Table A2–4). GLAST is therefore assumed 
to be mediating the function of system XAG- transport previously identified in CHO cells 
(Ash et al., 1993). Kyriakopoulos et al. (2013) similarly detected substantial expression 
of SLC1A3 with an additional small contribution to XAG- from SLC1A2. GLAST has 
also been detected at the protein level (Baycin-Hizal et al., 2012).   
The three uniporters of system y+ provide a high-affinity influx route for 
arginine and lysine (Fotiadis et al., 2013). CAT-1 exhibits the highest substrate affinity 
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of the three transporters and is preferentially expressed (Appendix Table A2–4), 
suggesting it is mediating the previously identified y+ transport in CHO cells (Rotoli et 
al., 1989). Kyriakopoulos et al. (2013) similarly detected transcript expression for 
SLC7A1 only and it is also the only y+ transporter detected at the protein level (Baycin-
Hizal et al., 2012). The two transporters belonging to system y+L are antiporters that 
preferentially export arginine and lysine for the influx of neutral amino acids such as 
glutamine or leucine (see Chapter 2; Table 2.1). It has therefore been proposed that 
systems y+ and y+L are functionally coupled in mammalian cells (Fotiadis et al., 2013). 
Both SLC7A6 and SLC7A7 were expressed with higher expression of the latter (Table 
4.1). Cell surface expression of these two transporters, as well as SLC7A5, was 
supported by high expression of SLC3A2 throughout culture for all cell lines (Table 
4.1). Interestingly, abundance of SLC7A1 and SLC7A6 was equivalent in the three cell 
lines across culture. Functional coupling of these two transporters may help support the 
function of system L by providing an additional influx route for leucine and subsequent 
mTORC1 activation in CHO cells. 
 
4.4.3 ASCT1, LAT1 and xCT Are Potential Markers for Antibody Production 
Differences in transporter expression between cell lines and across culture were then 
explored to identify how expression compares with performance parameters such as 
growth rate, cell viability, and productivity (Figure 4.5).  
Of the neutral transporters, SLC38A2 expression was high and approximately 
equivalent across the three cell lines, changing little throughout culture. However, 
SLC1A4 is the only transporter whose expression was significantly upregulated in T127 
cells compared to the other two cell lines at both exponential (2-fold increase) and 
stationary (3-fold increase) phase making it a potential marker of productivity 
throughout culture. SLC1A4 expression was also regulated within culture, being 
significantly upregulated at stationary phase for all cell lines. Kyriakopoulos et al. 
(2013) made the same observation in their GS-Null and two antibody-producing cell 
lines. ASCT1 may therefore have a key functional role at stationary phase such as 
supporting cell viability. SLC7A5 expression was significantly upregulated at stationary 
phase in T127 cells only (3-fold), suggesting increased system L activity may be 
required to support antibody production late in culture. 
Expression of the cationic transporters SLC7A1 and SLC7A6 was moderate and 
approximately equivalent across the three cell lines, changing little throughout culture. 
This is in contrast to measurements made by Kyriakopoulos et al. (2013) that 
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demonstrate SLC7A1 and SLC7A6 was upregulated and downregulated respectively in 
antibody-producers compared to their non-producer, a combination of transporter 
expression that would function to maximise arginine and lysine influx for their 
antibody-producers. 
The aspartate and glutamate transporter SLC1A3 was found to be significantly 
upregulated in the two glutamine synthetase expressing cell lines compared to the host 
throughout culture. This indicates a necessary remodeling of transporter function for 
increased aspartate and glutamate uptake to support glutamine synthetase activity and 
growth in glutamine-free media. GS-Null and T127 cells also demonstrated significant 
upregulation of SLC6A9 and SLC7A11 compared to the host throughout culture. 
Collectively, these three transporters provide the glutamate, glycine, and cysteine 
required for GSH synthesis, indicating that both GS-Null and T127 cells may have an 
increased requirement for GSH throughout culture. Consistent with observations by 
Kyriakopoulos et al. (2013), SLC7A11 expression was also regulated within culture, 
being significantly upregulated at stationary phase for all cell lines. Expression of 
SLC7A11 at stationary phase in T127 cells is 3-fold and 2-fold higher than the host and 
GS-Null cells respectively, making it a third potential marker of productivity.  
 
4.4.4 Increased SLC7A11 Expression During Stationary Growth Forms Part of An 
Adaptive Response That Supports Cellular Availability of GSH 
The upregulation of SLC7A11 at stationary phase was the largest change in expression 
of any transporter for CAT-S (5-fold), GS-Null (2.5-fold), and T127 (8-fold) cells. 
Likewise, Kyriakopoulos et al. (2013) found upregulation of SLC7A11 at stationary 
phase to be their biggest change in expression across all cell lines (up to 16-fold). The 
xCT transporter is the primary influx route for cystine in cultured mammalian cells 
(Ganapathy et al., 2009) and its activity is closely associated with GSH synthesis 
(Chung et al., 2005; Shih et al., 2006) (reviewed in Chapter 2; Section 2.4). 
Upregulation of SLC7A11 is suggestive of an increased requirement for cellular GSH at 
stationary phase in all cell lines. In support of this the GSH/GSSG ratio has been 
reported to decrease considerably during stationary phase (Templeton et al., 2013). This 
could be a consequence of increased cellular ROS resulting from a shift in TCA cycle 
function towards oxidative phosphorylation during this phase of culture as reported in 
other CHO cell lines (reviewed in Chapter 2; Section 2.1). The expression of enzymes 
involved in regulating cellular GSH levels was examined to investigate this hypothesis 
further (Section 4.3.3.3; Table 4.2). Interestingly, culture viability correlated well with 
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the number of expression changes made to maximise cellular GSH levels, such that 
T127 cells with three changes were best able to maintain high culture viability 
throughout late-stage culture. Unique to the T127 cell line was the 1.6-fold increase in 
glutathione reductase. Sengupta et al. (2011) hypothesised that increased flux through 
the PPP at stationary phase (reviewed in Chapter 2; Section 2.1) functions to support 
NADPH production for glutathione reductase activity. The data presented in this 
chapter suggests the relationship between SLC7A11 expression and GSH synthesis 
warrants further investigation. Future studies would benefit from measuring GSH and 
ROS levels, SLC7A11 expression, and GSH related enzyme expression/activity 
throughout culture.   
 
4.4.5 Changes in ASCT1, LAT1, and xCT Expression Could be an Adaptive 
Response to Support Antibody Production 
This chapter also examined amino acid transport rates throughout culture in all cell lines 
to investigate how they correlate with changes in transporter expression.  
ASCT1, identified above as a potential marker for productivity, is a high-affinity 
transporter of serine and threonine (see Chapter 2; Table 2.1), whose consumption rates 
remained high late in T127 culture compared to the other two non-producing cell lines 
(Figure 4.6). An analysis of the amino acid composition of a typical mammalian cell 
and IgG antibody (Table 4.7) reveals threonine and serine to be amongst the most 
abundant amino acids in an IgG. Furthermore, serine is a major requirement for cell 
biomass such that the cells must increase serine consumption to meet both biomass 
demands, as observed during exponential growth. Upregulation of SLC1A4 may 
therefore be a necessary adaptive response to support IgG production, explaining why 
this transporter represents a good marker for productivity throughout culture. The IgG 
also has a high requirement for leucine, tyrosine, and valine, all of which continued to 
be consumed at a high rate up to day 10 in T127 cells only. These amino acids are 
transported through LAT1 and may explain its 3-fold upregulation in T127 cells at 
stationary phase. A further two antibody-producing cell lines (T29 and T48) also 
maintained high consumption rates for leucine, threonine, tyrosine, serine, and valine at 
stationary phase, providing additional support for this hypothesis. 
Interestingly, cystine consumption was found to decrease late in culture in all 
cell lines despite significant upregulation of SLC7A11 expression. The explanation for 
this is not clear, however the extracellular concentration of cystine was an order of 
magnitude lower than the other 19 amino acids throughout culture across the three cell 
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lines (Appendix Figure A1). As the fed-batch culture progressed and the media became 
increasingly amino acid rich, the cells may have struggled to acquire the additional 
cystine that they require. Cystine transport is therefore a bottleneck and represents an 
attractive cell engineering target. Alternatively, improved media design may boost 
cytosolic levels of cysteine. For example, feeding chemically synthesised cysteine-
containing di/tripeptides. Kang et al. (2012) demonstrated that tyrosine-containing 
dipeptides had a significantly higher solubility than free tyrosine and feeding these 
dipeptides enhanced productivity and viability of an antibody-producing cell line. More 
recently, Kishishita et al. (2015) found that supplementing CHO cultures with a 
cysteine-serine-tyrosine tripeptide could significantly improve cell growth and 
productivity. High expression of SLC15A3 (Table 4.4) suggests the transport 
mechanism is in place for a variety of di/tripeptides to be experimentally tried out. 
Cysteine is also required for IgG production. Despite the IgG requirement being 
low, it represents a 8-fold increase in composition percentage compared to the cell 
biomass (Table 4.7). Consequently, there is an increased demand for cysteine in 
antibody-producing cells to support both antibody production and GSH synthesis during 
late-stage phase. This may explain why this transporter as suggested above represents a 
good additional marker for productivity late in culture.  
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Table 4.7 Amino acid composition of a mammalian cell and an IgG antibody 
 
Mammalian cell and standard IgG composition was taken from Hu, 2012. 
 
 
4.4.6 Summary 
In this chapter, transcriptomic analysis of three CHO cell lines has identified seven 
highly expressed transporters that can collectively facilitate the transport of all 20 
proteinogenic amino acids: ASCT1, CAT-1, GLAST, LAT1, SNAT2, xCT, and 
Amino Acid Cell Composition Standard IgG 
Composition
mAb-109 
Composition
Ala 9.0 5.3 5.3
Arg 4.7 2.4 3.2
Asn 3.5 3.9
Asp 4.0 3.9
Cys 0.3 2.4 2.4
Gln 5.0 4.5
Glu 5.2 4.4
Gly 9.1 7.0 7.2
His 2.2 1.7 1.7
Ile 5.7 2.4 2.3
Leu 9.0 6.8 7.7
Lys 6.9 7.0 6.6
Met 2.3 1.4 0.8
Phe 3.7 3.5 3.3
Pro 5.5 7.1 6.6
Ser 6.2 12.9 14.1
Thr 5.4 7.7 7.4
Trp - - 1.5
Tyr 2.7 4.1 4.8
Val 6.5 9.1 8.6
10.1
12.6
Percentage (%)
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y+LAT2. An analysis of transporter expression within culture and between cell lines, 
together with measured amino acid transport data, has identified three transporters 
whose functional contribution towards culture performance warrants further 
investigation: ASCT1, LAT1, and xCT. All three represent possible markers for 
productivity, while xCT may also have a critical role in maintaining culture viability 
late in culture. It should however also be noted that the three CHO cell lines examined 
are non-clonal and thus are functionally heterogeneous. Consequently, the 
measurements reported in this chapter represent population averages. As discussed in 
Chapter 1, high-throughput screening technology is used to isolate rare highly 
productive clonal cell lines from transfectant pools. It is therefore conceivable that 
amino acid transporter expression in these rare highly productive cells may diverge 
from the population average observations described in this chapter. Future studies 
would therefore benefit from looking at multiple clonal cell lines with different levels of 
productivity. Increased expression of SLC1A4, SLC1A5, and SLC7A11 in T127 cells 
was hypothesised above to support the influx of amino acids needed for IgG production. 
In support of this theory, Ley et al. (2015) compared the CHO transcriptomes of a high- 
and low-producer of erythropoietin (EPO), and found reduced expression of catabolic 
genes specific for the most abundant amino acids in EPO in the high-producer relative 
to the low-producer. Similarly, Dietmair et al. (2012b) found significant downregulation 
of metabolic pathways involved in isoleucine, leucine, lysine, and valine degradation in 
a recombinant HEK293 cell line producing an IgG fragment relative to the non-
producing host. The results presented in this chapter demonstrate for the first time an 
additional mechanism by which CHO cells may be modifying amino acid metabolism to 
support recombinant protein production. 
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Chapter 5 
Inhibition of Amino Acid Transport and its 
Effects on Cell Growth and Antibody Production 
 
This chapter evaluates the functional contribution that amino acid transport systems 
make to growth, viability, and productivity of CHO cell lines. Inhibitors were used to 
block amino acid entry through discrete transport systems at exponential and stationary 
phase of batch cultures. LAT1, GlyT1, and xCT transport activity were found to support 
antibody production during late-stage culture. xCT transport activity was also found to 
be a key determinant of culture viability throughout culture. This knowledge can help 
guide future cell line development processes in order to improve cell line productivity.  
 
 
5.1 Introduction 
In Chapter 4, RNA-sequencing was used to profile amino acid transporter gene 
expression in three CHO cell lines throughout a fed-batch process. Hypotheses about 
transporter function during culture were made based upon abundance and differential 
expression of transcripts, mapped amino acid transport rates, and a knowledge of how 
transporters support cellular processes from the literature. Importantly, ASCT1, LAT1, 
and xCT were identified as potential markers for antibody production. However, this 
hypothesis and others require further investigation, particularly because the correlation 
between mRNA and protein abundance is often poor (Hedge et al., 2003). Baycin-Hizal 
et al. (2012) compared mRNA and protein expression in CHO cells and found a 
correlation of r = 0.48. Measurement of transporter proteins using proteomic analysis or 
Western blotting can verify expression but manipulating transporter activity itself is 
required to evaluate their functional contribution to culture performance and 
experimentally test the hypotheses put forward in Chapter 4. 
Gene knockdown can be used to specifically target the expression of amino acid 
transporter genes. RNA interference (RNAi) has been used to downregulate the 
expression of ASCT2 (Hassanein et al., 2013; Nicklin et al., 2009; Wang et al., 2014), 
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LAT1 (Nicklin et al., 2009), SNAT1 (Kondoh et al., 2007), and xCT (Timmerman et 
al., 2013) transporters in cancer cell lines. Targeting individual transporters with RNAi 
allowed the authors to examine their functional contribution towards cell growth, amino 
acid transport, and other cellular processes such as activation of mTORC1 signaling. An 
alternative method of manipulating transporter activity is by treating cells with 
inhibitors that block amino acid entry through specific transporters. This approach is 
technically much simpler to implement than RNAi methods and can easily be used to 
evaluate transporter function at any time point in culture. Inhibitors have played a key 
role in the early identification of mammalian amino acid transport systems (Christensen 
et al., 1967; Oxender and Christensen, 1963) and are frequently used to investigate 
amino acid transport function in cancer cell lines (Chung et al., 2005; Gout et al., 2001; 
Hassaniein et al., 2013; Nicklin et al., 2009; Pinilla et al., 2011; Shennan et al., 2004; 
Timmerman et al., 2013). Inhibitors have helped identify the presence of system A and 
L transporters in adherent CHO-K1 cells (Bass et al., 1980; Shotwell et al., 1980) but 
have never been reported to be used with industrial CHO cell lines to investigate how 
amino acid transporter function contributes to culture performance. 
This chapter evaluates the functional contribution that transporters belonging to 
systems A, ASC, L, XC-, as well as the GlyT1 transporter, make to critical culture 
performance parameters (growth rate, cell viability, and antibody production). Inhibitors 
specific for these transporters were applied to the three cell lines from Chapter 4 (CAT-
S, GS-Null, and T127) at exponential and stationary phase of batch cultures. Two 
additional antibody-producing cell lines (T29 and T48) were also tested at exponential 
growth. A description of the inhibitors and hypotheses being tested from Chapter 4 are 
provided throughout the results section. 
 
 
5.2 Materials and Methods 
5.2.1 Inhibitor Treatment at Exponential Growth 
All cell lines were seeded at of 2 x 105 cells.mL-1 in 10 mL of CD-CHO medium (Life 
Technologies, Paisley, UK) in 50 mL vented TubeSpin® Bioreactors (TPP, 
Trasadingen, Switzerland) shaking at 170 rpm in 37oC and 5% CO2 air (Infors UK, 
Reigate, UK). CAT-S cells were supplemented with 8 mM L-glutamine (Life 
Technologies). Recombinant cells were not supplemented with MSX for all inhibitor 
experiments. At 24 hr after seeding all cultures were spun at 200g for 5 min and the 
medium was replaced with fresh test CD-CHO medium (supplemented with 8 mM 
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glutamine for CAT-S cells). BCH (2-amino-2-norbornanecarboxylic acid) (Sigma-
Aldrich, Dorset, UK) and MeAIB (α-(methylamino)isobutyric acid) (Sigma-Aldrich) 
were both diluted in CD-CHO medium. SAS (sulfasalazine) (Sigma-Aldrich), GPNA 
(L-γ-glutamyl-p-nitroanilide) (Sigma-Aldrich), and ALX 5407 HCL (Tocris, Bristol, 
UK) were all diluted in dimethyl sulfoxide (DMSO) (Sigma-Aldrich) before addition to 
CD-CHO medium. 
 
5.2.2 Inhibitor Treatment at Stationary Phase 
CAT-S, GS-Null, and T127 cell lines were seeded at of 2 x 105 cells.mL-1 in 140 mL of 
CD-CHO medium in 500 mL vented Erlenmeyer flasks (Corning, Surrey, UK) shaking 
at 140 rpm in 37oC and 5% CO2 air. CAT-S cells were supplemented with 8 mM L-
glutamine. Recombinant cells were not supplemented with MSX for all inhibitor 
experiments. Cells were grown until they reached stationary phase on day 5-6 (see 
Figure 5.1) and 9 mL culture aliquots were then transferred to 50 mL vented 
TubeSpin® Bioreactors. All inhibitors were diluted as described above but in 
conditioned (day 5-6) medium and applied to cells by spinning the cultures at 200g for 
5 min and replacing the medium with the test medium.  
 
5.2.3 Analysis of Factorial Experimental Data 
Design Expert 9 (Stat-Ease, Inc., Minneapolis, USA) was used to identify and model 
significant factors (both single and factor combinations) from the two-level factorial 
design. In brief, the effect of each factor was automatically calculated by subtracting the 
average response of all experiments at its –level from the average response of all 
experiments at its +level using equation 5.1: 
 Effect = ! R!n! − ! R!n!  
 
Where R is the response variable being investigated. For each factor the absolute effect 
value was automatically plotted on a half-normal probability plot. Factors with a large 
effect that markedly deviated from the other factors were manually identified. An 
analysis of variance (ANOVA) was then used to test each factor for significance and 
automatically generate a predictive model for the response variable in terms of the 
significant factors. Design Expert 9 automatically tested the generated models for 
normality by calculating the residuals (difference between predictive and actual 
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response) for each level combination and plotting them on a normal probability plot. 
These plots were manually examined to confirm that the residuals were normally 
distributed.  
 
 
5.3 Results 
Five CHO cell lines were investigated in this chapter: CAT-S, GS-Null, T29, T48, and 
T127. The growth and production characteristics for these cell lines were described in 
Chapter 4, however a summary is provided in Table 5.1. Transporter activity was 
inhibited at either exponential or stationary growth phase of batch cultures with the 
inhibitors described in Figure 5.1. For exponential growth studies, the five cell lines 
were treated for 3-4 days with inhibitors applied at 24 hr after seeding. At this time 
point in culture, all cell lines were approaching the end of their lag phase but also 
reached approximately the same cell density ensuring that the inhibitor “dose-per-cell” 
was equivalent between the cell lines. This design ensured that a comparison of 
responses (cell growth, culture viability, and productivity) could readily be made 
between the cell lines. The effect of transport inhibition at stationary phase was tested in 
CAT-S, GS-Null, and T127 cells only. In these experiments cells were grown until they 
reached stationary phase in batch cultures (day 5 for CATS and GS-Null cells, and day 
6 for T127 cells), then treated with the same inhibitor concentration ranges used during 
exponential growth. Consequently, the inhibitor “dose-per-cell” was lower than that of 
exponential phase experiments for all cell lines. Solubility issues with many of the 
inhibitors made it experimentally difficult to keep this variable equivalent between the 
two growth phases being examined. It should also be noted that the three cell lines all 
reached different peak densities at stationary phase. Therefore the inhibitor “dose-per-
cell” varied between the cell lines and a comparison of responses between cell lines 
cannot easily be made. 
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Table 5.1 Summary of growth and production characteristics of five CHO cell 
lines as assessed in 14-day fed-batch operations 
 
Data from all cell lines except T127 are from parallel duplicate 1-L bioreactors (mean ± 
SEM, n = 2). Data for T127 cells is from a single bioreactor. *Average µ calculated 
over 0–8 days for all cell lines except GS-Null cells, which are calculated over 0–6 
days. 
 
Cell line *Average µ 
(d-1)
Max VCD           
(x106 cells.mL-1)
Max titre    
(mg.L-1)
Average QmAb    
(pg mAb.cell-1.d-1)
CAT-S 0.32 ± 0.08 9.15 ± 0.16 - -
GS-Null 0.40 ± 0.10 6.55 ± 0.80 - -
T29 0.33 ± 0.07 7.88 ± 0.16 518 ± 18 7.5 ± 0.7
T48 0.31 ± 0.07 6.92 ± 1.05 935 ± 32 15.0 ± 1.1
T127 0.36 9.65 1457 17.7
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Figure 5.1 Inhibitors used to block amino acid transporter activity at exponential 
and stationary growth phases of batch cultures. 
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5.3.1 System L Transport Inhibition 
The four transporters of system L (LAT1–4) facilitate the transport of essential neutral 
amino acids with large, branched or aromatic side-chains that include isoleucine, 
leucine, and valine (see Chapter 2; Table 2.1). From Chapter 4, LAT1 is hypothesised to 
be the primary entry route for this group of amino acids in all cell lines, with increased 
activity required during late-stage culture in T127 cells to support antibody production. 
The leucine analog, 2-amino-2-norbornanecarboxylic acid (BCH) is a highly specific 
transportable inhibitor for LAT1-4 (Babu et al., 2003; Bodoy et al., 2005; Kanai et al., 
1998; Pineda et al., 1999) and has been used to examine LAT1 activity in a range of 
cancer cell lines (Nicklin et al., 2009; Shennan et al., 2004). BCH treatment is 
hypothesised to deplete cystosolic levels of essential amino acids leading to suppression 
of growth for all cell lines early in culture and inhibition of antibody production in T127 
cells treated during late-stage culture.  
Figure 5.2 shows the dose-response curves for cells treated with BCH during 
exponential growth. All cell lines exhibited a marked decrease in cell proliferation. 
However, small differences in sensitivity were apparent between the five cell lines as 
demonstrated by a comparison of their respective IC50 concentrations. T29 cells were 
most sensitive to BCH treatment with complete inhibition of growth at the higher 
concentrations tested. Both GS-Null and T48 cells had increased resistance to treatment, 
while CAT-S and T127 cells had the highest level of resistance. Culture viability 
measurements reflected these cell line differences with a high level of cell death 
observed in T29 cells, minor cell death observed in GS-Null and T48 cells, and no cell 
death observed in CAT-S and T127 cells (Figure 5.3 A–E).  
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Figure 5.2 The effect of BCH treatment on cell proliferation during exponential 
growth phase. Cells were treated for 4 days with BCH. Growth rates (d-1) were 
calculated and normalised to control cultures (0 mM BCH). Data is shown as the mean 
± SEM of three independently performed experiments (A., B., E.) or two independently 
performed experiments (C. & D.). An asterisk indicates the data point is from a single 
experiment (40 mM cultures for C. & D.). Non-linear regression analysis was used to fit 
dose-response curves and calculate the IC50 concentrations (table insert). 
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Figure 5.3 The effect of BCH treatment on culture viability and amino transport 
rates during exponential growth phase. Culture viability was measured on day 4 of 
BCH treatment. All control cultures (0 mM BCH) had viabilities >95%. Data is shown 
as the mean ± SEM of three independently performed experiments (A., B., E.) or two 
independently performed experiments (C. & D.). An asterisk indicates the data point is 
from a single experiment (40 mM cultures for C. & D.). Amino acid transport rates 
were calculated between days 1–3 for CAT-S cells (F.), and between days 1–4 for GS-
Null (G.) and T127 cells (H.). Closed bars are rates from control cultures and open bars 
are rates at 30 mM (CAT-S and GS-Null) and 40 mM BCH (T127). Data is the mean + 
SEM of three independently performed experiments. 
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Transport rates of classic system L substrates were measured for CAT-S, GS-
Null, and T127 cells in control and BCH treated cultures (Figure 5.3 F–H). Leucine 
transport rates could not be calculated as the amino acid quantification method (see 
Chapter 3; Section 3.2) measured BCH as leucine in treated cultures. Complete 
inhibition of uptake was observed for GS-Null and T127 cells at concentrations close to 
their IC50 (30 and 40 mM respectively). CAT-S cells continued to consume these amino 
acids around their IC50 (30 mM) but at a reduced rate with complete inhibition observed 
at 40 mM (data not shown). 
Antibody production was examined in T29, T48, and T127 cells (Figure 5.4). 
Specific productivity remained relatively constant over the concentration range tested in 
all the three cell lines with titre decreasing in a dose-dependent manner in response to a 
drop in IVCD. 
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Figure 5.4 The effect of BCH treatment on antibody production during 
exponential growth phase. Cells were treated for 3 days (A. & B.) or 4 days (C.) with 
BCH. IVCD (white bars), titre (grey bars) and QmAb (black bars) was calculated and 
normalised to control cultures (0 mM BCH). Data is shown as the mean + SEM of two 
independently performed experiments (A. & B.) or three independently performed 
experiments (C.). The asterisk indicates the data is from a single experiment at 40 mM 
BCH with T29 (A.) and T48 (B.) cells.  
 
 
The effect of BCH treatment during stationary phase was tested in CAT-S and 
T127 cells (Figure 5.5). For CAT-S cells, culture viability began to decrease at higher 
concentrations (30 and 40 mM BCH) after 24 hr of treatment. After 3 days, the viability 
of these two CAT-S cultures was markedly lower than control cultures. In contrast, 
viability of CAT-S cultures treated with lower concentrations of BCH (2.5, 5, 10, and 
20 mM) was noticeably higher than control cultures, suggesting low levels of system L 
inhibition can prolong stationary growth in the host cell line. For T127 cells, no change 
in culture viability was observed after 24 hr of treatment. Analysis of antibody 
production over the same time period did however show specific productivity to 
decrease in a dose-dependent manner. T127 cells formed large rings of cell debris on 
the culture vessel wall after 24 hr in control cultures, preventing an accurate assessment 
of culture performance past this time point. Interestingly, addition of BCH prevented 
the formation of these cell debris rings and culture viability remained above 90% after 3 
days for treated cultures at all concentrations (data not shown). 
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Figure 5.5 The effect of BCH treatment on CAT-S and T127 cells at stationary 
phase of batch culture. Culture viability was assessed for CAT-S cells at day 1 (A.), 
day 2 (B), and day 3 (C.) post-addition of BCH. T127 cells had their viability (D.) and 
antibody production (E.) assessed at day 1 post-addition of BCH. Control cultures 
represent cells incubated with 0 mM BCH. Data is shown as the mean + SEM of three 
independently performed experiments. An asterisk indicates data shown as the mean + 
SEM of two independently performed experiments.  
 
 
5.3.2 System A Transport Inhibition 
The three transporters of system A (SNAT1, 2, and 4) mediate the transport of small 
non-essential neutral amino acids such as alanine, asparagine, glutamine, and serine (see 
Chapter 2; Table 2.1). The alanine analog, α-(methylamino)isobutyric acid (MeAIB), is 
a highly specific transportable inhibitor for all system A transporters (Sugawara et al., 
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2000; Varoqui et al., 2000; Yao et al., 2000), and has been used to examine SNAT2 
activity in the MCF-7 breast cancer cell line (Pinilla et al., 2011). From Chapter 4, 
SNAT2 together with ASCT1 was hypothesised to be the main entry routes for this 
group of amino acids in all cell lines. Because of this transport redundancy, MeAIB 
treatment is hypothesised to reduce but not completely suppress cell growth for all cell 
lines early in culture. 
Figure 5.6 shows the dose-response curves for cells treated with MeAIB during 
exponential growth. MeAIB markedly affected growth in all cell lines expressing 
glutamine synthetase, while growth of CAT-S cells was only slightly reduced. Blocking 
system A transport does not lead to complete inhibition of cell proliferation. For that 
reason IC25 concentrations were calculated for cell lines expressing glutamine 
synthetase. A comparison of these values shows T29 cells to be slightly more sensitive 
to system A inhibition. Culture viability measurements demonstrate that decreased cell 
proliferation was not accompanied by cell death in any cell line (Figure 5.7 A–E).  
 
 
Figure 5.6 The effect of MeAIB treatment on cell proliferation during exponential 
growth phase. Cells were treated for 4 days with MeAIB. The specific growth rate (d-1) 
was calculated and normalised to control cultures (0 mM MeAIB). Data is shown as the 
mean ± SEM of three independently performed experiments. Non-linear regression 
analysis was used to fit dose-response curves and calculate the IC25 values (table insert). 
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Figure 5.7 The effect of MeAIB treatment on culture viability and amino transport 
rates during exponential growth phase. Culture viability was measured on day 4 of 
MeAIB treatment (A. – E.). All control cultures (0 mM MeAIB) had viabilities >95%. 
Data is shown as the mean ± SEM of three independently performed experiments. 
Amino acid transport rates were calculated between days 1–3 for CAT-S cells (F.), and 
between days 1–4 for GS-Null (G.) and T127 cells (H.). Closed bars are rates from 
control cultures and open bars are rates at 40 mM (CAT-S), 10 mM (GS-Null), and 5 
mM MeAIB (T127). Data is the mean + SEM of three independently performed 
experiments.  
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Transport rates of classic system A substrates were measured for CAT-S, GS-
Null, and T127 cells in control and MeAIB treated cultures (Figure 5.7 F–H). 
Consumption of these amino acids was reduced but not completely inhibited in GS-Null 
and T127 cells at concentrations close to their IC25 (10 and 5 mM respectively). This 
was also observed in CAT-S cells at the maximum MeAIB concentration (40 mM). 
Significant consumption of asparagine and serine continued in GS-Null and T127 cells 
at 40 mM MeAIB demonstrating that complete inhibition of system A substrates did not 
occur in these two cell lines either (data not shown). 
Antibody production was examined in T29, T48, and T127 cells (Figure 5.8). 
Specific productivity remained relatively constant over the concentration range tested in 
the low producer (T29) with titre decreasing in a dose-dependent manner in response to 
a drop in IVCD. The two high producers (T48 and T127) however showed a slight 
reduction in specific productivity in response to MeAIB treatment. 
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Figure 5.8 The effect of MeAIB treatment on antibody production during 
exponential growth phase. Cells were treated for 3 days (A. & B.) or 4 days (C.) with 
MeAIB. IVCD (white bars), titre (grey bars) and QmAb (black bars) was calculated and 
normalised to the control cultures (0 mM MeAIB). Data is shown as the mean + SEM 
of three independently performed experiments.  
 
 
The effect of MeAIB treatment during stationary phase was tested in CAT-S, 
GS-Null, and T127 cells (Figure 5.9). For CAT-S and GS-Null cells, no change in 
culture viability was observed after 2 days of treatment. For T127 cells, no change in 
culture viability or antibody production was observed after 24 hr of treatment. T127 
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cells formed large rings of cell debris on the culture vessel wall after 24 hr in control 
and treated cultures, preventing an accurate assessment of culture performance past this 
time point 
 
 
Figure 5.9 The effect of MeAIB treatment on CAT-S, GS-Null, and T127 cells at 
stationary phase of batch culture. Culture viability was assessed for CAT-S cells (A.) 
and GS-Null cells (B.) at day 2 post-addition of MeAIB. T127 cells had their viability 
(C.) and antibody production (D.) assessed at day 1 post-addition of MeAIB. Control 
cultures represent cells incubated with 0 mM MeAIB. Data is shown as the mean + 
SEM of three independently performed experiments. 
 
 
5.3.3 System XC- Transport Inhibition 
Chapter 4 hypothesised that the system XC- transporter xCT has a critical role in 
supporting cell viability in all cell lines. xCT activity was also hypothesised to support 
antibody production in T127 cells during late-stage culture. Sulfasalazine (SAS) is a 
clinically approved drug for the treatment of inflammatory bowel diseases and 
rheumatoid arthritis but has also been demonstrated as an effective inhibitor of cystine 
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uptake through the xCT transporter in a range of cancer cell lines (Chung et al., 2005; 
Gout et al., 2001; Timmerman et al., 2013). However, SAS also has two reported off-
target effects. It can inhibit activation of the transcription factor nuclear factor-κB (NF-
κB), which is involved in the activation of genes involved in cell proliferation and anti-
apoptosis (Robe et al., 2004; Wahl et al., 1998). It can also inhibit glutathione S-
transferases (GSTs), which catalyze the conjugation of GSH and electrophiles to 
prevent cell damage (Awasthi et al., 1994; Bach et al., 1985). Cells were treated with 
SAS to inhibit xCT activity, which is hypothesised to inhibit cystine uptake and induce 
cell death in all cell lines.  
Figure 5.10 shows the dose-response curves for cells treated with SAS during 
exponential growth. All cell lines exhibited a marked decrease in cell proliferation. 
However, differences in sensitivity were apparent between the five cell lines as 
demonstrated by a comparison of their respective IC50 concentrations. CAT-S, GS-Null, 
and T29 cells were most sensitive to SAS treatment with both GS-Null and T29 cells 
showing complete inhibition of growth at 1 mM SAS. T48 cells were slightly more 
resistant to treatment, particularly at lower concentrations of SAS, while T127 cells 
were found to be most resistant. Interestingly, there was a small improvement in growth 
rate for T29 and T127 cells in response to treatment with 0.3 mM SAS compared to 
control cultures. T127 cells treated with 0.3 mM SAS continued to have a faster growth 
rate (21.9 ± 1.6%; mean ± SEM, n = 3) than control cultures by day 4 of treatment. 
Culture viability measurements on day 3 of inhibition demonstrate that moderate levels 
of cell death accompanied decreased cell proliferation for CAT-S, GS-Null, and T29 
cells (Figure 5.11 A–E). Minor cell death was observed in the two high producers (T48 
and T127). An assessment of culture viability after 4 days of treatment found substantial 
cell death in all cell lines with no obvious differences in sensitivity between them at 
higher SAS concentrations. 
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Figure 5.10 The effect of SAS treatment on cell proliferation during exponential 
growth phase. Cells were treated for 3 days with SAS. The specific growth rate (d-1) 
was calculated and normalised to the vehicle control cultures (0.2% DMSO v/v CD-
CHO medium with 0 mM SAS). Data is shown as the mean ± SEM of three 
independent cultures. Non-linear regression analysis was used to fit dose-response 
curves and calculate the IC50 concentrations (table insert). 
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Figure 5.11 The effect of SAS treatment on culture viability and amino transport 
rates during exponential growth phase. Culture viability was measured on day 3 
(open squares) and day 4 (closed squares) of SAS treatment (A. – E.). All vehicle 
control cultures (0.2% DMSO v/v CD-CHO medium with 0 mM SAS) had viabilities 
>95% on both days. Data is shown as the mean ± SEM of three independent cultures. 
Amino acid transport rates were calculated between days 1–3 (F. – K.). Closed bars are 
rates from vehicle control cultures and open bars are rates at 0.7 mM (CAT-S and GS-
Null) and 0.8 mM SAS (T127). Data is the mean + SEM of three independently 
performed experiments.  
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Transport rates of cystine and glutamate were measured for CAT-S, GS-Null, 
and T127 cells in control and SAS treated cultures (Figure 5.11 F–H). All cell lines 
showed a small decrease in cystine consumption at concentrations close to their IC50. 
No change in glutamate transport was observed in CAT-S and T127 cells but GS-Null 
cells demonstrated an increase in glutamate uptake. Cystine starvation has been shown 
to induce the amino acid response (AAR) signalling pathway in mammalian cells (Lee 
et al., 2008). The amino acid transporters SNAT2, CAT-1 as well as xCT itself are three 
well-studied target genes of the AAR pathway whose expression is upregulated in 
response to its activation. To investigate if this pathway was activated by system XC- 
inhibition, the transport rates of representative substrates for the SNAT2 and CAT-1 
transporters were measured. SAS was found to increase the consumption of the SNAT2 
substrate asparagine in a dose-dependent manner in the three cell lines (example data 
given at IC50 concentrations in Figure 5.11 I–K). Glutamine consumption in CAT-S 
cells increased in the same way. However, transport rates of the CAT-1 substrates 
arginine and lysine did not change in response to SAS treatment.  
Antibody production was examined in T29, T48, and T127 cells (Figure 5.12). 
For T127 cells, day 4 titres decreased in a dose-dependent manner in response to a drop 
in both IVCD and specific productivity. The improvement in T127 growth rate 
observed with 0.3 mM SAS treatment led to an increased titre. For T29 and T48 cells, 
antibody data was measured in cultures treated with 0.3 and 0.8 mM SAS only. Day 3 
titres decreased at the higher concentration for both cell lines in response to a drop in 
IVCD only. Treatment of 0.3 mM SAS in T29 cells boosted specific productivity in 
addition to growth resulting in ~40% increase in titre. 
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Figure 5.12 The effect of SAS treatment on antibody production during 
exponential growth phase. Cells were treated for 3 days (A. & B.) or 4 days (C.) with 
SAS. IVCD (white bars), titre (grey bars) and QmAb (black bars) was calculated and 
normalised to the vehicle control cultures (0.2% DMSO v/v CD-CHO medium with 0 
mM SAS). Data is shown as the mean + SEM of three independent cultures. The 
asterisk indicates 0.8 mM data is shown as the mean + SEM of two independent 
cultures with (A.) T29 and (B.) T48 cells. 
 
 
The effect of SAS treatment during stationary phase was tested in CAT-S, GS-
Null, and T127 cells (Figure 5.13). The three cell lines displayed a striking increase in 
sensitivity to system XC- inhibition with cell death taking place just hours after SAS 
treatment. The reduced SAS “dose-per-cell” at stationary phase compared to 
exponential growth underscores this increase in sensitivity across the three cell lines. 
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Analysis of antibody production in T127 cells found specific productivity to decrease in 
a dose-dependent manner in response to SAS treatment at stationary phase. 
 
 
Figure 5.13 The effect of SAS treatment on CAT-S, GS-Null, and T127 cells at 
stationary phase of batch culture. Culture viability was assessed for CAT-S cells (A.) 
and GS-Null cells (B.) at 13 hrs post-addition of SAS. T127 cells had their viability (C.) 
and mAb production (D.) assessed at 11 hrs post-addition of SAS. Data is shown as the 
mean + SEM of three independently performed experiments, except QmAb (D.) where 
the data shown is the mean + SEM of two independently performed experiments at all 
concentrations. 
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ASCT1 during late-stage culture in all cell lines also lead to the suggestion that it may 
have a key role in supporting cell viability. The glutamine analog, L-γ-glutamyl-p-
nitroanilide (GPNA), contains a phenyl ring on the amide nitrogen group that mediates 
binding to the ASCT2 transporter (Esslinger et al., 2005). GPNA has been demonstrated 
as an effective inhibitor of glutamine uptake in HeLa cells (Nicklin et al., 2009) and the 
A549 lung cancer cell line (Hassaniein et al., 2013). Because ASCT1 and ASCT2 
exhibit ~60% amino acid sequence identity with each other (Kanai et al., 2013), it is 
possible that GPNA may also bind to ASCT1. GPNA treatment is hypothesised to 
suppress cell growth during exponential phase and induce cell death at stationary phase 
in all cell lines. Treatment is also expected to have a negative effect on antibody 
production in T127 cells. 
Figure 5.14 shows the dose-response curves for cells treated with GPNA during 
exponential growth. All cell lines exhibited a marked decrease in cell proliferation, 
however large differences in sensitivity exist. CAT-S and GS-Null cells were most 
sensitive to GPNA treatment sharing an IC50 concentration of 0.2 mM but having quite 
different dose-response curves. There was a considerable amount of variability in 
growth responses amongst the antibody producing cell lines, which did not correlate 
with productivity. T127 cells were by far the most resistant cell line of the five tested, 
having an IC50 concentration that is a magnitude higher than the host cell line. Whereas 
T48, also a high producer was very sensitive to GPNA treatment. The low producer T29 
was found to be more resistant than T48 cells but also more sensitive than T127 cells. 
Culture viability measurements on day 3 of treatment reflected these cell line 
differences with T127 cells being most resistant to cell death (Figure 5.15 A–E). An 
assessment of culture viability after 4 days of treatment found substantial cell death in 
all cell lines except T127 cells, which continued to demonstrate a high level of 
resistance. 
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Figure 5.14 The effect of GPNA treatment on cell proliferation during exponential 
growth phase. Cells were treated for 3 days with GPNA. The specific growth rate (d-1) 
was calculated and normalised to the vehicle control cultures (0.2% DMSO v/v CD-
CHO medium with 0 mM GPNA). Data is shown as the mean ± SEM of three 
independent cultures. An asterisk indicates data shown as the mean ± SEM of two 
independent cultures (2 mM cultures for D. only). Non-linear regression analysis was 
used to fit dose-response curves and calculate the IC50 concentrations (table insert). 
 
 D.        T48 
-4.5 -4.0 -3.5 -3.0 -2.5
*
 E.    T127 
-4.5 -4.0 -3.5 -3.0 -2.5
 B.       GS-Null
log[GPNA], M
G
ro
w
th
 ra
te
, d
-1
 (%
 o
f v
eh
ic
le
 c
on
tro
l)
 C.        T29 
-4.5 -4.0 -3.5 -3.0 -2.5
0
20
40
60
80
100
120
 A.      CAT-S
20
40
60
80
100
120
Cell line 
 
IC50  
(mM) 
 
r2 
 
 CAT-S 
 
0.2 0.93 
 
 GS-Null 
 
0.2 0.93 
 
 T29 
 
1.3 0.87 
 
 T48 
 
0.3 0.91 
 
 T127 
 
3.1 0.91 
!101 
 
Figure 5.15 The effect of GPNA treatment on culture viability and amino 
transport rates during exponential growth phase. Culture viability was measured on 
day 3 (open squares) and day 4 (closed squares) of GPNA treatment. All vehicle control 
cultures (0.2% DMSO v/v CD-CHO medium with 0 mM GPNA) had viabilities >95% 
on both days. Data is shown as the mean ± SEM of three independent cultures. An 
asterisk indicates data shown as the mean ± SEM of two independent cultures (2 mM 
cultures for D. only). Amino acid transport rates were calculated between days 1–3 (F. – 
H.). Closed bars are rates from vehicle control cultures and open bars are rates at 0.2 
mM (CAT-S and GS-Null) and 3.7 mM GPNA (T127). Data is the mean + SEM of 
three independent cultures 
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Transport rates of classic system ASC substrates were measured for CAT-S, GS-
Null, and T127 cells in control and GPNA treated cultures (Figure 5.15 F–H). GPNA 
treatment was found to increase consumption of asparagine and serine in a dose-
dependent manner in the sensitive CAT-S and GS-Null cell lines. Glutamine 
consumption in CAT-S cells increased in the same way. This counterintuitive 
observation may be explained by activation of the AAR pathway in these cells resulting 
in increased expression of SNAT2 but the simultaneous downregulation of global 
protein synthesis. In support of this, cystine uptake through the xCT transporter was 
also found to increase in a dose-dependent manner. At 0.2 mM GPNA, cystine 
consumption increased by 16.2 ± 6.2% and 48.6 ± 7.0% (mean ± SEM, n = 3) in CAT-S 
and GS-Null cells respectively. For resistant T127 cells, consumption of asparagine and 
serine was reduced but not completely inhibited at the maximum GPNA concentration 
(3.7 mM). Consumption of cystine was approximately equivalent in control and 3.7 mM 
GPNA treated T127 cells (-3.7 ± 0.2 versus -3.8 ± 0.1 x10-5 nmol.cell-1.d-1; mean ± 
SEM, n = 3). 
Antibody production was examined in T29, T48, and T127 cells (Figure 5.16). 
For T29 and T127 cells, which demonstrated a high level of resistance to GPNA, 
specific productivity remained constant over the concentration range tested and titre 
decreased in a dose-dependent manner in response to a drop in IVCD. For T48 cells, 
titre decreased in response to a drop in both IVCD and specific productivity. 
 
!103 
 
Figure 5.16 The effect of GPNA treatment on antibody production during 
exponential growth phase. Cells were treated for 3 days with GPNA. IVCD (white 
bars), titre (grey bars) and QmAb (black bars) was calculated and normalised to the 
vehicle control cultures (0.2% DMSO v/v CD-CHO medium with 0 mM GPNA). Data 
is shown as the mean + SEM of three independent cultures. The asterisk indicates data 
from a single experiment at 3.0 mM GPNA with T29 (A.) and T48 (B.) cells.  
 
 
The effect of GPNA treatment during stationary phase was tested in CAT-S, 
GS-Null, and T127 cells (Figure 5.17). For CAT-S cells, no change in culture viability 
was observed after 2 days of treatment with the same concentration range used during 
exponential growth (0.05 – 0.8 mM GPNA). Increasing the concentration further (up to 
3 mM) still did not induce cell death, suggesting they are no longer sensitive to system 
ASC inhibition. GS-Null cells remain sensitive to system ASC inhibition during 
stationary phase with cell death observed after 2 days of GPNA treatment. For T127 
cells, no change in culture viability or antibody production was observed after 24 hr of 
treatment. 
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Figure 5.17 The effect of GPNA treatment on CAT-S, GS-Null, and T127 cells at 
stationary phase of batch culture. Culture viability was assessed at day 1 and day 2 
post-addition of GPNA for CAT-S and GS-Null cells (A. – D.). T127 cells had their 
viability (E.) and mAb production (F.) assessed at day 1 post addition of GPNA. Data is 
shown as the mean + SEM of three independently performed experiments. An asterisk 
indicates data shown as the mean + SEM of two independently performed experiments 
(3 mM cultures for CAT-S only). 
 
 
5.3.5 GlyT1 Transport Inhibition 
Chapter 4 demonstrated that changes to GlyT1 expression correlated well with changes 
in expression of the cystine xCT transporter. It is therefore hypothesised that GlyT1 
may be mediating the influx of glycine to support GSH synthesis. The glycine analog, 
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5407 HCl (N-[(3R)-3-([1,1'-Biphenyl]-4-yloxy)-3-(4-fluorophenyl)propyl]-N-
methylglycine hydrochloride), is a sarcosine analog that is a potent non-transportable 
inhibitor for GlyT1 (Atkinson et al., 2001). Because of the above observations with the 
transcriptomic data, ALX 5407 HCl treatment is hypothesised to induce cell death in all 
cell lines.  
CAT-S, GS-Null, and T127 cells were treated with ALX 5407 HCl during 
exponential growth (Figure 5.18). Blocking GlyT1 transport reduced cell proliferation 
in all three cell lines but did not result in complete inhibition of growth (Figure 5.18 A–
C). A comparison of IC25 values shows T127 cells to be slightly more resistant to GlyT1 
inhibition. Culture viability measurements found no significant cell death for any of the 
three cell lines (Figure 5.18 D–F). Analysis of antibody production in T127 cells found 
specific productivity to remain constant over the concentration range tested with titre 
decreasing in response to a drop in IVCD (Figure 5.18 G). 
Transport rates of glycine were measured for the three cell lines in control and 
ALX 5407 HCl treated cultures (Figure 5.18 H–J). ALX 5407 HCl treatment was found 
to increase production of glycine in the three cell lines. Glycine transport through 
GlyT1 is coupled to Na+ and Cl- transport making it effectively unidirectional for 
glycine import (see Chapter 2; Table 2.1). GlyT1 inhibition must therefore be limiting 
glycine consumption while glycine export via other transport processes continues thus 
demonstrating that glycine is simultaneously both produced and consumed within cells 
through different transporters. 
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Figure 5.18 The effect of ALX 5407 HCl treatment on CAT-S, GS-Null, and T127 
cells during exponential growth phase. Cells were treated for 3 days with ALX 5407 
HCl. The specific growth rate (d-1) was calculated and normalised to the vehicle control 
cultures (0.2% DMSO v/v CD-CHO medium with 0 µM ALX 5407 HCl) (A. – C.). 
Non-linear regression analysis was used to fit dose-response curves and calculate the 
IC25 values (table insert). Culture viability was measured on day 3 of treatment (D. – 
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F.). All vehicle control cultures had viabilities >95%. Production of mAb was also 
assessed on day 3 of treatment for T127 cells (G.). Data is shown as the mean ± SEM of 
three independently performed experiments. An asterisk indicates data shown as the 
mean ± SEM of two independently performed experiments (50 µM cultures for A. – F.) 
and mAb data from a single experiment at 50 µM (G.). Amino acid transport rates were 
calculated between days 1–3 (H. – J.). Closed bars are rates from vehicle control 
cultures and open bars are rates at 50 µM GPNA ALX 5407 HCl.  
 
 
The cell lines were also treated with ALX 5407 HCl during stationary phase 
(Figure 5.19). For CAT-S cells there was some minor cell death in treated cultures 
compared to control cultures. GS-Null cells had an increased sensitivity to GlyT1 
inhibition at stationary phase, with moderate levels of cell death observed in treated 
cultures. For T127 cells, no change in culture viability was observed after 24 hr of 
treatment but an assessment of antibody production showed decreased specific 
productivity in treated cultures. 
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Figure 5.19 The effect of ALX 5407 HCl treatment on CAT-S, GS-Null, and T127 
cells at stationary phase of batch culture. Culture viability was assessed at day 1 and 
day 2 post-addition of ALX 5407 HCl for CAT-S and GS-Null cells (A. – D.). T127 
cells had their viability (E.) and mAb production (F.) assessed at day 1 post-addition of 
ALX 5407 HCl. Data is shown as the mean + SEM of three independently performed 
experiments. 
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5.3.6 Multi-Transporter Inhibition in T127 Cells During Exponential Growth 
Finally, the effect of inhibiting multiple transport systems simultaneously on growth 
rate, culture viability, and specific productivity was investigated in the antibody-
producing T127 cell line. Four transport systems (factors) were studied: A, ASC, L, and 
XC- using MeAIB, GPNA, BCH, and SAS respectively. A two-level factorial design 
was conducted as this can reveal interactions between the transport systems that would 
not otherwise be revealed through a one-factor-at-a-time (OFAT) experiment. Each 
inhibitor was applied at either 0 mM (– level) or its respective IC25 concentration (+ 
level) resulting in 16 (=24) level combinations (Appendix Table B1). IC25 
concentrations were determined from the earlier dose-response curves (MeAIB = 5 
mM; GPNA = 0.4 mM; BCH = 10 mM; SAS = 0.6 mM). Figure 5.20 shows the data for 
the three response variables. 
 
!110 
 
Vehicle B S M G MG MS BG MB BS MBS MBG SG MSG BSG MBSG
0
20
40
60
80
100
120
Inhibitor combination
G
ro
w
th
 ra
te
, d
-1
 (%
 o
f v
eh
ic
le
 c
on
tro
l)
A.
* *ctrl
Vehicle B M MB BG MBG G MG MS S BS MBS SG MSG BSG MBSG
0
20
40
60
80
100
120
Inhibitor combination
Vi
ab
ili
ty
 (%
 o
f v
eh
ic
le
 c
on
tro
l)
B.
* *ctrl
Vehicle B BG MB MG G M MBG S MBS MSG MBSG BS SG BSG MS
0
20
40
60
80
100
120
Inhibitor combination
Q
m
A
b, 
pg
 m
A
b.
ce
ll-
1 .d
-1
 (%
 o
f v
eh
ic
le
 c
on
tro
l)
* *ctrl
C.
!111 
Figure 5.20 The effect of multi-transporter inhibition on T127 cells during 
exponential growth phase. Cells were treated for 4 days with different combinations of 
transport system inhibitors. The specific growth rate (d-1) (A.), culture viability (%) (B.) 
and specific antibody production (qmAb, pg mAb.cell-1.d-1) (C.) was calculated and 
normalised to the vehicle control cultures (0.2% DMSO v/v CD-CHO medium with no 
inhibitor). Inhibitors were applied at their IC25 values: B, BCH (10 mM); S, SAS (0.6 
mM); M, MeAIB (5 mM); G, GPNA (0.4 mM). Data is shown as the mean + SEM of 
four independently performed experiments (A. & B.) or three independently performed 
experiments (C.). An asterisk indicate data shown as the mean + SEM of three 
independently performed experiments (A. & B.) or two independently performed 
experiments (C.).  
 
 
5.3.6.1 Multi-Transporter Inhibition and Growth Rate 
A half-normal probability plot created in Design Expert 9 (see 5.2 Materials and 
Methods) identified inhibition of systems A, ASC, L, and XC- alone as significant 
factors affecting growth rate in T127 cells (Appendix Figure B1). These significant 
factors were fitted to the following predictive model: 
 
Growth rate = 55.2 – 7.3*MeAIB – 8.6*BCH – 13.3*SAS – 11.6*GPNA 
 
An ANOVA confirmed that the model and each of the model terms is statistically 
significant (Model: F(4,11) = 26.73, P < 0.0001; MeAIB: F(1,11) = 13.04, P = 0.0041; 
BCH: F(1,11) = 18.08, P = 0.0014; SAS: F(1,11) = 42.77, P < 0.0001; GPNA: F(1,11) = 
33.03, P = 0.0001). A normal probability plot of residuals confirmed normality of 
residuals (Appendix Figure B2). 
 A comparison of the factor coefficients indicates that the inhibition of systems 
ASC and XC- has the biggest impact upon growth rate in T127 cells during exponential 
growth. Inhibition of systems A and L has an approximately equivalent negative impact 
upon growth that is less than that observed with the former two systems. Inhibiting 
multiple transport systems simultaneously demonstrates synergistic effects on growth 
rate in T127 cells (Figure 5.20 A). No interactions such as the inhibition of one 
transport system potentiating the inhibition of a second transport system were identified 
in the factorial experiment. 
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5.3.6.2 Multi-Transporter Inhibition and Culture Viability 
A half-normal probability plot identified inhibition of systems L, XC-, and ASC alone, 
as well as interactions of systems L*XC-, L*ASC, and XC-*ASC as significant factors 
affecting culture viability in T127 cells (Appendix Figure B3). These significant factors 
were fitted to the following predictive model: 
 
Culture viability = 88.0 – 1.5*BCH – 9.4*SAS – 4.8*GPNA – 1.7*BCH*SAS + 
0.9*BCH*GPNA – 3.2*SAS*GPNA 
 
An ANOVA confirmed that the model and each of the model terms is statistically 
significant (Model: F(6,9) = 204.01, P < 0.0001; BCH: F(1,9) = 22.63, P = 0.0010; SAS: 
F(1,9) = 850.46, P < 0.0001; GPNA: F(1,9) = 219.78, P < 0.0001; BCH*SAS: F(1,9) = 
26.58, P = 0.0006; BCH*GPNA: F(1,9) = 7.24, P = 0.0248; SAS*GPNA: F(1,9) = 97.35, 
P < 0.0001). A normal probability plot of residuals confirmed normality of residuals 
(Appendix Figure B4). 
Inhibition of systems XC- has the biggest impact upon culture viability in T127 
cells, followed by inhibition of system ASC. Interestingly, inhibiting system ASC at the 
same time as system XC- potentiates the negative effect the latter has on culture viability 
(Appendix Figure B5 A). System L inhibition makes a small but significant impact 
upon culture viability, however its inhibition can potentiate the effect of system XC- 
inhibition (Appendix Figure B5 B) or help minimise the effect of system ASC 
inhibition (Appendix Figure B5 C). 
 
5.3.6.3 Multi-Transporter Inhibition and Specific Productivity 
A half-normal probability plot identified only system XC- as a significant factor 
affecting specific productivity in T127 cells (Appendix Figure B6). This further 
confirms the observations above in which only SAS treatment induced a large effect on 
specific productivity. The dependence of specific productivity on XC- inhibition was 
predicted using: 
 
Specific productivity = 85.2 – 12.9*SAS 
 
An ANOVA confirmed that the model is statistically significant (F(1,14) = 37.23, P < 
0.0001). A normal probability plot of residuals confirmed normality of residuals 
(Appendix Figure B7).
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5.4 Discussion 
The work presented here is the second chapter of two that characterises the system of 
amino acid transporters in industrial CHO cell lines and complements the work of 
Chapter 4. In this second chapter, inhibitors were used to block amino acid entry 
through discrete transport systems in order to help understand how their transport 
function contributes to culture performance parameters. The inhibitors used were mostly 
analogs of natural proteinogenic amino acids and were selected based on prior use in the 
literature, their inability to be metabolised (e.g. ALX 5407 HCl over sarcosine for 
GlyT1 transporter), and had to be non-toxic to the cell itself (e.g. BCH over melphalan, 
a second inhibitor of system L transport which is also an alkylating agent). The exact 
mechanisms by which inhibiting a transport system induced changes to cell growth, 
viability or antibody production were not explored but hypotheses are provided in the 
discussion that follows. 
 
5.4.1 System L Inhibition Blocks Essential Amino Acid Uptake, Suppresses Cell 
Growth, and Inhibits Antibody Production 
BCH is a highly specific inhibitor for the four transporters that make up system L (Babu 
et al., 2003; Bodoy et al., 2005; Kanai et al., 1998; Pineda et al., 1999). In this chapter, 
BCH treatment completely inhibited the uptake of classic system L amino acids (Figure 
5.3 F–H). This is consistent with the hypothesis put forward in Chapter 4 that system L 
is the major uptake route for essential amino acids. Many cancer cell lines preferentially 
increase their expression of LAT1 over the other three system L transporters to support 
increased growth rates (Fuchs and Bode, 2004), which was also seen in the three CHO 
cell lines examined in Chapter 4 (see Section 4.4.1). Based upon this, LAT1 is assumed 
to be mediating the majority of system L transport. The present results cannot confirm 
this but it could be investigated in future studies using siRNA knockdown of LAT1 
mRNA as demonstrated previously in HeLa cells (Nicklin et al., 2009).  
BCH treatment resulted in complete or near complete suppression of cell growth 
in the five cell lines tested during exponential growth (Figure 5.2) with varying degrees 
of cell death also observed (Figure 5.3). For the three antibody-producing cell lines, titre 
was coupled to cell growth with specific productivity unaffected (Figure 5.4). The 
mechanism of growth suppression was not investigated but system L inhibition was 
assumed to deplete cytosolic levels of essential amino acids including leucine. Previous 
work has demonstrated that BCH induced depletion of intracellular leucine induces 
caspase-mediated apoptotic cell death in cancer cells (Kim et al., 2008). Inhibiting 
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leucine uptake in HeLa cells with BCH suppresses mTORC1 signaling (Nicklin et al., 
2009). Removing leucine, akin to BCH treatment, suppresses mTORC1 signaling and 
stimulates the AAR pathway in CHO cells (Fomina-Yadlin et al., 2014). This group 
also demonstrated downregulation of genes involved in cell cycle progression, DNA 
replication, nucleotide biosynthesis, and lipid biosynthesis in response to leucine 
withdrawal, which could explain the responses seen in this chapter. The present results 
found differences in sensitivity between the cell lines in response to BCH treatment as 
demonstrated by a comparison of their IC50 values. This cannot be readily explained. 
Similarly, Fomina-Yadlin et al. (2014) observed variable levels of growth inhibition and 
cell death in five antibody-producing and parental CHO cell lines in response to leucine 
withdrawal. 
Chapter 4 identified LAT1 as a potential marker for productivity during late-
stage culture, which was hypothesised to support an increased essential amino acid 
demand for antibody production. Consistent with this hypothesis, specific productivity 
decreased in a BCH dose-dependent manner at stationary phase (Figure 5.5). 
Interestingly, low concentrations of BCH prolonged the viability of CAT-S cultures 
during late-stage culture. This cannot be readily explained, however further work to 
elucidate the mechanism could benefit the design of nutrient feeds for fed-batch 
processes where manipulating the essential amino acid composition may lead to 
prolonged culture viability. 
 
5.4.2 Dependence Upon System A and ASC Transport for Cell Growth Differs 
Between Cell Lines 
Many cancer cell lines preferentially increase their expression of ASCT2 to support the 
uptake of small non-essential neutral amino acids (Fuchs and Bode, 2004; Ganapathy et 
al., 2009). Transcriptomic data from the three cell lines examined in Chapter 4 
identified high expression of SNAT2 and ASCT1 (the second system ASC transporter). 
ASCT2 was missing from the reference genome but has been previously identified at 
the genomic, transcriptomic, and proteomic level in CHO cells by several groups 
(Appendix Table A1), and is therefore assumed to also be present. The conditionally 
essential requirement for asparagine and glutamine in CHO cells suggests that activity 
of these transporters must be critical to exponential growth, however their relative 
functional contribution to this phase of culture was previously unknown.  
The present results found cell lines expressing glutamine synthetase to be more 
sensitive to system A inhibition than the parental host (Figure 5.6). Across the cell lines 
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MeAIB impacted upon asparagine consumption the most, yet it failed to completely 
inhibit the transport of this and other classic system A amino acids (Figure 5.7 F–H), 
confirming the existence of additional transport processes for these substrates and 
explains why there was no complete suppression of cell growth. Interestingly, MeAIB 
minimally inhibited glutamine consumption in the parental host, even at 40 mM, a 
concentration at which it would completely outcompete glutamine. Collectively, these 
data suggest that recombinant glutamine synthetase cells are more sensitive to system A 
inhibition due to their increased dependence on asparagine, whereas the parental host 
also has access to glutamine whose primary entry route is not through system A in these 
cells. In support of this it has been demonstrated that asparagine and glutamine both 
significantly contribute to TCA cycle replenishment during exponential growth (Dean 
and Reddy, 2013). Recombinant GS-CHO cells grown in glutamine free media increase 
their consumption of asparagine (Zhang et al., 2006), limitation of which has been 
shown to limit GS-CHO cell growth while its removal leads to complete suppression of 
growth (Duarte et al., 2014). Removing asparagine has been shown to induce G1-phase 
cell cycle arrest in CHO cells (Fomina-Yadlin et al., 2014), whereas serine limitation 
has been shown to have less of a negative impact on GS-CHO cell growth (Duarte et al., 
2014). 
In contrast to the lack of sensitivity observed with system A inhibition, the 
parental host was found to be highly sensitive to system ASC inhibition (Figure 5.14). 
GS-Null cells were equally sensitive and T127 cells were most resistant as 
demonstrated by a comparison of their IC50 concentrations. Resistance to GPNA 
however did not correlate with productivity (comparison of T29, T48, and T127) but 
did correlate with ASCT1 mRNA levels (see Chapter 4; Table 4.1). Assessment of 
amino acid transport rates indicated activation of the AAR pathway in CAT-S and GS-
Null cells (Figure 5.15 F–H). Removal of asparagine or glutamine from CHO cells has 
previously been shown to activate the AAR pathway (Fomina-Yadlin et al., 2014). The 
present results cannot confirm GPNA mediated AAR activation but it could be 
investigated in future studies by measuring expression of AAR targets. ASCT1 was 
significantly upregulated at stationary phase in all cell lines leading to the hypothesis 
that it may be required to support cell viability. However, cell death in response to 
GPNA was observed with GS-Null cells only suggesting this hypothesis may not hold 
true for all cell lines.  
Upregulation of ASCT1 in T127 cells compared to the two non-producing cell 
lines throughout culture also lead to the suggestion that this transporter acts as a marker 
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for antibody production. It was hypothesised that this was to due to a high abundance of 
serine and threonine in the antibody. Yet, specific productivity was unaffected at both 
exponential and stationary growth in response to GPNA treatment in T127 cells. 
However, system A inhibition did cause a slight reduction in specific productivity in the 
two high-producers T48 and T127 (Figure 5.8), suggesting this hypothesis may still 
hold true. It could be that the concentration range of GPNA was not high enough in 
T127 cells to induce a reduction in specific productivity. In support of this, GPNA 
sensitive high-producing T48 cells demonstrated a decrease in titre in response to a drop 
in both IVCD and specific productivity (Figure 5.16).  
 
5.4.3 The xCT Transporter Supports Cell Viability in all Cell Lines and Antibody 
Production During Late-Stage Culture 
Cystine uptake through the xCT transporter is a prerequisite for GSH synthesis in 
cultured mammalian cells. In Chapter 4, the xCT transporter is reported to be 
significantly upregulated at stationary phase in all cell lines. It was hypothesised that 
this formed part of an adaptive response to support the availability of GSH and help 
maintain cell viability. In this chapter, SAS treatment resulted in cell death confirming 
that xCT transporter activity supports cell viability. Cell death was almost immediate 
during late-stage culture (Figure 5.13), whereas it only became substantial after 3–4 
days of treatment during early-stage culture for all cell lines (Figure 5.11 A–E). Chapter 
4 also identified xCT expression in T127 cells to be significantly higher than CAT-S 
and GS-Null cells at stationary phase. It was hypothesised that this was to help support 
an increased demand for cysteine in these cells for antibody production. Consistent with 
this hypothesis, specific productivity decreased in a SAS dose-dependent manner at 
stationary phase (Figure 5.13). Furthermore, specific productivity was also inhibited in 
a similar manner in T127 cells during exponential growth phase (Figure 5.12). The 
ability for T127 cells to significantly increase their expression of xCT may explain why 
they have an increased resistance to SAS treatment compared to the other cell lines 
examined during exponential growth. The high-producing T48 cell line may also have 
the same capability. 
SAS treatment reduced cystine uptake in all cell lines as expected (Figure 5.11 
F–H) but the precise mechanism of cell death was not explored. Previous groups have 
demonstrated that SAS depletes GSH levels and increases ROS levels (Chung et al., 
2005; Timmerman et al., 2013). Chung et al. (2005) investigated growth inhibition 
further and found SAS induced S-phase cell cycle arrest followed by caspase-mediated 
!117 
apoptotic cell death in glioma cells. Cells treated with SAS during exponential growth 
in this chapter followed this pattern of an initial decrease in cell proliferation and then 
cell death suggesting a similar mechanism is taking place. The rapid cell death observed 
in cells treated later in culture suggest high ROS levels at the time of SAS treatment. A 
shift in TCA cycle function towards oxidative phosphorylation as reported in other 
CHO cell lines during stationary phase (Zagari et al., 2012) could be the source of 
increased ROS (reviewed in Chapter 2; Section 2.1). 
Despite the cellular responses to xCT inhibition being in agreement with 
proposed hypotheses, a major limitation of this investigation is that the SAS off-target 
inhibition effects on NF-κB and GSTs were not investigated. A number of methods 
could be used in future work to investigate this such as testing whether the response to 
SAS can be repeated by a second xCT inhibitor such as the cyclic glutamate analog, S-
4-carboxy-phenylglycine (S-4-CPG) (Chung and Sontheimer, 2009; Patel et al., 2004), 
or siRNA reduction of xCT mRNA (Timmerman et al., 2013). 
 
5.4.4 The GlyT1 Transporter Supports Antibody Production During Late-Stage 
Culture 
Expression of the GlyT1 transporter correlated reasonably well with xCT expression in 
CAT-S, GS-Null, and T127 cells and was hypothesised to help support GSH synthesis 
(see Chapter 4). Similarly, Kyriakopoulos et al. (2013) found significant upregulation of 
GlyT1 expression in all cell lines at stationary phase.  
The present results found ALX 5407 HCl treatment mediated some inhibition of 
cell proliferation in all cell lines during exponential growth with minimal cell death 
(Figure 5.18). As with xCT inhibition, CAT-S and GS-Null cells were more sensitive to 
GlyT1 inhibition during late-stage culture demonstrating significant cell death after 2 
days of treatment (Figure 5.19). Specific productivity decreased in response to ALX 
5407 HCl treatment in T127 cells. Interestingly, glycine is the fifth most abundant 
amino acid in the IgG antibody (see Chapter 4; Table 4.7). This suggests that GlyT1 
transport activity may help support antibody production during late-stage culture.  
 
5.4.5 Conclusions and Future Perspectives 
Inhibitors of individual amino acid transporters (GlyT1, xCT) and transport systems (A, 
ASC, L) were used to evaluate how transporter function contributes to CHO culture 
performance parameters (growth rate, viability, and specific productivity). The results 
demonstrate that GlyT1, xCT, and system L transport support antibody production 
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during late-stage culture in T127 cells. System A and xCT transport also support 
specific productivity during exponential growth in these cells. Transcriptomic data 
suggests that LAT1 and SNAT2 are the main mediators of system L and A activity 
respectively. xCT transport activity is also a key determinant of culture viability 
throughout culture for all cell lines. Increased sensitivity to xCT inhibition was 
observed during late-stage culture, which correlates with a significant upregulation in 
expression of this transporter and decreased cystine transport, suggesting that xCT 
transport represents a bottleneck for all cell lines. Of noticeable difference between the 
cell lines is the increased dependence of recombinant glutamine synthetase cells for 
system A transport activity. Whereas, the parental host has an increased dependence for 
system ASC transport activity compared to T127 cells. A factorial experiment with 
T127 cells during exponential growth showed that xCT was the only transporter to have 
a strong significant negative effect on growth rate, viability, and specific productivity. It 
also revealed an interaction between xCT and system ASC transport whereby 
simultaneous inhibition of the latter potentiates cell death.  
It should also be noted that despite the specificity of the inhibitors used in this 
study (Figure 5.1), it cannot conclusively be said that the effect they have on growth, 
viability or productivity is directly related to the inhibition of their target transporters. 
As discussed in Chapter 2 (see 2.4 Amino Acid Transporters in Cancer), amino acid 
transporters can be functionally coupled such that the activity of a single transporter can 
limit/control the activity of a second. Therefore, transport inhibition of one transporter 
or transporter system may perturb the transport activity of a second, which may also 
have an impact upon cell line performance parameters. More targeted experimental 
approaches such as siRNA knock down or gene overexpression would generate the 
same concerns. Consequentially, results from inhibitor studies are actually more 
informative about how the activity of individual transporters operating within the 
context of a wider system of transporters contributes to cell line productivity.  
The knowledge from this chapter can help guide future cell line development 
(CLD) processes in a number of ways. Firstly, screening transfectant pools or clones 
early in CLD. Both xCT and system ASC transport act as markers of productivity. 
Application of SAS and GPNA can be used to rapidly enrich or select for cells with 
these transport capabilities (explored further in Chapter 6). Secondly, improving 
transport capabilities of cystine or essential amino acid transport by genetically 
engineering the host cell line to make it better suited for antibody production. Thirdly, 
improve media design (explored further in chapter 7). 
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Chapter 6 
Evolving Resistance to Amino Acid Transport 
Inhibition for Improved Cell Line Performance 
 
Both ASCT1 and xCT transporters were previously identified as potential markers of 
antibody production, with xCT also found to be critical in facilitating cystine influx and 
supporting culture viability. In this chapter, a directed evolution strategy was developed 
to isolate sub-populations of parental CAT-S cells and antibody-producing T127 cells 
resistant to GPNA and SAS transport inhibition. Evolved cell lines were hypothesised to 
have an increased capability for system ASC or xCT transport. Compared to the 
unevolved host, SAS-resistant CAT-S cells demonstrated an increased capacity for GSH 
synthesis, increased resistance to a ROS insult, and a heritable improvement in cell 
growth. However, neither SAS- or GPNA-resistant CAT-S cells could outperform the 
unevolved host in the transient production of a recombinant IgG. For SAS-resistant 
T127 cells, long-term exposure to the DMSO vehicle was found to have a negative 
impact upon cell growth and specific productivity. However, when this was controlled 
for, evolved T127 cells were capable of increased specific productivity leading to an 
increase in overall titres. The work in this chapter demonstrates that it is possible to 
isolate cell lines with desirable characteristics for biomanufacturing through 
manipulation of amino acid transport processes. 
 
 
6.1 Introduction  
As discussed in Chapter 1, production of recombinant therapeutic antibodies requires 
the isolation of cell lines that can stably produce high product titres with the necessary 
quality attributes. Because the majority of antibody synthesis is uncoupled from cell 
growth, the cell line must be capable of rapidly generating high cell densities that can be 
maintained for extended periods at high viabilities. Strategies used to maximise the 
potential of recombinant cell lines include improved expression vector design, 
optimisation of bioreactor control parameters, media optimisation, and cell engineering 
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approaches. Amino acid transporter proteins are unique in that they interface with both 
the intra- and extracellular environment such that the knowledge gained in Chapters 4 
and 5 can be used to improve media design (explored further in Chapter 7) or direct cell 
engineering strategies.  
Mammalian cell engineering strategies have traditionally involved the over-
expression or silencing of individual genes involved in cellular processes including 
metabolism, apoptosis and protein folding to introduce desirable characteristics for 
biomanufacturing (strategies reviewed in Lim et al., 2010). More recently, studies have 
explored the potential of exploiting the inherent heterogeneity of parental cell 
populations as an alternative to genetic manipulations. Davies et al. (2012) created a 
library of 199 untransfected clones from Lonza’s proprietary parental CHOK1SV cell 
line and demonstrated significant clone-specific variation in cell growth rates and ability 
to transiently express either GFP or an IgG antibody. This panel of host clones was 
subsequently used to help isolate cell lines that can transiently and stably outperform the 
transfected parental CHOK1SV host (O’Callaghan et al., 2015). Genetic instability of 
the CHO-K1 cell line is the primary source of such heterogeneity in parental 
populations. Early karyotype studies demonstrated the existence of large-scale deletions 
and rearrangements of chromosomes between different CHO cell lines (reviewed in 
Wurm and Hacker, 2011), while recent genome sequencing projects has provided a 
deeper analysis of genetic instability detailing missing genes, single-nucleotide 
polymorphisms (SNPs), short insertions and deletions, as well as gene copy number 
variations (CNVs) between industrial CHO cell lines (Lewis et al., 2013; Xu et al., 
2011). In addition to genetic alterations, DNA methylation has also been found to be a 
strong contributor to production instability in CHO cell populations resulting in gene 
silencing without loss of the gene itself (Kim et al., 2011; Yang et al., 2010b). Directed 
evolution of CHO cell lines (and any other genetically instable mammalian cell line) 
represents a method of exploiting genetic diversity to isolate sub-populations of cells 
with desirable phenotypic characteristics for biomanufacturing from a heterogeneous 
background. In this approach a selective pressure(s) is applied and resistant cells are 
selected. The process is typically repeated over many rounds until a stable population of 
cells with the required phenotype is obtained. Matsumura et al. (1991) demonstrated 
that by subjecting an antibody-producing hybridoma cell line to gradual increases in 
ammonia concentrations a sub-population of cells resistant to this stress could be 
isolated. Similarly, a human promyelocytic HL-60 cell line resistant to inhibitory levels 
of lactate and ammonia was isolated from a sensitive parental population (Schumpp and 
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Schlaeger, 1992). The resistant cells were capable of an extended stationary phase 
compared to non-resistant cells. Prentice et al. (2007) described a method of “bioreactor 
evolution” in which a parental and recombinant CHO cell line was adapted to the 
environmental conditions of decline phase in a fed-batch process. The evolved parental 
host cells attained a 2-fold increase in peak viable cell density, while the evolved 
recombinant cell line attained a ~40% increase in peak viable cell density resulting in a 
~40% gain in final titre in fed-batch cultures over the respective non-evolved cells. 
Directed evolution has also been used to adapt CHO cells to growth in glutamine free 
media (Bort et al., 2010; Taschwer et al., 2012). For an untransfected parental host, the 
glutamine-free adapted cells exhibited increased consumption of aspartate, asparagine, 
and glutamate (Bort et al., 2010). These latter studies demonstrate that directed 
evolution is a useful alternative to genetic manipulations for metabolic engineering 
strategies. 
The above evolution studies demonstrate that modifying the environmental 
conditions of CHO and other mammalian cell lines can successfully result in the 
isolation of sub-populations with improved manufacturing properties. This chapter 
examines the utility of directed evolution as a method of manipulating CHO amino acid 
transport processes with the aim to isolate cells with improved cell line manufacturing 
characteristics. In this chapter, inhibitors of amino acid transport from Chapter 5 (SAS 
and GPNA) are used as selective agents to isolate sub-populations of the parental CAT-
S host and T127 non-clonal IgG expressing cell line resistant to the effects of these 
compounds with the hypothesis that these resistant cells will have an increased 
capability for system xCT or ASC transport. In Chapters 4 and 5, the cystine-glutamate 
xCT antiporter was identified as a key determinant of culture viability in all cell lines, 
particularly during stationary phase. This correlated with a significant upregulation of 
xCT expression for all cells at this point in culture. Transcriptomic data indicates that 
this forms part of an adaptive response to support the availability of GSH by ensuring 
the cell has a sufficient supply of cystine. Furthermore, xCT expression in antibody-
producing T127 cells is significantly higher than the parental CAT-S host and the GS-
Null cell line, indicating that cystine import through the xCT transporter may also be 
required to support antibody production. Inhibitor data supports this hypothesis with 
T127 cells demonstrating a SAS dose-dependent decrease in specific productivity at 
exponential and stationary phase. Engineering the cell to have increased xCT transport 
functionality may therefore enhance culture longevity and boost specific productivity. 
This chapter first describes a direction evolution method that uses SAS as a selective 
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pressure to isolate a resistant sub-population of cells from the parental CAT-S host. 
These cells were then characterised by examining their growth, capacity for GSH 
synthesis and ability to transiently produce a recombinant IgG antibody. This adaptation 
method was also applied to the antibody-producing T127 cell line to investigate if 
evolving further resistance to SAS could further improve productivity. Finally, this 
chapter also explores if an increased capability for system ASC transport can support 
antibody synthesis as hypothesised in Chapter 4. This was investigated by repeating the 
evolution process with the parental CAT-S but with GPNA as the selective pressure. 
The growth and capacity of these cells to transiently produce a recombinant IgG 
antibody was also assessed. 
 
 
6.2 Materials and Methods 
6.2.1 Transient Transfection 
6.2.1.1 Expression Vectors 
The mAb-109 vector containing genes for both the heavy and light chains of a human 
IgG monoclonal antibody was kindly provided by MedImmune. A vector encoding GFP 
(phCMV C-GFP; Genlantis, San Diego, USA) was used to assess transfection 
efficiency. 
 
6.2.1.2 Lipofection 
Prior to transfection cells were sub-cultured at 5 x 105 cells.mL-1 in 100 mL of CD-
CHO medium supplemented with 8 mM L-glutamine (Life Technologies, Paisley, UK) 
in 500 mL vented Erlenmeyer flasks (Corning, Surrey, UK) for 24 hr until they reached 
1 x 106 cells.mL-1. Culture aliquots of 10 mL were then transferred to 50 mL vented 
TubeSpin® Bioreactors (TPP, Trasadingen, Switzerland). Cells were transfected using 
Lipofectamine® LTX with Plus™ Reagent (Life Technologies). For each transfection 
12 µg of DNA was incubated with 24 µL of Lipofectamine® LTX Reagent and 12 µL 
of PLUS™ Reagent for 5 min at room temperature. Both DNA and Lipofectamine® 
LTX Reagent were diluted in Opti-MEM® I Reduced Serum Medium (Life 
Technologies) prior to incubation. The DNA-Lipid complex was then added to cultures 
and incubated at 37oC in 5% CO2 air shaking at 170 rpm (Infors UK, Reigate, UK). 
Cultures were maintained by feeding 10% of the initial culture volume of CHO CD 
EfficientFeed™ A and B (1:1 ratio) (Life Technologies) at 48 and 96 hr post-
transfection.  
!123 
6.2.2 Flow Cytometry 
The Attune Autosampler® flow cytometer (Life Technologies) was used to measure 
GFP expression for transfection efficiency investigations. Cell events were plotted by 
measurements of both side-scatter (SSC; marker of granularity) and forward-scatter 
(FSC; marker of cell size) (Figure 6.1).  
 
 
Figure 6.1 Gated population of viable cells. 10, 000 viable cells were used to measure 
GFP expression in all experiments.   
 
 
The population of viable cells was gated and a daughter plot was generated to 
assess GFP expression. GFP was excited using a 488 nm laser passing through a 530/30 
centre/bandpass filter (BL1). Non-transfected control cells were used to detect 
autofluorescence and gate the daughter plot for GFP expression (Figure 6.2). A sample 
of 10, 000 viable cells were used to measure GFP expression in all experiments. Data 
was analysed using Attune® Cytometric Software v2.1 (Life Technologies). 
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Figure 6.2 Example daughter plot for GFP expression. (A.) Non-transfected cells 
were used to detect autofluorescence (GFP-) and gate the daughter plot. (B.) Detection 
of GFP (GFP+) expression in transfected cells.  
 
 
6.2.3 Cellular Glutathione Quantification 
Samples of 3 x 106 cells were centrifuged at 200g for 5 min, washed once in PBS and 
recentrifuged. Cells were diluted in fresh PBS and triplicate 10, 000 cells were 
dispensed per well in 96-well plates. Intracellular GSH levels were then measured using 
a GSH-Glo™ Glutathione Assay kit (Promega, Southampton, UK). Luminescence was 
read using a Fluoroskan Ascent™ FL (Thermo Scientific, Loughborough, UK). TCEP 
(tris(2-carboxyethyl)phosphine hydrochloride) solution (Sigma-Aldrich, Dorset, UK) 
was used to reduced oxidised GSH (GSSG) and measure total intracellular GSH levels. 
Cells were preincubated in a final concentration of 1 mM TCEP for 30 min at room 
temperature before proceeding with the GSH-Glo™ Glutathione Assay.  
 
6.2.4 Inhibitor Treatment 
Cells were treated following the method described previously (see Chapter 5; Section 
5.2.1). Hydrogen peroxide (Sigma-Aldrich) was diluted in CD-CHO medium (Life 
Technologies).   
 
6.2.5 Batch Overgrow Shake Flask Cultures 
Cells were seeded at 3 x 105 cells.mL-1 in 35 mL of CD-CHO medium (Life 
Technologies) in 125 mL vented Erlenmeyer flasks (Corning) shaking at 140 rpm in 
37oC and 5% CO2 air (Infors UK). CAT-S cells and evolved sub-populations were 
A. B. 
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supplemented with 8 mM L-glutamine (Life Technologies). T127 cells and evolved 
sub-populations were supplemented with 50 µM L-methionine sulfoximine (Sigma-
Aldrich) and grown in a humidified incubator.  
 
6.2.6 Fed-Batch Overgrow Shake Flask Cultures 
Cells were seeded at 3 x 105 cells.mL-1 in 35 mL of CD-CHO medium (Life 
Technologies) in 125 mL vented Erlenmeyer flasks (Corning) shaking at 140 rpm at 
37oC in 5% CO2 air (Infors UK). Cultures were supplemented with 8 mM glutamine at 
day 0 and then maintained by feeding 10% of the initial culture volume of CHO CD 
EfficientFeed™ A and B (1:1 ratio) (Life Technologies) every 72 hr from day 3 
onwards. 
 
 
6.3 Results 
6.3.1 Creation of a SAS-Resistant CAT-S Cell Line (CAT-R-S700) 
A sub-population of cells resistant to SAS mediated inhibition of the xCT transporter 
was isolated from the parental CAT-S host over an eight-week period (CAT-R-S700; 
Figure 6.3 A). A vehicle control cell line (CAT-CTRL) was created in parallel by sub-
culturing the parental host over the same time period with 0.2% DMSO v/v CD-CHO 
medium. SAS resistance was initiated by sub-culturing the parental host every 3–4 days 
with CD-CHO medium supplemented with 500 µM SAS. After 10 generations the 
viability of SAS treated cultures recovered to >90% (data not shown) and the SAS 
concentration was increased to 700 µM. Following a further 20 generations the growth 
rate of SAS treated cultures was comparable to equivalently aged CAT-CTRL cells over 
3–4 day sub-culturing periods. Yet, routine batch overgrows during sub-culturing 
demonstrated that maximal cell densities and culture viabilities were still significantly 
reduced in SAS treated cultures at day 6 (data not shown). After 50 generations growth 
had completely recovered and the CAT-R-S700 cell line was established. The CAT-R-
S700 cell line was characterised by performing a SAS dose-response study during 
exponential growth and comparing it to the curve generated for the parental host in 
Chapter 5 (Figure 6.3 B–C). The IC50 SAS concentration for the parental host was 
previously determined as 790 µM. However, SAS treatment had no effect on cell 
proliferation and culture viability in CAT-R-S700 cells at all concentrations tested. 
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Figure 6.3 Creation of a SAS-resistant CAT-S cell line. (A.) Parental CAT-S host 
cells were initially treated with 500 µM SAS that was increased to 700 µM SAS as 
indicated by the arrow (CAT-R-S700; blue line). A vehicle control cell line was created 
in parallel by sub-culturing the host with 0.2% DMSO v/v CD-CHO medium (CAT-
CTRL; red line). (B. – C.) Parental (black) and CAT-R-S700 (blue) cells were treated 
for 3 days with SAS. The specific growth rate (hr-1) was calculated and culture viability 
was measured on day 3 of treatment. Data is shown as the mean ± SEM of three 
independently performed experiments. 
 
 
6.3.1.1 Growth Profile of the CAT-R-S700 Cell Line 
A comparison of the CAT-R-S700 and parental CAT-S dose-response curves 
demonstrates that the former has a higher specific rate of cell proliferation at a non-
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inhibitory SAS concentration (300 µM) over 3 days (Figure 6.3 B–C). The growth 
performance of the parental and CAT-R-S700 cell lines was explored further in batch 
and fed-batch overgrow shake flask cultures (Figure 6.4). Batch growth profiles for both 
cell lines grown under control conditions (0% DMSO v/v CD-CHO medium with 0 µM 
SAS) found CAT-R-S700 cells to exhibit a 15% and 40% increase in average specific 
proliferation rate and cumulative IVCD respectively. The CAT-R-S700 cell line also 
demonstrated enhanced cell growth over the parental host in fed-batch cultures. 
However, it has previously been shown that CHO cells will typically increase their 
proliferation rate over extended sub-culturing regimes (Davies et al., 2012). To confirm 
that the improved ability of CAT-R-S700 cells to accumulate biomass is a consequence 
of SAS resistance rather than an artifact of the evolution method the growth profile of 
the CAT-CTRL cell line was also assessed. CAT-CTRL cells exhibited an equivalent 
growth profile to the parental host and remained sensitive to SAS treatment in batch 
culture. It is therefore concluded that the improved growth properties of CAT-R-S700 
cells is due to an evolved resistance to the inhibitory effect of SAS rather than a 
consequence of an extended sub-culturing regime or long-term DMSO vehicle 
exposure. Distinct from the improved performance observed during early culture, the 
CAT-R-S700 cell line was found to perform poorly late in culture compared to the 
parental host. It exhibited a shorter stationary phase and a higher magnitude of cell 
death during the decline phase, which was more noticeable in fed-batch overgrow 
cultures. For batch cultures this is expected to be a consequence of nutrient depletion 
and a build-up of waste products (e.g. ammonia and lactate). In fed-batch cultures, it is 
expected that re-optimisation of the feeding regime would lead to an improved 
performance for CAT-R-S700 cells. 
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Figure 6.4 Batch and fed-batch culture growth curves for parental, CAT-CTRL 
and CAT-R-S700 cells. (A. – C.) Viable cell density (VCD). (D. – F.) Culture 
viability. Open circles are control cultures (0% DMSO v/v CD-CHO medium), closed 
circles are vehicle control cultures (0.2% DMSO v/v CD-CHO medium), and closed 
squares are cultures treated with 700 µM SAS at seeding. Black, red and blue lines are 
parental, CAT-CTRL, and CAT-R-S700 cell lines respectively. Table insert compares 
average µ calculated over 0–6 days and cumulative IVCD over 8 days for batch and 
fed-batch control cultures. Data is shown as the mean ± SEM of four independently 
performed experiments. 
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6.3.1.2 Intracellular Glutathione Content and Cell Line Responses to Reactive Oxygen 
Species Exposure 
It is hypothesised that resistance to SAS is mediated by increased expression of the xCT 
transporter. This should provide CAT-R-S700 cells with an improved ability for cystine 
import and GSH synthesis. Cystine transport rates were not measured but the 
intracellular concentration of reduced (GSH) and oxidised glutathione (GSSG) was 
measured in both the parental and CAT-R-S700 cell lines at day 3 of exponential 
growth in batch cultures (Figure 6.5 A). Total glutathione (GSH and GSSG) is 40% 
higher in the CAT-R-S700 cell line indicating a higher rate of GSH synthesis for these 
cells. Furthermore, the parental host had a lower ratio of GSH:GSSG than the CAT-R-
S700 cell line (0.62 ± 0.04 versus 1.02 ± 0.27; mean ± SEM, n = 4) suggesting 
increased levels of oxidative stress in the parental host. Unexpectedly, neither GSH nor 
GSSG was detected in the CAT-R-S700 cell line at stationary phase (day 6) of batch 
cultures. This could however be due to a depletion of nutrients resulting from the 
improved growth rate. GSSG was detected in the parental host but this was considerably 
reduced compared to exponential growth measurements and extremely variable between 
experiments (41.0 ± 33.7 x10-5 pg.µm-3 cell volume; mean ± SEM, n = 3). To assess if 
increased GSH synthesis in CAT-R-S700 cells offers a protective effect against reactive 
oxygen species (ROS) both cell lines were exposed to H2O2 during exponential growth 
(Figure 6.5 B–C). CAT-R-S700 cells were found to be more resistant to ROS exposure 
than the parental host as demonstrated by a comparison of their IC50 H2O2 
concentrations (450 versus 278 µM H2O2 for CAT-R-S700 and parental cells 
respectively; Figure 6.5 B). Collectively, these data reveal that evolved resistance to 
SAS treatment has increased rates of GSH synthesis, which provides protection from 
oxidative stress. 
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Figure 6.5 Glutathione content and effect of H2O2 treatment on parental and CAT-
R-S700 cells during exponential growth phase. (A.) Glutathione content was 
measured on day 3 of batch cultures and normalised by cell volume. Black bars are 
reduced glutathione (GSH) and white bars are total glutathione (reduced and oxidised 
glutathione; GSH and GSSG). Data is shown as the mean + SEM of four independently 
performed experiments. (B. – C.) Parental (black) and CAT-R-S700 (blue) cells were 
treated for 2 days with H2O2. The specific growth rate (hr-1) was calculated and 
normalised to control cultures (0 mM H2O2). Culture viability was measured on day 2 
of H2O2 treatment with all control cultures having viabilities >95%. Data is shown as 
the mean ± SEM of four independently performed experiments. 
 
 
6.3.1.3 Heritability of the CAT-R-S700 Phenotype 
The CAT-R-S700 cell line was next grown for over 100 generations under control 
conditions (0% DMSO v/v CD-CHO medium with 0 µM SAS) to examine if it could 
retain its enhanced growth performance during extended sub-culture without the 700 
µM SAS selective pressure (Figure 6.6). After every 17 generations 8-day batch 
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overgrow shake flask cultures were performed to assess growth rate, cumulative IVCD, 
and culture viability under non-treated and SAS-treated conditions. The improved 
ability of the CAT-R-S700 cell line to accumulate biomass was retained over 100 
generations in non-treated cultures. However, after 50 generations SAS treatment began 
to inhibit both cell proliferation and maximum attainable viable cell densities indicating 
that SAS resistance was gradually being lost.   
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Figure 6.6 Heritability of the CAT-R-S700 phenotype. The CAT-R-S700 cell line 
was sub-cultured for over 100 generations without the 700 µM SAS selective pressure. 
Batch growth curves were performed at approximately every 17 generations. White bars 
are control cultures (0% DMSO v/v CD-CHO medium), grey bars are vehicle control 
cultures (0.2% DMSO v/v CD-CHO medium) and black bars are cultures treated with 
700 µM SAS at seeding. (A.) Average µ calculated over 0–6 days. (B.) Cumulative 
IVCD over 8 days. (C.) Culture viability on day 6. Data at generation 0 is shown as the 
mean + SEM of four independently performed experiments. 
 
 
6.3.2 Creation of a GPNA-Resistant CAT-S Cell Line (CAT-R-G200) 
In Chapter 4, it is reported that ASCT1 is significantly upregulated in antibody-
producing T127 cells at both growth phases of culture compared to CAT-S and GS-Null 
cells (see Chapter 4; Section 4.3.3). It was hypothesised that ASCT1 may be 
upregulated to support serine and threonine consumption for antibody synthesis. Yet, 
inhibition of system ASC with GPNA inhibited specific productivity in antibody-
producing T48 cells but not T127 cells (see Chapter 5; Section 5.3.4). Evolving 
resistance to GPNA treatment in the CAT-S host and examining its ability to transiently 
produce an antibody was therefore performed to further investigate the role of system 
ASC transport and antibody production.  
A sub-population of cells with increased resistance to GPNA mediated 
inhibition of system ASC transport was isolated from the parental CAT-S host over a 
ten-week period (CAT-R-G200; Figure 6.7 A). As before, a vehicle control cell line 
(CAT-CTRL) was created in parallel by sub-culturing the parental host over the same 
time period with 0.2% DMSO v/v CD-CHO medium. GPNA resistance was initiated by 
sub-culturing the parental host every 4 days with CD-CHO medium supplemented with 
50 µM GPNA. After 30 generations the growth rate of GPNA treated cultures was 
comparable to equivalently aged CAT-CTRL cells over 4 day sub-culturing periods and 
the GPNA concentration was then increased to 200 µM. Growth deteriorated over the 
subsequent 10 generations before gradually recovering. After 70 generations growth had 
completely recovered and the CAT-R-G200 cell line was established. The CAT-R-G200 
cell line was characterised by performing a GPNA dose-response study during 
exponential growth and comparing it to the curve generated for the parental host in 
Chapter 5 (Figure 6.7 B–C). The CAT-R-G200 cell line was less sensitive to GPNA 
treatment than the parental host as demonstrated by a comparison of their IC50 GPNA 
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concentrations (1.3 mM versus 0.2 mM GPNA; Figure 6.7 B). However, this was still 
considerably lower than the antibody-producing T127 cell line (IC50 = 3.1 mM; see 
Chapter 5, Figure 5.14). These data therefore confirm that the CAT-R-G200 cell line 
has evolved a degree of resistance to the inhibitory effect of GPNA but with a longer 
period of evolution it should be possible to isolate a sub-population with improved 
resistance. 
 
 
Figure 6.7 Creation of the GPNA-resistant CAT-S cell line. (A.) Parental CAT-S 
host cells were initially treated with 50 µM GPNA that was increased to 200 µM GPNA 
as indicated by the arrow (CAT-R-G200; blue line). A vehicle control (0.2% DMSO v/v 
CD-CHO medium) cell line (CAT-CTRL; red line) was also created. An asterisk 
indicates a freeze/thaw event. (B. – C.) Parental (black line) and CAT-R-G200 (blue 
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line) cells were treated for 3 days with GPNA. The specific growth rate (hr-1) was 
calculated and culture viability was measured on day 3 of treatment. Data is shown as 
the mean ± SEM of three independently performed experiments. 
 
 
6.3.2.1 Growth Profile of the CAT-R-G200 Cell Line 
The growth performance of the CAT-R-G200 cell line was explored further in batch and 
fed-batch overgrow shake flask cultures (Figure 6.8). Growth profiles of the parental 
and CAT-R-G200 cell lines grown under control conditions (0% DMSO v/v CD-CHO 
medium with 0 µM GPNA) in batch culture were identical. However, the CAT-R-G200 
cell line demonstrated an enhanced ability to accumulate biomass in fed-batch cultures, 
exhibiting a 9% and 20% increase in average specific proliferation rate and cumulative 
IVCD respectively. CAT-CTRL cells remained sensitive to GPNA treatment in batch 
cultures confirming that an extended sub-culturing regime or long-term DMSO vehicle 
exposure is not the cause of GPNA resistance in the CAT-R-G200 cell line. 
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Figure 6.8 Batch and fed-batch culture growth curves for parental, CAT-CTRL 
and CAT-R-G200 cells. (A. – C.) Viable cell density (VCD). (D. – F.) Culture 
viability. Open circles are control cultures (0% DMSO v/v CD-CHO medium), closed 
circles are vehicle control cultures (0.2% DMSO v/v CD-CHO medium), and closed 
squares are cultures treated with 200 µM GPNA at seeding. Black, red, and blue lines 
are parental, CAT-CTRL, and CAT-R-G200 cell lines respectively. Table insert 
compares average µ calculated over 0–6 days and cumulative IVCD over 8 days for 
batch and fed-batch control cultures. Data is shown as the mean ± SEM of four 
independently performed experiments (except the CAT-R-G200 control batch culture 
data, which is shown as the mean ± SEM of three independently performed 
experiments). 
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6.3.2.2 Heritability of the CAT-R-G200 Phenotype 
The heritability of the CAT-R-G200 phenotype was examined by sub-culturing the cell 
line over 28 generations without the 200 µM GPNA selective pressure (Figure 6.9). 8-
day batch overgrow shake flask cultures were performed to assess growth rate, 
cumulative IVCD and culture viability under non-treated and GPNA-treated conditions 
after 20 and 28 generations. Resistance to GPNA treatment had declined within 20 
generations but was not completely lost. These data indicate that GPNA resistance is 
unstable in the evolved cell line. 
 
 
Figure 6.9 Heritability of the CAT-R-G200 phenotype. The CAT-R-G200 cell line 
was sub-cultured for 28 generations without the 200 µM GPNA selective pressure. 
Batch growth curves were performed after 20 and 28 generations. White bars are 
control cultures (0% DMSO v/v CD-CHO medium), grey bars are vehicle control 
cultures (0.2% DMSO v/v CD-CHO medium) and black bars are cultures treated with 
200 µM GPNA at seeding. (A.) Average µ calculated over 0–6 days. (B.) Cumulative 
IVCD over 8 days. (C.) Culture viability on day 6. Data at generation 0 is shown as the 
mean + SEM of four independently performed experiments (except the control batch 
culture data, which is shown as the mean + SEM of three independently performed 
experiments). 
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6.3.3 Transfection Efficiency and Transient Production of a Recombinant IgG 
Antibody in Parental and Resistant Cell Lines 
The evolved cell lines were examined to see if they have an improved ability to produce 
a recombinant IgG antibody. 12 µg of a vector containing genes for both the heavy and 
light chains of a human IgG monoclonal antibody was transfected by lipofection into 
the parental, CAT-R-G200 and CAT-R-S700 cell lines. For each transfection cell 
growth and viability was assessed at 48, 72, and 96 hr post-transfection (Figure 6.10 A–
F). Transfection efficiency was also determined for each cell line at the same time 
points by performing an additional transfection with 12 µg of a GFP vector (see 6.2 
Materials and Methods; Figure 6.10 G–I). The effect of DNA transfection on cell 
growth and viability was equivalent between GFP and antibody transfections for each 
cell line at all time points (Figure 6.10 A–F; comparison of green and black bars). 
Growth and viability was inhibited to the same degree in transfected parental and CAT-
R-G200 cells but the CAT-R-S700 cell line was noticeably more resistant to 
transfection conditions. This observation was reflected in measurements of transfection 
efficiency which was approximately 80% in the parental and CAT-R-G200 cell lines at 
all time points but 60% in CAT-R-S700 cells at 48 hr post-transfection decreasing to 
50% after 96 hr (Figure 6.10 G–I). Collectively, these data indicate that evolved 
resistance to SAS treatment has made this cell line more resistant to DNA:lipid complex 
based transfections. 
Measurement of antibody production demonstrated no differences in titre or 
specific productivity between the parental and CAT-R-G200 cell lines at all time points 
post-transfection (Figure 6.11). However, the CAT-R-S700 cell line was markedly poor 
at antibody production compared to the parental host. 
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Figure 6.10 Growth characteristics of parental and resistant CAT-S cells 
transiently expressing GFP and an IgG monoclonal antibody. Each cell line was 
transfected with either the phCMV C-GFP vector (green bars) or mAb-109 vector 
(black bars) by lipofection. Cumulative IVCD (A. – C.) and culture viability (D. – F.) 
was compared within cell lines at 48, 72 and 96 hr post-transfection. Non-transfected 
cells (white bars) were performed as a control. Transfection efficiency and median 
fluorescence intensity (MFI) of GFP transfections was also assessed over the same time 
points (G. – I.). Non-transfected and GFP data shown is the mean + SEM of three 
independent experiments. Antibody data shown is the mean + SEM of two independent 
experiments, where in a single experiment antibody transfections were performed in 
duplicate and measurements were averaged.  
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Figure 6.11 Transient production of an IgG monoclonal antibody in parental and 
resistant CAT-S cells. Each cell line was transfected with the mAb-109 vector by 
lipofection. Volumetric titres (A.) and cell specific production rates (B.) were measured 
at 48, 72 and 96 hr post-transfection. Data shown is the mean + SEM of two 
independent experiments, where in a single experiment antibody transfections were 
performed in duplicate and measurements were averaged. 
 
 
6.3.4 Creation of SAS-Resistant T127 Cell Lines 
The T127 antibody-producing cell line is a stable transfectant pool (non-clonal) and is 
hypothesised to be functionally heterogeneous. The SAS evolution method was 
therefore applied to the T127 cell line to investigate if a sub-population of cells could be 
isolated with improved performance characteristics. Two resistant cell lines were 
isolated from T127 cells over a twenty-week period (T127-R-S500 & T127-R-S700; 
Figure 6.12). The T127-R-S500 cell line was created by sub-culturing T127 cells every 
4 days with CD-CHO medium supplemented with 500 µM SAS for 120 generations. 
After the first 20 generations a second shake flask was initiated from T127-R-S500 cells 
and sub-cultured with 700 µM SAS for a further 100 generations to create the T127-R-
S700 cell line. As with the parental host, a vehicle control cell line (T127-CTRL) was 
created in parallel by sub-culturing T127 cells over 120 generations with 0.2% DMSO 
v/v CD-CHO medium. All cell lines were supplemented with 50 µM MSX throughout 
the evolution process. 
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Figure 6.12 Creation of SAS-resistant T127 cell lines. Recombinant T127 cells stably 
expressing an IgG antibody were treated with 500 µM SAS over an extended sub-
culturing regime (T127-R-S500; light blue line). After 20 generations, a second shake 
flask was initiated from T127-R-S500 cells (as indicated by the arrow) and sub-cultured 
with 700 µM SAS (T127-R-S700; dark blue line). A vehicle control cell line was 
created in parallel by sub-culturing the T127 cell line with 0.2% DMSO v/v CD-CHO 
medium (T127-CTRL; red line). 
 
 
6.3.4.1 Growth and Antibody Production Characteristics for Non-Evolved and Resistant 
T127 Cell Lines 
Performance of the non-evolved and two resistant T127 cell lines were assessed in batch 
overgrow shake flask cultures (Figure 6.13 & 6.14). T127-CTRL cells exhibited a lower 
growth rate and achieved a reduced maximal viable cell density than non-evolved T127 
cells, indicating a prolonged exposure to DMSO has a negative impact on cell growth. 
In support of this, non-evolved T127 cells treated with DMSO achieved a slightly lower 
maximal viable cell density than those without DMSO (Figure 6.13 A). Both T127-R-
S500 and T127-R-S700 cells demonstrated resistance to SAS that was not due to an 
extended sub-culturing regime (non-evolved versus T127-CTRL cells) or prolonged 
exposure to DMSO (resistant cells versus T127-CTRL cells). T127-R-S500 cells 
demonstrate a small increase in both growth rate and IVCD compared to non-evolved 
T127 cells when cultured in the presence of SAS but exhibit a shorter stationary phase. 
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However, compared to the T127-CTRL cells, average growth rate and IVCD is 
enhanced by 20% and 40% respectively in T127-R-S500 cells. T127-R-S700 cells 
exhibit comparable growth to T127-CTRL cells when cultured in the presence of SAS. 
For cultures without SAS treatment, the cells became visibly clumpy from day 5 
onwards preventing accurate assessment of cell densities passed day 7. 
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Figure 6.13 Batch culture growth curves for non-evolved T127, T127-CTRL, T127-R-S500 and T127-R-S700 cells. (A. – D.) Viable cell density 
(VCD). (E. – H.) Culture viability. Open circles are control cultures (0% DMSO v/v CD-CHO medium), closed circles are vehicle control cultures 
(0.2% DMSO v/v CD-CHO medium), and squares and diamonds are cultures treated with 500 µM and 700 µM SAS respectively at seeding. Data is 
shown as the mean ± SEM of three independently performed experiments. 
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Antibody production in the two resistant cell lines was measured and compared 
to production in the non-evolved (Figure 6.14 A) and T127-CTRL cells (Figure 6.14 
B.). The latter comparison was made due to the inhibitory effect of prolonged exposure 
to DMSO on growth. Specific productivity is reduced in T127-R-S500 cells compared 
to non-evolved cells leading to a decrease in overall titre. Yet, specific productivity in 
T127-R-S500 cells was equivalent to that in T127-CTRL cells indicating that prolonged 
DMSO exposure has a negative effect on this performance parameter in addition to 
growth. When compared to the T127-CTRL cells, T127-R-S500 cells have an increased 
titre resulting from an increased IVCD. Interestingly, T127-R-S700 cells have an 
increased titre compared to T127-CTRL cells resulting from a higher specific 
productivity. This indicates that adaptation to higher concentrations of SAS may have a 
positive effect on antibody productivity.  !
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Figure 6.14 Comparison of growth and production characteristics for non-evolved 
T127, T127-CTRL, T127-R-S500 and T127-R-S700 cells as assessed in batch 
cultures. Average growth rate (µ; d-1) was calculated over 0–6 days. Integral viable cell 
density (IVCD; 109 cell.d.L-1) is the cumulative IVCD over 8 days. IgG titre (mg.L-1) is 
taken at day 6. Specific productivity (QmAb; pg mAb.cell-1.d-1) is taken between days 3 
and 6. (A.) Parameter values normalised to non-evolved T127 cells. (B.) Parameter 
values normalised to T127-CTRL cells. Data is shown as the mean + SEM of three 
independently performed experiments. 
 
 
6.4 Discussion 
The initial objective of this chapter was to isolate a sub-population of CAT-S cells with 
increased xCT transport activity using directed evolution. These cells would be 
expected to have a greater capacity for cystine import, which is predicted to support 
increased rates of GSH and antibody synthesis than unevolved CAT-S cells. The 
directed evolution method used SAS as a selective pressure during an extended sub-
culturing regime of the parental CAT-S host. A population of CAT-S cells resistant to 
SAS treatment was isolated within eight weeks (CAT-R-S700). The CAT-R-S700 cell 
line demonstrated higher rates of GSH synthesis and was better able to cope with an 
oxidative stress insult than the non-adapted parental host. It is hypothesised that this is 
due to increased xCT transporter expression in CAT-R-S700 cells although this was not 
measured. In support of this, overexpression of the xCT transporter has previously been 
shown to increase GSH synthesis and provide protection from oxidative stress in 
astrocytes (Shih et al., 2006). 
Unexpectedly, CAT-R-S700 cells demonstrated an improved growth rate and 
attained higher cell densities than the non-adapted parental host in batch and fed-batch 
cultures. The reason for this growth advantage is not clear. However, it is hypothesised 
that in addition to increased xCT transporter expression the evolution process also 
selected for other genes involved in amino acid transport and biosynthesis via activation 
of the amino acid response (AAR) pathway. SAS inhibits cystine uptake in a variety of 
mammalian cell lines (Chung et al., 2005; Gout et al., 2001; Timmerman et al., 2013), 
including the parental CAT-S cell line (see Chapter 5; Figure 5.11). Cystine starvation 
is known to induce the AAR pathway in mammalian cells (Lee et al., 2008), a cellular 
process that inhibits global protein synthesis but simultaneously upregulates a number 
of genes via activating transcription factor 4 (ATF4) including the amino acid 
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transporters xCT, SNAT2 and CAT-1, as well as asparagine synthetase (Kilberg et al., 
2009). The expression of these four genes has previously been shown to be upregulated 
in response to AAR pathway activation in industrial CHO cell lines (Fomina-Yadlin et 
al., 2014). In Chapter 5, treating CAT-S cells with SAS was found to increase average 
consumption of the SNAT2 substrates asparagine and glutamine by 25% and 20% 
respectively (see Chapter 5; Figure 5.11), indicating SAS exposure stimulates the AAR 
pathway in the parental host. It is therefore hypothesised that early in the creation of the 
CAT-R-S700 cell line, the AAR pathway was activated and there was upregulation of 
all or some of these four metabolic genes. As CAT-R-S700 cells developed resistance to 
SAS treatment, cytosolic concentrations of cysteine was restored and the AAR pathway 
was suppressed. However, cell proliferation is the primary selective pressure during 
sub-culture and increased expression of SNAT2, CAT-1 and asparagine synthetase may 
have been selected for to support cell growth (e.g. increased glutamine consumption 
capacity). This would make their increased expression a stable feature of the CAT-R-
S700 cell line. In agreement with this, the improved growth performance of CAT-R-
S700 cells was heritable over 100 generations in the absence of the SAS selective 
pressure. Yet, resistance to SAS treatment began to decrease after 50 generations. A 
possible explanation for this latter observation is that in the absence of SAS, oxidative 
stress would act as the main selection pressure for maintenance of high xCT expression 
to support GSH synthesis. However, this is typically experienced during stationary 
phase of culture (see Chapter 2; Section 2.1). Expression of xCT would therefore be 
expected to decrease over successive generations during sub-culture where cells are 
kept in exponential growth. Loss of SAS resistance after 50 generations also provides 
further evidence to suggest that the mechanism conferring the growth advantage in 
CAT-R-S700 cells is distinct from SAS resistance. 
Transient production of a recombinant IgG antibody was tested in CAT-R-S700 
cells. CAT-R-S700 cells were found to be extremely poor at producing an antibody 
compared to the non-adapted parental host. However, this reflected the low transfection 
efficiency measured with this cell line. Davies et al. (2012) demonstrated considerable 
clone-specific variation in “transfectability” using lipofection than electroporation. This 
suggests that transient transfections in both the parental and CAT-R-S700 cell lines 
should be repeated using electroporation to help achieve equivalent transfection 
efficiencies. 
The evolution process was repeated but with GPNA as the selective pressure 
until a sub-population of parental CAT-S cells with increased resistance to GPNA 
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inhibition was isolated (CAT-R-G200). GPNA resistance has previously been shown to 
correlate well with ASCT1 mRNA levels (Chapters 4 & 5). It is therefore assumed that 
increased expression of system ASC transporters (ASCT1 and/or ASCT2) is the source 
of resistance in these cells although this was not measured. In Chapter 4, it was 
hypothesised that system ASC transport is upregulated in T127 cells to support serine 
and threonine consumption for antibody synthesis. CAT-R-G200 cells with an increased 
capability for system ASC transport may therefore be able to produce higher quantities 
of antibody than unevolved CAT-S cells. Transient production of a recombinant IgG 
antibody was performed in CAT-R-G200 cells and compared to the performance of the 
CAT-S host to test this hypothesis. Antibody production was equivalent in the two cell 
lines indicating that the CAT-R-G200 cell line is not able to outperform the CAT-S host 
in a transient system. However, transient systems have previously been demonstrated to 
be a poor predictor of stable transfection performance (O’Callaghan et al., 2015). Future 
work would benefit from creating and comparing the performance of stable transfectant 
pools before this hypothesis is rejected. The growth performance of the CAT-R-G200 
cell line was also characterised. In fed-batch cultures CAT-R-G200 cells exhibited an 
increased growth rate and achieved a higher IVCD than the CAT-S host. This indicates 
that the nutrient feed composition complements the evolved metabolic capabilities of 
the CAT-R-G200 cells. Compared to the CAT-R-S700 cell line, the CAT-R-G200 cell 
line took longer to create and resistance was unstable. It is hypothesised that this is 
because the GPNA-based directed evolution process was selecting for a small sub-
population of cells that inherently have increased expression levels of ASCT1-2. In 
contrast, the SAS-based directed evolution process is fast as the whole cell population is 
being adapted via the AAR pathway. Fluorescence activated cell sorting (FACS) and 
magnetic activated cell separation (MACS) have been demonstrated as useful 
techniques in reducing the time length of CHO evolution strategies by sorting out viable 
cells (Bort et al., 2010; Taschwer et al., 2012). Therefore the use of FACS and/or 
MACS could help create a more stable GPNA resistant cell line in a shorter time period. 
The SAS selection process was also applied to the T127 antibody-producing cell line. 
Interestingly, it took longer for growth and viability to recover in T127 cells than the 
CAT-S host (120 versus 60 generations). This could be due to the negative effects of 
both MSX and SAS on GSH metabolism. MSX is known to inhibit γ-glutamylcysteine 
synthetase, the first enzymatic step in GSH synthesis (Richman et al., 1973), while SAS 
has an off-target inhibition effect on glutathione S-transferases (GSTs), which catalyse 
the conjugation of GSH and electrophiles (Awasthi et al., 1994; Bach et al., 1985). 
!147 
Together they may impede adaptation but using FACS or MACS in future studies as 
discussed above could speed this up. In batch cultures both T127-R-S500 and T127-R-
S700 cells were able to achieve higher IgG antibody titres than T127-CTRL cells. This 
was due to either an increase in IVCD (T127-R-S500) or specific productivity (T127-R-
S700). However, the evolved cell lines were unable to outperform the non-evolved 
T127 cell line. This is believed to be a result of prolonged exposure to DMSO, which 
had an inhibitory effect on both growth and specific productivity. Future evolution 
strategies would benefit from circumventing the need to solubilise SAS in this vehicle. 
An alternative method of getting SAS into solution involves dissolving the drug in 
NaOH and adjusting the pH with HCl (correspondence with Professor Sontheimer’s lab, 
The University of Alabama, USA). However, the osmolarity of the solution would need 
to be checked as well as the balance between ions as the activity of many amino acid 
transporters is ion dependent. In contrast to the CAT-R-S700 cell line, growth of T127-
R-S500 and T127-R-S700 cells was dependent upon supplementation with SAS. The 
reason for this is not clear. One hypothesis is that these two isolated sub-populations 
may have a very high capacity for xCT transport activity that may increase cystine 
influx and/or glutamate efflux in a way that disrupts growth. For example, high 
intracellular levels of cysteine have been shown to induce cell death in mammalian cells 
(Ji et al., 2016), whereas a high intracellular availability of glutamate is essential during 
cell proliferation to replenish TCA cycle intermediates (see 2.1 Mammalian Cell 
Metabolism). However, in the presence of SAS there remains an inhibitory block on 
excessive xCT activity. This hypothesis would suggest that xCT transport activity must 
be finely tuned in CHO cells and that the directed evolution method can select for sub-
populations with increased xCT transport function that has adverse effects on cell 
growth. Further work characterising these cell lines is required to explore this 
hypothesis. 
Directed evolution is a process in which a selective pressure is used to isolate a 
population of cells with a desired phenotype from a heterogeneous background. In 
contrast to single gene changes using genetic engineering tools, directed evolution has 
the potential to alter the expression of multiple genes simultaneously (Majors et al., 
2009). In this chapter it has been hypothesised that SAS and GPNA have selected for 
cell populations with increased xCT and system ASC transporter expression 
respectively. Activation of the AAR pathway has been postulated as one mechanism by 
which the xCT transporter is upregulated. However, as discussed above (see 6.1 
Introduction), CHO cell populations are genetically diverse and certain nucleotide 
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variations inside and outside of the coding sequence may have been selected for that 
affect transporter expression or function. SNPs outside the coding sequence for example 
can impact gene expression by affecting cellular processes such as mRNA stability, 
gene splicing, or promoter activity. SNPs inside the coding region may however result 
in silent or missense mutations. One way in which silent mutations may affect gene 
expression is by switching to more or less abundant codons that speed-up or slow-down 
protein synthesis respectively. Conversely, missense mutations may lead to an increase 
or decrease in transporter function, particularly if the amino acid change is in the site of 
the transporter involved in translocation of amino acid substrates across the cell 
membrane. The directed evolution process may therefore have selected sub-populations 
of cells with missense mutations in the coding sequence resulting in increased 
transporter activity rather than cells with increased transporter expression as postulated 
so far. Future work could look at the cDNA of the xCT and system ASC transporters to 
look for potential sequence variants in the evolved cell lines compared to the parental 
population.  
In this chapter, a directed evolution method is described that was able to isolate 
cell lines with desirable characteristics for biomanufacturing. Evolution of the parental 
CAT-S host using SAS as a selective agent proved to be particularly successful with a 
stable improvement in growth performance achieved. This study would benefit from 
further characterisation of the evolved cell lines such as measurements of amino acid 
transport rates and expression of amino acid transporters, particularly with the CAT-R-
S700 cell line. A priority for future work should be to compare the relative performance 
of the CAT-S host and CAT-R-S700 cells to transiently and stably produce an IgG 
antibody using electroporation as the preferred transfection method.  
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Chapter 7 
Rational Design of Culture Media From an 
Understanding of Amino Acid Transport 
Mechanisms 
 
In this chapter, a mechanistic model to describe essential amino acid transport 
processes in CHO cells is constructed from transcriptomic (Chapter 4) and inhibitor 
(Chapter 5) data. This model demonstrates how the consumption rate of aromatic, 
branched-chain and cationic amino acids is dependent upon their extracellular 
concentrations. This model can be used to direct the optimisation of amino acid 
concentrations in basal and feed media to maximise cell growth and antibody 
production.  
 
 
7.1 Introduction 
The optimisation of basal and feed media is a key activity in the development of fed-
batch processes. For example, variations in nutrient composition have been 
demonstrated to have a significant effect on cell growth, culture longevity and IgG 
production in a single CHO cell line (Yu et al., 2011). Design of experiments (DoE) is a 
statistical method frequently used in media development (Jiang et al., 2012; Parampalli 
et al., 2008; Zhang et al., 2013). In this approach factorial experiments are used to 
screen for nutrients and other media components that either alone or in combination 
have a statistically significant effect on cell growth and/or antibody production. 
Regression models and response surface methodology (RSM) is then used to find the 
optimal levels of media components to improve cell line productivity.  
Optimisation of amino acid concentrations is arguably one of the most important 
goals in CHO cell media development because of their role in central metabolism (Dean 
and Reddy, 2013; Duarte et al., 2014), signaling to pathways that regulate global protein 
synthesis (Fomina-Yadlin et al., 2014) and synthesis of recombinant proteins with 
correct glycosylation profiles (Chen and Harcum, 2005; Fan et al., 2014). Spent media 
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analysis (SMA) is one approach commonly used to optimise amino acid concentrations 
(Altamirano et al., 2004; Kishishita et al., 2015; Kyriakopoulos and Kontoravdi, 2014; 
Ma et al., 2009; Sellick et al., 2011). In this approach cell lines are first grown in batch 
culture and amino acid concentrations are measured. A feed is then designed in which 
selected amino acids are fed-back at concentrations found in the basal medium (Sellick 
et al., 2011) or based upon specific consumption rates and predicted cell growth 
(Altamirano et al., 2004; Kyriakopoulos and Kontoravdi, 2014). CHO metabolic models 
have also been used to optimise amino acid concentrations (Xing et al., 2011) or suggest 
further improvements to a SMA optimised process (Kyriakopoulos and Kontoravdi, 
2014). Metabolic models have an advantage over DoE and SMA methods in that they 
take into account biomass and recombinant protein composition within the reaction 
network.  
However, none of the above approaches consider potential limitations in amino 
acid transport that may affect uptake. Individual transporters typically facilitate the 
movement of multiple amino acids (see Chapter 2; Section 2.3) such that extracellular 
concentrations can influence which amino acids are preferentially transported. 
Furthermore, functional relationships exist between individual transporters (Nicklin et 
al., 2009). Yang et al. (2010) examined alanine, glutamine and serine transport 
competition through system A transporters in cultured hepatocytes and constructed 
equations from empirical data that can predict the transport rate of these amino acids in 
terms of their concentrations in the culture medium. A similar better understanding of 
the relationship between CHO transporter activity and amino acid uptake would be a 
major benefit to future developments of culture media for improved cell line 
productivity. This chapter explores how the data generated in Chapters 4 and 5 can be 
used to optimise amino acid concentrations in culture media based upon knowledge of 
biomass composition (cell and product) as well as the transport capabilities of the CHO 
cell line. 
 
 
7.2 Materials and Methods 
7.2.1 Generation of Amino Acid Transport Profile Data 
CAT-S, GS-Null and T127 cells were all treated with BCH, MeAIB, SAS, GPNA and 
ALX 5407 HCl during exponential growth of batch cultures in Chapter 5. Transport 
rates for each of the 20 amino acids was measured in control and treated cultures, and 
are analysed in this chapter. 
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7.2.1.1 CAT-S Transport Profiles 
62 individual transport profiles for the 20 amino acids were generated for CAT-S cells 
from the following culture conditions: BCH (0, 10, 20, 30 and 40 mM), MeAIB (10, 20 
and 40 mM), SAS (0, 300, 600, 700 and 1000 µM), GPNA (50, 100, 200, 400 and 800 
µM) and ALX 5407 HCl (0, 10 and 50 µM). 
  
7.2.1.2 GS-Null Transport Profiles 
64 individual transport profiles for the 20 amino acids were generated for GS-Null cells 
from the following culture conditions: BCH (0, 5, 20, 30 and 40 mM), MeAIB (1, 5, 10 
and 40 mM), SAS (0, 300, 600, 700 and 1000 µM), GPNA (50, 100, 200, 400 and 800 
µM) and ALX 5407 HCl (0, 10 and 50 µM).  
 
7.2.1.3 T127 Transport Profiles 
71 individual transport profiles for the 20 amino acids were generated for T127 from the 
following culture conditions: BCH (0, 10, 20, 30 and 40 mM), MeAIB (2.5, 5, 10 and 
40 mM), SAS (0, 300, 600, 700, 800 and 1000 µM), GPNA (0, 0.4, 0.8, 1.0, 2.0 and 3.7 
mM) and ALX 5407 HCl (0, 10 and 50 µM).  
 
7.2.3 Statistical Analysis 
Spearman’s rank correlation was performed in RStudio (R Core Team, 2014) using the 
corr.test function in the psych package (Revelle, 2014) unless otherwise stated. 
Correlation coefficients (ρ), raw probability, and adjusted probability values to account 
for multiple tests were reported. The Holm (1979) method was used to calculate 
adjusted probability values. The corrplot package (Wei, 2013) was used to plot a 
correlogram of the statistical outputs from the Spearman rank correlation test. 
 
 
7.3 Results 
In Chapter 5, inhibitors of amino acid transport were applied to five CHO cell lines 
during exponential growth of batch cultures. The transport rates for each of the 20 
amino acids was measured for each perturbation in CAT-S, GS-Null, and T127 cells. A 
total of 62, 64, and 71 individual transport profiles were measured for these three cell 
lines respectively (see 7.2 Materials and Methods). The total specific transport rate (sum 
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of absolute consumption and production rates of all amino acids) for each profile was 
plotted against the growth rate resulting from that perturbation (Figure 7.1).  
 
 
Figure 7.1 Relationships between total specific amino acid transport rates and 
growth rates in CAT-S, GS-Null and T127 cells. Each data point represents an 
individual amino acid transport profile in which absolute consumption and production 
rates of the 20 amino acids were summed. A total of 62, 64 and 71 transport profiles are 
plotted for (A.) CAT-S, (B.) GS-Null, and (C.) T127 cells respectively. Section 7.2 
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Materials and Methods provides further details on the source of these profiles. 
Spearman’s rank correlation was performed using GraphPad Prism v6.0 (GraphPad 
Software, San Diego, USA) to analyse these relationships (outputs in main body of 
text). 
 
 
For CAT-S cells, there is a significantly strong negative correlation between 
growth rate and total specific transport rate (ρ = -0.71; P = < 0.0001). This correlation is 
weak in GS-Null cells but still significant (ρ = -0.37; P = 0.003), while no correlation 
exists in T127 cells (ρ = 0.06; P = 0.6). These relationships were explored further for 
each cell line by plotting the specific transport rates of each amino acid against growth 
rates (Appendix Figure C1). CAT-S cells were found to increase their consumption and 
metabolism of amino acids associated with energy production as cell proliferation 
decreased. Consumption of asparagine, cystine, glutamine and serine, and production of 
alanine, aspartate, glutamate and glycine all increased with decreasing growth rates. 
These changes primarily came from the perturbations made by GPNA (system ASC 
inhibitor) and SAS (system XC- inhibitor). Asparagine, glutamine and serine are all 
substrates of the SNAT2 transporter, while cystine is a substrate of the xCT transporter. 
Both transporters are well known targets of the amino acid response (AAR) pathway, 
which is activated by depletion of intracellular amino acid levels (see Chapter 2; Section 
2.2.2). For GS-Null cells, consumption of asparagine, cystine and serine, and 
production of alanine, aspartate, glutamate, glutamine and glycine all increased with 
decreasing growth rates. Again, these changes primarily came from GPNA and SAS 
inhibited cultures. While for T127 cells, only alanine, aspartate and glycine production 
increased with decreasing growth rates. However, these cells were more resistant to 
GPNA and SAS inhibition (see Chapter 5).  
Many of the amino acids in Appendix Figure C1 showed very similar patterns of 
correlation against growth rate, suggestive of shared amino acid transport processes. 
These were therefore explored further. For each profile, the specific transport rate for an 
individual amino acid was plotted against the specific transport rate of the remaining 19 
amino acids generating 190 unique amino acid comparisons. Strong linear relationships 
were found to exist between many amino acids in each of the three cell lines (data not 
shown). The strength of these relationships was analysed further using Spearman’s rank 
correlation with the statistical outputs plotted as a correlogram for visual interpretation 
(Figure 7.2; numerical values are also provided in Appendix Table C1–3).  
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Figure 7.2 Correlations between the 20 proteinogenic amino acids in CAT-S, GS-
Null and T127 cells. Data was analysed using Spearman’s rank correlation and the 
statistical output visualised as correlograms. Ellipses represent correlation coefficients 
(ρ) with the width and colour signifying the strength of the coefficient. Crosses indicate 
non-significant correlation coefficients (significant if P < 0.01). Raw and adjusted 
probabilities are used above and below the diagonal respectively. Black boxes are used 
to group key correlations discussed in the main body of text. Broken boxes group 
correlations between essential amino acids. Solid boxes group correlations between 
non-essential amino acids. 
 
 
7.3.1 Essential Amino Acid Correlations 
For CAT-S cells, the transport of cationic (arginine and lysine), branched-chain 
(isoleucine, leucine and valine), and aromatic (histidine, phenylalanine, tryptophan and 
tyrosine) amino acids, in addition to methionine, threonine, and proline all have 
significantly strong positive correlations (typically ρ ≥ 0.9). These correlations are 
highly conserved in recombinant glutamine synthetase cell lines (GS-Null and T127) 
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with all but isoleucine and leucine. Both isoleucine and leucine maintain a significantly 
strong positive correlation with each other (ρ = 1.0) and to valine (ρ = 0.8 – 0.9) but 
have a weak-moderate correlation to the other essential amino acids in these cells (ρ = 
0.4 – 0.8). These positive correlations imply essential amino acids must share some 
common transport mechanism. A mechanistic model of transport for these amino acids 
is inferred from literature (Chapter 2), transcriptomic (Chapter 4) and inhibitor (Chapter 
5) data and summarised in Figure 7.3.  
 
 
Figure 7.3 Proposed mechanistic model of essential amino acid transport in CAT-
S, GS-Null and T127 cells. Growth of GS-Null and T127 cells in glutamine free media 
is proposed to recruit the activity of either (or both) LAT3 or LAT4 uniporters to 
support consumption of isoleucine, leucine and valine through LAT1.  
 
 
The four transporters of system L (LAT1–4) facilitate the transport of branched-chain 
amino acids with the LAT1–2 antiporters also capable of transporting the four aromatic 
amino acids (see Chapter 2; Table 2.1). BCH (system L inhibitor) treatment results in 
complete inhibition of uptake for these amino acids (see Chapter 5; Section 5.3.1) and 
transcriptomic data demonstrate that the LAT1 transporter is preferentially expressed 
over LAT2 (see Chapter 4; Section 4.3.3). In contrast, intracellular accumulation of the 
two cationic amino acids is facilitated by the uniporters of system y+ (see Chapter 2; 
Table 2.1) of which CAT-1 is preferentially expressed across the three CHO cell lines 
(see Chapter 4; Section 4.3.3). The two transporters belonging to system y+L (y+LAT1–
System y+L 
 
y+LAT2 
(SLC7A6) 
System y+ 
 
CAT-1 
(SLC7A1) 
System L 
 
LAT1 
(SLC7A5) 
Arginine 
Lysine 
Histidine 
Methionine 
Leucine 
 + 
(Glutamine) 
Tryptophan 
Phenylalanine 
Tyrosine 
 
Isoleucine 
Leucine 
Valine 
 
Histidine 
Methionine 
Arginine 
Lysine 
Histidine 
Methionine 
Leucine 
System L 
 
LAT3-4 
(SLC43A1-2) 
Isoleucine 
Leucine 
Valine 
Intracellular 
Extracellular 
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2) have an obligatory antiport transport mechanism in which intracellular arginine and 
lysine are exported for the import of glutamine, histidine, leucine, and methionine, 
thereby connecting the activities of LAT1 and CAT-1 (see Chapter 2; Table 2.1). 
Transcriptomic data demonstrate that y+LAT2 is preferentially expressed over y+LAT1 
(see Chapter 4; Section 4.3.3). In support of such a mechanism intracellular histidine, 
leucine, and methionine have been shown to strongly trans-stimulate amino acid influx 
through LAT1 (Meier et al., 2002). Glutamine is a poor efflux substrate of LAT1 (Meier 
et al., 2002) but its high intracellular concentration means its export is preferentially 
coupled to amino acid influx through LAT1 (Nicklin et al., 2009). Interestingly, influx 
of isoleucine and leucine is no longer coupled to aromatic amino acid transport in GS-
Null and T127 cells grown in glutamine free media indicating that they must instead be 
entering the cell through a separate transporter. BCH data implies that this must still be 
a system L transporter, and therefore must be through either (or both) the LAT3 or 
LAT4 system L uniporters.  
To help validate the model, the relationship between consumption and medium 
composition of essential amino acids was investigated. The magnitude of transport rate 
for a given amino acid through a single transporter will be dependent upon the 
extracellular concentrations of competing amino acids and the kinetic parameters (Km 
and Vmax) that each of those amino acids has for that transporter. If the aromatic, 
branched-chain, and cationic amino acids are transported through two distinct 
transporters as proposed in Figure 7.3 then their consumption rates relative to one 
another should match their extracellular concentrations (assuming equivalent kinetic 
properties). The concentration of amino acids in the cell culture medium was measured 
and transport rates were calculated using control cultures (i.e. inhibitor free cultures) 
from Chapter 5 (Table 7.1).  
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Table 7.1 Specific transport rates of amino acids in CAT-S, GS-Null and T127 cells 
grown under control conditions 
 
All values are shown as mean ± SD (n = 9). Amino acids are grouped by their overall 
charge with neutral amino acids further divided into three groups based upon the 
chemical nature of their side-chain. Negative and positive rates represent consumption 
and production respectively. 
Amino acid CAT-S GS-Null T127
1. Neutral
   A. Branched-chain amino acids
 Ile -7.9 ± 1.4 -9.4 ± 1.4 -9.9 ± 1.6
Leu -13.7 ± 2.4 -15.4 ± 1.8 -17.0 ± 2.9
Val -9.9 ± 1.3 -9.9 ± 0.9 -10.6 ± 1.7
   B. Aromatic amino acids
His -4.3 ± 0.5 -3.7 ± 0.4 -3.2 ± 0.9
Phe -4.9 ± 0.5 -4.1 ± 0.3 -4.0 ± 0.8
Trp -1.6 ± 0.3 -1.8 ± 0.3 -1.5 ± 0.6
Tyr -5.3 ± 0.8 -4.8 ± 0.8 -5.3 ± 1.0
   C. Amide, hydroxyl, sulfur, cyclic and small amino acids
Asn -56.5 ± 3.7 -55.3 ± 5.8 -58.5 ± 3.8
Gln -80.3 ± 12.8 4.3 ± 3.6 10.0 ± 1.2
Thr -6.7 ± 1.0 -5.1 ± 1.2 -5.3 ± 1.5
Ser -33.0 ± 3.0 -35.1 ± 6.9 -49.8 ± 6.9
Met -3.6 ± 0.3 -3.2 ± 0.2 -2.6 ± 0.6
Cys2 -3.6 ± 0.5 -3.0 ± 0.7 -3.0 ± 0.4
Pro -6.7 ± 1.1 -6.0 ± 1.5 -4.8 ± 2.6
Gly 12.9 ± 1.9 16.0 ± 6.9 27.1 ± 7.0
Ala 35.6 ± 4.5 2.5 ± 1.8 2.4 ± 1.6
2. Cationic
Arg -9.5 ± 1.0 -7.5 ± 0.6 -6.8 ± 1.5
Lys -12.7 ± 1.3 -10.7 ± 1.0 -10.0 ± 2.2
3. Anionic
Asp 15.0 ± 2.3 3.2 ± 1.2 0.8 ± 1.9
Glu 13.2 ± 3.0 -3.1 ± 1.1 -4.5 ± 2.0
Specific transport rate                               
(x10-5 nmol.cell-1.d-1)
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The aromatic and branched-chain amino acids proposed to be transported exclusively by 
system L, ranked in order of concentration, is Leu > Val > Ile > Tyr ≈ Phe > Trp (data 
not shown). Kinetic parameters for these amino acids through LAT1 have been shown 
to be approximately equivalent (Yanagida et al., 2001) indicating that their transport 
rate should match their concentration order. The transport rates for these six amino 
acids do indeed match this order exactly in CAT-S, GS-Null and T127 cells (Table 7.1). 
Similarly for cationic amino acids, the concentration of Lys is greater than Arg (data not 
shown) and both amino acids have approximately equivalent kinetic parameters through 
the CAT-1 transporter (Closs et al., 2006). The transport rate of lysine is consistently 
higher than arginine in CAT-S, GS-Null and T127 cells (Table 7.1). This understanding 
of essential amino acid transport has important implications in medium design to 
maximise cell or antibody synthesis (discussed in Section 7.4). 
 
7.3.2 Non-Essential Amino Acid Correlations 
The non-essential amino acids alanine, aspartate, asparagine, glutamate, glutamine, 
glycine, and serine are closely associated with central metabolic pathways that support 
energy metabolism in addition to the biosynthesis of macromolecules other than 
proteins (e.g. lipids and nucleic acids) during exponential growth (see Chapter 2; 
Section 2.1). For CAT-S cells, these amino acids form a group of statistically significant 
linear relationships distinct from the essential amino acids (Figure 7.2 A). Strong 
positive correlations (ρ ≥ 0.8) exist between the consumption of asparagine, serine, and 
glutamine, and the production of alanine, asparatate, glutamate, and glycine. The 
transport rates for these seven amino acids are also inversely correlated. This is 
hypothesised to be a consequence of metabolic reactions that mediate the 
interconversion of these seven amino acids, for example deamination and 
transamination reactions. These interconversion reactions mean that unlike essential 
amino acid relationships, positive correlations do not necessarily imply a common 
transport process. For CAT-S and GS-Null cells, the xCT substrate cystine has a 
significantly moderate-strong positive correlation with the SNAT2 substrates 
asparagine, glutamine (CAT-S only) and serine (ρ = 0.7 – 0.9). This correlation reflects 
the increased consumption of these amino acids in response to decreasing growth rates 
as discussed above.  
The linear relationships between non-essential amino acids are severely 
disrupted in recombinant glutamine synthetase cell lines grown in glutamine free media 
(Figure 7.2 B–C). Furthermore, correlation loss is greatest in T127 cells, associating 
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well with glutamine synthetase gene expression, which is 8-fold higher in T127 cells 
than GS-Null cells (3220 versus 440 FPKM). Despite these differences a significantly 
strong positive correlation between aspartate and glutamate (ρ = 0.9) is highly 
conserved across the three cell lines. Additionally, in both GS-Null and T127 cells these 
two anionic amino acids also now have a significantly moderate positive correlation 
with all essential amino acids except isoleucine, leucine, and valine (ρ = 0.6 – 0.8). The 
same essential amino acids also have a significantly moderate positive correlation with 
asparagine in T127 cells (ρ = 0.6 – 0.7). 
 
 
7.4 Discussion 
An analysis of amino acid profiles generated in Chapter 5 identified linear relationships 
between amino acids in CAT-S, GS-Null and T127 cells. Correlation matrices were 
used to further analyse these profiles and in conjunction with data from previous 
chapters a mechanistic model for essential amino acid transport was devised (Figure 
7.3). Importantly, this analysis reveals that consumption rates of aromatic, branched-
chain and cationic amino acids is dependent upon the concentration of these amino 
acids in culture medium. It is therefore hypothesised that by modulating the 
extracellular concentrations of these amino acids it should be possible to control which 
amino acids are preferentially consumed. This would represent an important benefit in 
the optimisation of basal and feed media to meet the changing biomass objectives 
throughout a fed-batch process. 
Essential amino acids such as isoleucine, leucine and valine play an important 
role in supporting cell growth by directing their carbon atoms towards intermediates of 
the TCA cycle and stimulating the mTORC1 signaling pathway whose activation 
promotes cell growth (see Chapter 2 and Figure 2.1). However, 13C-MFA studies with 
CHO cells provide evidence that glucose, asparagine and glutamine are the main donors 
of carbon to the TCA cycle (see 2.1.1 Aerobic Glycolysis and Glutaminolysis Support 
Cell Proliferation). The bulk of consumed essential amino acids are therefore likely to 
be directed towards protein synthesis to support growth. Host cell protein synthesis is 
hypothesised to dominate over antibody production to support cell growth and division 
during exponential growth. Selvarasu et al. (2012) analysed the amino acid composition 
of five industrially relevant CHO cell lines including CHO-K1, CHO DG44 and CHO 
DXBII. For aromatic and branched-chained amino acids the relative concentration of 
these amino acids from highest to lowest was found to follow as Leu > Val > Ile > Phe 
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> Tyr > Trp. For cationic amino acids this was Lys > Arg. This order of abundance 
corresponds well with the composition of the cell culture medium indicating that these 
amino acids are already optimised for host cell protein synthesis. However, antibody 
production is hypothesised to dominate protein synthesis late in culture and has a very 
different composition of essential amino acids to host cell proteins. For the IgG 
antibody used throughout the work in this thesis the order of essential amino acids is 
now Val > Leu > Tyr > Phe > Ile > Trp (see Chapter 4; Table 4.7). For the cationic 
amino acids Lys remains greater than Arg but the relative difference is now 2-fold 
compared to 1.5-fold for host cell proteins. Therefore, in order to optimise the 
productivity of a fed-batch process, feed additions during exponential growth should be 
designed to maintain the relative essential amino acid composition observed in the cell 
culture medium. However, feed additions during late exponential-stationary growth 
phase should have an altered essential amino acid composition to help maximise 
antibody synthesis. BCH (system L inhibitor) treatment during late-stage culture 
decreases specific antibody productivity in a dose-dependent manner (see Chapter 5; 
Section 5.3.1) highlighting the importance of optimising essential amino acid 
consumption.  
Expanding this mechanistic model to include transport of the seven non-
essential amino acids (alanine, asparagine, aspartate, cysteine, glutamine, glutamate, 
and glycine) is highly desirable for media design and development of feeding regimes. 
Asparagine and glutamine consumption rates far exceed that of the other amino acids in 
CHO cell lines (see Figure 4.6 and Figure 4.8) and 13C-MFA studies with CHO cells 
demonstrate that these two amino acids significantly contribute to TCA cycle 
replenishment via aspartate and glutamate to support cell proliferation (see 2.1.1 
Aerobic Glycolysis and Glutaminolysis Support Cell Proliferation and Figure 2.1). 
However, deamination of these amino acids results in high secretion of ammonia, which 
is toxic to cell growth and antibody production. Maintenance of ammonia levels at low 
concentrations is a key objective of fed-batch processes and is primarily achieved 
through careful control of asparagine and glutamine feeding. The correlation matrices 
revealed that aspartate and glutamate transport is highly conserved irrespective of 
extracellular glutamine or the expression level of recombinant glutamine synthetase 
(Figure 7.2). Only transporters belonging to system XAG- are capable of facilitating the 
transport of both anionic amino acids (see Chapter 2; Table 2.1), and transcriptomic 
data demonstrate that GLAST (SLC1A3) is preferentially expressed (see Chapter 4; 
Section 4.3.3). Functional coupling between transporters of non-essential and essential 
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amino acids has also been demonstrated in HeLa cells (Nicklin et al., 2009). In GS-Null 
and T127 cells anionic amino acid transport is correlated with consumption of most 
essential amino acids suggesting some mechanistic link may exist between GLAST, 
CAT-1, and LAT1 transporters. However, further work is required to elucidate the 
interplay of essential and non-essential transporters as well as the role of media 
components (e.g. extracellular glutamine presence) and metabolic reactions of non-
essential amino acids (including recombinant glutamine synthetase expression). 
In summary, this is the first time that an understanding of CHO transport 
processes has been used to direct the hypothetical optimisation of amino acid 
concentrations in culture media. The mechanistic model described here serves as a 
starting point for the development of a mathematical model that can predict transport 
rates of essential amino acids. Further characterisation of essential amino acid transport 
would aid this. For example, performing a DoE experiment in which the extracellular 
concentrations of essential amino acids are varied.  
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Chapter 8 
Conclusions and Future Work 
 
 
8.1 Conclusion 
8.1.1 Characterisation of Amino Acid Transport Processes 
The first aim of this thesis was to understand how the function of CHO amino acid 
transporters might support culture performance parameters such as cell growth, culture 
viability and specific productivity. To investigate this, transporter gene expression was 
first measured using Illumina next-generation sequencing in a parental host and two 
recombinant cell lines throughout a fed-batch process (Chapter 4). In agreement with 
previously reported transcriptomic (Kyriakopoulos et al., 2013) and proteomic (Baycin-
Hizal et al., 2012) CHO cell measurements, the following seven transporters were found 
to be highly expressed across the three cell lines: ASCT1 (SLC1A4, system ASC), 
CAT-1 (SLC7A1, system y+), GLAST (SLC1A3, system XAG-), LAT1 (SLC7A5, 
system L), SNAT2 (SLC38A2, system A), xCT (SLC7A11, system XC-) and y+LAT2 
(SLC7A6, system y+L). Collectively, these seven transporters facilitate the transport of 
all 20 proteinogenic amino acids. By increasing the expression of just a few 
transporters, CHO cells can access all extracellular amino acids at a reduced metabolic 
burden to the cell.  
Building upon Chapter 4, inhibitors of amino acid transport were then used to 
evaluate transporter function at exponential and stationary phase of batch cultures 
(Chapter 5). The xCT cystine transporter was found to be essential for culture viability 
in all CHO cell lines examined. In agreement with observations by Kyriakopoulos et al. 
(2013), transcriptomic data revealed upregulation of xCT at stationary phase to be the 
largest change in expression for any transporter in any cell line. xCT activity is closely 
associated with GSH synthesis (Chung et al., 2005; Shih et al., 2006) and the results in 
Chapter 4 revealed that xCT upregulation forms part of a larger adaptive response that 
can support the cellular availability of GSH during late culture. Surprisingly, 
upregulation of xCT did not result in increased cystine consumption and all cell lines 
demonstrated increased sensitivity to xCT inhibition late in culture compared to early in 
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culture. Collectively, the results presented suggest that despite the inclusion of 
antioxidants in culture media (Whitford, 2006) CHO cells continue to depend on de 
novo GSH synthesis to maintain high culture viabilities. Yet, cystine influx could be a 
bottleneck in GSH synthesis. Future work is required to explore this further (discussed 
in Section 8.2). 
Previous studies have found producer cells downregulate the expression of 
catabolic genes specific for amino acids that are abundant in the composition of a 
recombinant protein (Dietmier et al., 2012b; Ley et al., 2015). This thesis proposes for 
the first time that upregulation of amino acid transporter expression also supports 
productivity by increasing consumption rates of amino acids that are abundant in an IgG 
antibody. Antibody-producing cells (T29, T48 and T127) maintained high consumption 
rates of leucine, threonine, tyrosine, serine and valine throughout stationary phase, all of 
which are abundant amino acids in the IgG antibody. This correlated with upregulation 
of ASCT1 (serine and threonine) and LAT1 (leucine, tyrosine and valine) transporters 
in T127 cells. Furthermore, inhibition of LAT1 (in addition to GlyT1 and xCT) 
transport during late-stage culture negatively impacted upon specific productivity. 
Transport activity of ASCT1, GlyT1, LAT1 and xCT transporters is therefore 
concluded to be important in supporting antibody production. Kyriakopoulos et al. 
(2013) proposed LAT4 (SLC43A2) and GLT-1 (SLC1A2) as potential markers of 
productivity based upon gene expression measurements. Like LAT1, LAT4 also 
belongs to system L but transports branched-chain amino acids only. The biological 
significance of GLT-1 upregulation is unclear. 
Overall, the combination of RNA-sequencing and amino acid transport 
inhibition has helped to achieve the first aim of this thesis. Yet both experimental 
approaches have their limitations. For transcriptomic data, the correlation between 
mRNA and protein expression can often be poor with a correlation of r = 0.48 
previously reported for CHO cells (Baycin-Hizal, 2012). Ideally, Western blots should 
be performed to verify expression of the main transporters reported in this thesis at the 
protein level (discussed further in Section 8.2). Inhibitors have the disadvantage of 
being non-specific such that they i) commonly target transport systems (multiple 
transporters), and ii) can have off-target effects on other biological processes. 
Transfection of cells with small inhibitory RNA (siRNA) molecules can be used in 
future work as a more targeted alternative method to inhibitors. The knockdown in 
expression of specific transporters with siRNA can help verify how their biological 
function supports key culture performance parameters (discussed further in Section 8.2). 
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8.1.2 Improving Cell Growth and Productivity 
The second aim of this thesis was to use the above knowledge of CHO amino acid 
transport processes as a basis for exploring ways to improve cell growth and antibody 
production. Chapter 6 explored a directed evolution strategy to isolate sub-populations 
of the host cell line with increased resistance to system ASC or XC- transport inhibition. 
It was expected that these cells would have an improved capability to produce an 
antibody. However, evolved cells were unable to outperform the non-evolved host in 
the transient production of a recombinant IgG antibody. Yet for XC- evolved cells the 
results also demonstrated that transfection conditions were sub-optimal. It is suggested 
that future work should address this as well as compare stable transfection performance 
in both evolved and non-evolved parental cell lines. Interestingly, XC- evolved cells 
demonstrated a substantial improvement in growth performance over non-evolved host 
cells in batch and fed-batch cultures. Importantly for biomanufacturing, this phenotype 
was heritable for over 100 generations. It is suggested that enhanced cell growth is due 
to the evolution process selecting for increased expression of additional genes involved 
in amino acid transport and biosynthesis via activation of the AAR pathway. The XC- 
evolution process was also applied to the antibody-producing T127 cell line to see if a 
sub-population of cells with improved productivity could be isolated. The results from 
this work were inconclusive. Evolved T127 cells were unable to outperform non-
evolved T127 cells, however long-term exposure to DMSO was found to have a 
negative impact on cell growth and specific productivity. When this was controlled for, 
evolved T127 cells were demonstrated to be capable of achieving higher titres due to 
increased specific productivity. The work in this chapter demonstrates that it is possible 
to isolate cell lines with desirable characteristics for biomanufacturing through 
manipulation of amino acid transport processes. However, this chapter would vastly 
benefit from further characterisation of the evolved cell lines. In particular, the 
measurement of transporter expression at the transcript (qRT-PCR) or protein (Western 
blot) level, and a comparison of amino acid transport profiles in evolved and non-
evolved cells. 
Finally, Chapter 7 presented a mechanistic model to describe essential amino 
acid transport processes in CHO cells. Constructed from data generated in Chapters 4 
and 5, this model provides a hypothetical approach to controlling the consumption rate 
of essential amino acids through simple modulations to their extracellular 
concentrations. This model can therefore be used to optimise amino acid concentrations 
in basal and feed media to match the changing biomass requirements throughout 
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culture. This is the first time to my knowledge that an understanding of transport 
capabilities has been used to direct the optimisation of culture media for CHO cells.  
 
 
8.2 Future Work 
Future work should primarily focus on validating several of the results in this thesis to 
help strengthen the conclusions made. RNA-sequencing identified ASCT1, CAT-1, 
GLAST, LAT1, SNAT2, xCT, and y+LAT2 as the key transporters supporting culture 
performance. Furthermore, significant differences in expression of ASCT1, GLAST, 
LAT1 and xCT existed either between cell lines, within culture or both. A number of 
conclusions regarding the function of these transporters were made based upon these 
observations. Western blots should be performed to i) verify the expression of these 
seven transporters at the protein level, and ii) determine if significant differences in 
mRNA levels are reflected at the protein level. The work in Chapters 4 and 5 also 
identified ASCT1, GlyT1, LAT1 and xCT transporters as having an important role in 
supporting antibody production. siRNA knockdown of these transporters in the 
antibody-producing T127 cell line can be used to verify this result. The transcriptomic 
analysis performed in this thesis was limited in that it only looked at the transporter 
component of amino acid metabolism. However, as discussed above, previous studies 
have found downregulation of catabolic genes for amino acids that are abundant in the 
recombinant protein (Dietmier et al., 2012b; Ley et al., 2015). To build a more complete 
picture of amino acid metabolism, expression data for genes involved in amino acid 
metabolic pathways should be extracted and mapped to transporter data.  
Further work is also required to characterise the relationship between xCT 
transporter activity, GSH synthesis, and culture viability. This is particularly important, 
as extended periods of high culture viability are required during stationary phase to 
maximise antibody production. Western blots can first confirm if upregulation of xCT 
mRNA levels at stationary phase is translated to changes at the protein level. Whereas 
targeted manipulation of xCT expression can be used to verify its functional role. 
siRNA knockdown can be performed at exponential and stationary phase of cultures, 
followed by examination of GSH synthesis, GSH/GSSG ratios, cystine transport, ROS 
levels, as well as culture performance (e.g. cell viability). Similarly, xCT 
overexpression can also be performed followed by measurement of the above 
parameters. Collectively, these experiments would provide a detailed description of 
xCT function in CHO cells. Amino acid measurements in this thesis also identified 
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cystine transport as a potential bottleneck to GSH synthesis. It was suggested that this is 
due to the low solubility of this amino acid. Previous work has demonstrated that 
tyrosine-containing dipeptides have a significantly higher solubility than free tyrosine 
and feeding these dipeptides can enhance culture viability and productivity (Kang et al., 
2012). More recently, Kishishita et al. (2015) found that supplementing CHO cultures 
with a cysteine-serine-tyrosine tripeptide could significantly improve cell growth and 
productivity. Future work should explore the utility of di/tripeptides as a means of 
increasing cytosolic levels of cysteine and whether this can have a positive effect upon 
culture viability.  
The amino acid transport model described in Chapter 7 opens up two 
engineering possibilities that can be explored for improving CHO cell growth and 
productivity, i) optimised media formulations, and ii) modulation of transporter 
expression. For the first engineering avenue, optimised media formulation, the 
mechanistic model and correlation matrices serve as a starting point for the 
development of a mathematical model that can predict transport rates of essential amino 
acids as a function of their extracellular concentrations. Such a model can then be used 
to optimise the concentrations of essential amino acids in basal and feed media to 
maximise cell growth and antibody production. Expanding the mechanistic model to 
include non-essential amino acid (NEAA) transport is highly desirable. Work from 
Chapters 4 and 5 indicate that GLAST, SNAT2 and system ASC transporters facilitate 
NEAA transport in CHO cells. However, the relative contribution that each transporter 
makes to NEAA transport differs between cell lines. siRNA knockdown of these 
transporters can help verify their function in each cell line. The second possible 
engineering avenue, modulation of transporter expression, involves increasing the 
diversity of transport options for essential amino acid uptake. The transport rate of any 
branched-chain or aromatic amino acid is currently constrained by the transport of other 
similar essential amino acids as they compete with one another to enter the cell through 
LAT1 (overlapping selectivity). Engineering the cell to express additional transporters 
with the intent of minimising overlapping substrate selectivity can help maximise the 
transport rate of these amino acids. For example, overexpression of LAT3 or LAT4 
(branched-chain amino acid transporters) can help increase the uptake of aromatic 
amino acids through LAT1. 
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Appendix A 
 
Table A1 CHO amino acid transporters identified in genome, transcriptome and 
proteome studies 
 
Gene name    
(SLC ID)
Protein name NCBI gene ID Transcript literature Protein literature
Proteinogenic amino acid transporters:
SLC1A1 EAAC1, EAAT3 100760895 Birzele et al., 2010; 
Kyriakopoulos et al., 2013 
-
SLC1A2 GLT-1, EAAT2 100752285 Birzele et al., 2010; 
Kyriakopoulos et al., 2013 
-
SLC1A3 GLAST, EAAT1 100689464
Becker et al., 2011; Birzele et al., 
2010; Ji et al., 2007; 
Kyriakopoulos et al., 2013
Baycin-Hizal et al., 2012 
SLC1A4 ASCT1, SATT 100689351
Birzele et al., 2010; Clarke et al., 
2011; Doolan et al., 2010; 
Kyriakopoulos et al., 2013; 
Marin et al., 2003
Baycin-Hizal et al., 2012 
SLC1A5 ASCT2, AAAT 100763902
Becker et al., 2011; Birzele et al., 
2010; Clarke et al., 2011; 
Kyriakopoulos et al., 2013; Shen 
et al., 2010
Baycin-Hizal et al., 2012 
SLC1A6 EATT4 100770833 - -
SLC1A7 EATT5 100767052 - Baycin-Hizal et al., 2012 
SLC3A1 rBAT 100765887 Birzele et al., 2010; 
Kyriakopoulos et al., 2013
-
SLC3A2 4F2hc 100689315
Becker et al., 2011; Birzele et al., 
2010; Clarke et al., 2011; 
Fenczik et al., 1997; 
Kyriakopoulos et al., 2013
Baycin-Hizal et al., 2012 
SLC6A5 GlyT2 100761450 Kyriakopoulos et al., 2013 -
SLC6A7 PROT 100764967 - -
SLC6A9 GlyT1 100774471 Birzele et al., 2010; 
Kyriakopoulos et al., 2013
-
SLC6A14 ATB0,+ 100751194 - -
SLC6A15 B0AT2, v7-3, NTT7-3 100758864 Becker et al., 2011; Birzele et al., 
2010; Kyriakopoulos et al., 2013
-
SLC6A17 XT1, NTT4 100769158 - -
SLC6A18 B0AT3, XT2 100762871 - -
SLC6A19 B0AT1, HND 100762288 Kyriakopoulos et al., 2013 -
SLC6A20 XT3, Xtrp3 - Kyriakopoulos et al., 2013 -
SLC7A1 CAT-1, ATRC1 100689176 Becker et al., 2011; Birzele et al., 
2010; Kyriakopoulos et al., 2013
Baycin-Hizal et al., 2012 
SLC7A2 CAT-2A and -2B, ATRC2 100772617 Kyriakopoulos et al., 2013 -
SLC7A3 CAT-3, ATRC3 100771829 Birzele et al., 2010; 
Kyriakopoulos et al., 2013
-
SLC7A5/SLC3A2 LAT1/4F2hc 100768667 Becker et al., 2011; 
Kyriakopoulos et al., 2013
Baycin-Hizal et al., 2012 
SLC7A6/SLC3A2 y+LAT2/4F2hc 100760403 Becker et al., 2011; Birzele et al., 
2010; Kyriakopoulos et al., 2013
-
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Gene name    
(SLC ID)
Protein name NCBI gene ID Transcript literature Protein literature
SLC7A7/SLC3A2 y+LAT1/4F2hc 100768258 Birzele et al., 2010; 
Kyriakopoulos et al., 2013
-
SLC7A8/SLC3A2 LAT2/4F2hc 100770731 Birzele et al., 2010; 
Kyriakopoulos et al., 2013
-
SLC7A9/SLC3A1 b0,+AT/rBAT 100759612 Kyriakopoulos et al., 2013 -
SLC7A10/SLC3A2 Asc-1/4F2hc 100769905 Kyriakopoulos et al., 2013 -
SLC7A11/SLC3A2 xCT/4F2hc 100764546 Becker et al., 2011; Birzele et al., 
2010; Kyriakopoulos et al., 2013
-
SLC7A12 Asc-2 - - -
SLC7A13 AGT-1, XAT2 - - -
SLC7A15 ArpAT - - -
SLC16A10 TAT1, MCT10 100774015 Kyriakopoulos et al., 2013 -
SLC36A1 PAT1 - Birzele et al., 2010; 
Kyriakopoulos et al., 2013
-
SLC36A2 PAT2 100765800 Kyriakopoulos et al., 2013 -
SLC36A4 PAT4 100752115 Becker et al., 2011; Birzele et al., 
2010; Kyriakopoulos et al., 2013
-
SLC38A1 SNAT1 100769511 - -
SLC38A2 SNAT2 100689188
Becker et al., 2011; Birzele et al., 
2010; Kyriakopoulos et al., 2013; 
Lopez-Fontanals et al., 2003; 
Shen et al., 2010
Baycin-Hizal et al., 2012 
SLC38A3 SNAT3 100754504 Birzele et al., 2010; 
Kyriakopoulos et al., 2013
-
SLC38A4 SNAT4 100769795 Birzele et al., 2010; 
Kyriakopoulos et al., 2013
-
SLC38A5 SNAT5 100767098 Birzele et al., 2010; 
Kyriakopoulos et al., 2013
-
SLC38A7 SNAT7 100762550 Becker et al., 2011; Birzele et al., 
2010
Baycin-Hizal et al., 2012 
SLC43A1 LAT3 100757617 Kyriakopoulos et al., 2013 -
SLC43A2 LAT4 100767730 Becker et al., 2011; Birzele et al., 
2010; Kyriakopoulos et al., 2013
-
Orphan transporters:
SLC7A4 CAT-4 100757506 - -
SLC7A14 100764763 Birzele et al., 2010 -
SLC36A3 PAT3 100759799 Kyriakopoulos et al., 2013 -
SLC38A6 SNAT6 100752560 Birzele et al., 2010 -
SLC38A8 100750441 - -
SLC38A9 100767955 Becker et al., 2011; Birzele et al., 
2010
-
SLC38A10 100763275 Becker et al., 2011; Birzele et al., 
2010
-
SLC38A11 100753232 - -
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Dash entries indicate that no data exists. 
  
Gene name    
(SLC ID)
Protein name NCBI gene ID Transcript literature Protein literature
SLC43A3 EEG1 100760704 - -
Di/Tripeptide transporters:
SLC15A1 PepT1 100760826 Birzele et al., 2010 -
SLC15A2 PepT2 100766001 - -
SLC15A3 PhT2 100775005 Birzele et al., 2010; 
Kyriakopoulos et al., 2013
-
SLC15A4 PhT1 100761469 Birzele et al., 2010; 
Kyriakopoulos et al., 2013
-
Other amino acid transporters:
SLC6A1 GAT1 100760370 Birzele et al., 2010 -
SLC6A6 TauT 100765478 Birzele et al., 2010; 
Kyriakopoulos et al., 2013
Baycin-Hizal et al., 2012 
SLC6A11 GAT-B, GAT-3 100752493 Birzele et al., 2010 -
SLC6A12 BGT1 100752445 - -
SLC6A13 GAT2 100752749 Birzele et al., 2010 -
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Table A2 Transcript abundance of CAT-S amino acid transporter genes at 
exponential and stationary growth phase of culture  
 
SLC ID Protein name Gene ID Exponential Stationary Log2 (fold 
change)
Proteinogenic amino acid transporters:
SLC1A1 EAAC1, EAAT3 CHOv3_017091 0.00 0.01 0.00
SLC1A2 GLT-1, EAAT2 CHOv3_000503 0.99 2.22 1.17
SLC1A3 GLAST, EAAT1 CHOv3_015276 11.09 13.38 0.27
CHOv3_015277 15.83 19.36 0.29
Total: 26.91 32.74 0.28
SLC1A4 ASCT1, SATT CHOv3_014644 39.08 70.68 0.86
SLC1A5 ASCT2, AAAT - - - -
SLC1A6 EATT4 CHOv3_005410 0.00 0.00 0.00
SLC1A7 EATT5 CHOv3_000133 0.08 0.11 0.49
SLC3A1 rBAT CHOv3_015117 0.11 0.10 -0.22
SLC3A2 4F2hc CHOv3_012684 113.23 128.09 0.18
SLC6A5 GlyT2 CHOv3_015162 0.00 0.04 0.00
SLC6A7 PROT - - - -
SLC6A9 GlyT1 CHOv3_001777 4.65 8.40 0.85
SLC6A14 ATB0,+ - - - -
SLC6A15 B0AT2, v7-3, NTT7-3 CHOv3_006384 21.29 28.16 0.40
SLC6A17 XT1, NTT4 - - - -
SLC6A18 B0AT3, XT2 CHOv3_013987 0.27 0.17 -0.70
SLC6A19 B0AT1, HND CHOv3_001277 0.06 0.03 -1.03
CHOv3_005126 0.00 0.00 0.00
CHOv3_012010 0.73 1.00 0.45
CHOv3_013987 0.27 0.17 -0.70
Total: 1.06 1.19 0.17
SLC6A20 XT3, Xtrp3 CHOv3_001648 0.12 0.17 0.55
SLC7A1 CAT-1, ATRC1 CHOv3_017350 23.07 24.65 0.10
SLC7A2 CAT-2A and -2B, ATRC2 - - - -
SLC7A3 CAT-3, ATRC3 CHOv3_005547 0.74 0.73 -0.02
SLC7A5 LAT1 CHOv3_013995 58.57 77.31 0.40
FPKM
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SLC7A6 y+LAT2 CHOv3_017011 23.98 23.86 -0.01
SLC7A7 y+LAT1 CHOv3_014453 7.88 9.48 0.27
SLC7A8 LAT2 CHOv3_013127 0.07 0.11 0.61
SLC7A9 b0,+AT - - - -
SLC7A10 Asc-1 - - - -
SLC7A11 xCT CHOv3_014733 0.49 2.71 2.45
CHOv3_014734 2.40 12.65 2.40
Total: 2.89 15.36 2.41
SLC7A12 Asc-2 - - - -
SLC7A13 AGT-1, XAT2 - - - -
SLC7A15 ArpAT CHOv3_011147 11.64 12.54 0.11
SLC16A10 TAT1, MCT10 CHOv3_014950 0.00 0.00 0.00
SLC36A1 PAT1 CHOv3_008024 7.57 9.97 0.40
SLC36A2 PAT2 - - - -
SLC36A4 PAT4 CHOv3_011956 14.06 19.67 0.48
SLC38A1 SNAT1 - - - -
SLC38A2 SNAT2 CHOv3_000065 28.24 38.04 0.43
CHOv3_000066 61.63 69.43 0.17
Total: 89.87 107.48 0.26
SLC38A3 SNAT3 CHOv3_006952 0.03 0.00 0.00
SLC38A4 SNAT4 CHOv3_000064 3.38 5.92 0.81
SLC38A5 SNAT5 CHOv3_006268 0.02 0.06 1.73
SLC38A7 SNAT7 CHOv3_017260 19.29 22.08 0.19
SLC43A1 LAT3 - - - -
SLC43A2 LAT4 CHOv3_013395 28.42 26.07 -0.12
Orphan transporters:
SLC7A4 CAT-4 - - - -
SLC7A14 CHOv3_013091 0.00 0.02 0.00
SLC36A3 PAT3 - - - -
SLC38A6 SNAT6 CHOv3_017371 15.38 15.55 0.02
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All FPKM values are the average of two independently sequenced samples. Significant 
fold changes are in bold (Q-value < 0.05). Transporters with multiple gene entries had 
their FPKM values summed to calculate total fold change, which was designated 
significant if at least one gene entry exhibited a significant fold change. Dash entries 
indicate that no transcriptomic data exists. 
  
SLC38A8 CHOv3_013991 0.00 0.02 0.00
SLC38A9 CHOv3_015616 7.41 9.84 0.41
SLC38A10 CHOv3_013664 103.11 130.61 0.34
SLC38A11 CHOv3_000880 0.00 0.00 0.00
SLC43A4 EEG1 - - - -
Di/Tripeptide transporters:
SLC15A1 PepT1 CHOv3_004436 0.00 0.00 0.00
SLC15A2 PepT2 CHOv3_014577 0.02 0.22 3.76
SLC15A3 PhT2 CHOv3_008787 36.95 43.88 0.25
SLC15A4 PhT1 CHOv3_000890 12.50 20.46 0.71
Other amino acid transporters:
SLC6A1 GAT1 - - - -
SLC6A6 TauT CHOv3_017568 82.25 87.67 0.09
SLC6A11 GAT-B, GAT-3 CHOv3_016377 0.00 0.02 0.00
SLC6A12 BGT1 CHOv3_011902 0.01 0.01 0.10
SLC6A13 GAT2 - - - -
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Table A3 Transcript abundance of GS-Null amino acid transporter genes at 
exponential and stationary growth phase of culture  
 
SLC ID Protein name Gene ID Exponential Stationary Log2 (fold 
change)
Proteinogenic amino acid transporters:
SLC1A1 EAAC1, EAAT3 CHOv3_017091 0.00 0.01 0.00
SLC1A2 GLT-1, EAAT2 CHOv3_000503 2.25 4.01 0.83
SLC1A3 GLAST, EAAT1 CHOv3_015276 19.42 21.50 0.15
CHOv3_015277 27.22 29.49 0.12
Total: 46.64 50.99 0.13
SLC1A4 ASCT1, SATT CHOv3_014644 39.76 80.95 1.03
SLC1A5 ASCT2, AAAT - - - -
SLC1A6 EATT4 CHOv3_005410 0.00 0.00 0.00
SLC1A7 EATT5 CHOv3_000133 0.07 0.20 1.62
SLC3A1 rBAT CHOv3_015117 0.07 0.27 1.83
SLC3A2 4F2hc CHOv3_012684 136.64 138.43 0.02
SLC6A5 GlyT2 CHOv3_015162 0.00 0.00 0.00
SLC6A7 PROT - - - -
SLC6A9 GlyT1 CHOv3_001777 10.31 12.25 0.25
SLC6A14 ATB0,+ - - - -
SLC6A15 B0AT2, v7-3, NTT7-3 CHOv3_006384 27.38 31.66 0.21
SLC6A17 XT1, NTT4 - - - -
SLC6A18 B0AT3, XT2 CHOv3_013987 0.23 0.16 -0.55
SLC6A19 B0AT1, HND CHOv3_001277 0.00 0.06 0.00
CHOv3_005126 0.00 0.00 0.00
CHOv3_012010 0.81 0.66 -0.30
CHOv3_013987 0.23 0.16 -0.55
Total: 1.04 0.88 -0.25
SLC6A20 XT3, Xtrp3 CHOv3_001648 0.06 0.22 1.96
SLC7A1 CAT-1, ATRC1 CHOv3_017350 25.71 26.00 0.02
SLC7A2 CAT-2A and -2B, ATRC2 - - - -
SLC7A3 CAT-3, ATRC3 CHOv3_005547 1.21 1.48 0.29
SLC7A5 LAT1 CHOv3_013995 81.76 82.27 0.01
FPKM
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SLC7A6 y+LAT2 CHOv3_017011 23.54 21.69 -0.12
SLC7A7 y+LAT1 CHOv3_014453 12.05 12.73 0.08
SLC7A8 LAT2 CHOv3_013127 0.06 0.06 0.02
SLC7A9 b0,+AT - - - -
SLC7A10 Asc-1 - - - -
SLC7A11 xCT CHOv3_014733 1.41 3.91 1.47
CHOv3_014734 8.04 18.67 1.22
Total: 9.45 22.58 1.26
SLC7A12 Asc-2 - - - -
SLC7A13 AGT-1, XAT2 - - - -
SLC7A15 ArpAT CHOv3_011147 9.65 12.31 0.35
SLC16A10 TAT1, MCT10 CHOv3_014950 0.01 0.04 2.12
SLC36A1 PAT1 CHOv3_008024 9.53 12.40 0.38
SLC36A2 PAT2 - - - -
SLC36A4 PAT4 CHOv3_011956 17.43 23.72 0.44
SLC38A1 SNAT1 - - - -
SLC38A2 SNAT2 CHOv3_000065 45.01 54.82 0.28
CHOv3_000066 82.21 94.28 0.20
Total: 127.22 149.09 0.23
SLC38A3 SNAT3 CHOv3_006952 0.00 0.00 0.00
SLC38A4 SNAT4 CHOv3_000064 5.01 8.40 0.75
SLC38A5 SNAT5 CHOv3_006268 0.02 0.23 3.70
SLC38A7 SNAT7 CHOv3_017260 20.14 16.74 -0.27
SLC43A1 LAT3 - - - -
SLC43A2 LAT4 CHOv3_013395 18.41 14.62 -0.33
Orphan transporters:
SLC7A4 CAT-4 - - - -
SLC7A14 CHOv3_013091 0.00 0.01 0.00
SLC36A3 PAT3 - - - -
SLC38A6 SNAT6 CHOv3_017371 18.60 14.76 -0.33
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All FPKM values are the average of two independently sequenced samples. Significant 
fold changes are in bold (Q-value < 0.05). Transporters with multiple gene entries had 
their FPKM values summed to calculate total fold change, which was designated 
significant if at least one gene entry exhibited a significant fold change. Dash entries 
indicate that no transcriptomic data exists. 
  
SLC38A8 CHOv3_013991 0.00 0.01 0.00
SLC38A9 CHOv3_015616 9.27 9.99 0.11
SLC38A10 CHOv3_013664 91.86 146.91 0.68
SLC38A11 CHOv3_000880 0.01 0.03 1.77
SLC43A4 EEG1 - - - -
Di/Tripeptide transporters:
SLC15A1 PepT1 CHOv3_004436 0.00 0.02 0.00
SLC15A2 PepT2 CHOv3_014577 0.01 0.03 2.37
SLC15A3 PhT2 CHOv3_008787 44.78 58.50 0.39
SLC15A4 PhT1 CHOv3_000890 11.45 17.04 0.57
Other amino acid transporters:
SLC6A1 GAT1 - - - -
SLC6A6 TauT CHOv3_017568 41.07 32.55 -0.34
SLC6A11 GAT-B, GAT-3 CHOv3_016377 0.00 0.01 0.00
SLC6A12 BGT1 CHOv3_011902 0.00 0.02 0.00
SLC6A13 GAT2 - - - -
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Table A4 Transcript abundance of T127 amino acid transporter genes at 
exponential and stationary growth phase of culture  
 
SLC ID Protein name Gene ID Exponential Stationary Log2 (fold 
change)
Proteinogenic amino acid transporters:
SLC1A1 EAAC1, EAAT3 CHOv3_017091 0.00 0.00 0.00
SLC1A2 GLT-1, EAAT2 CHOv3_000503 0.90 2.55 1.50
SLC1A3 GLAST, EAAT1 CHOv3_015276 8.04 23.44 1.54
CHOv3_015277 31.31 36.51 0.22
Total: 39.35 59.95 0.61
SLC1A4 ASCT1, SATT CHOv3_014644 76.81 243.63 1.67
SLC1A5 ASCT2, AAAT - - - -
SLC1A6 EATT4 CHOv3_005410 0.00 0.00 0.00
SLC1A7 EATT5 CHOv3_000133 0.03 0.11 1.78
SLC3A1 rBAT CHOv3_015117 0.18 0.16 -0.12
SLC3A2 4F2hc CHOv3_012684 161.58 215.08 0.41
SLC6A5 GlyT2 CHOv3_015162 0.00 0.04 0.00
SLC6A7 PROT - - - -
SLC6A9 GlyT1 CHOv3_001777 7.07 13.14 0.89
SLC6A14 ATB0,+ - - - -
SLC6A15 B0AT2, v7-3, NTT7-3 CHOv3_006384 16.66 20.06 0.27
SLC6A17 XT1, NTT4 - - - -
SLC6A18 B0AT3, XT2 CHOv3_013987 0.34 0.27 -0.34
SLC6A19 B0AT1, HND CHOv3_001277 0.00 0.00 0.00
CHOv3_005126 0.00 0.00 0.00
CHOv3_012010 0.68 0.81 0.25
CHOv3_013987 0.34 0.27 -0.34
Total: 1.02 1.08 0.08
SLC6A20 XT3, Xtrp3 CHOv3_001648 0.10 0.14 0.39
SLC7A1 CAT-1, ATRC1 CHOv3_017350 26.09 28.31 0.12
SLC7A2 CAT-2A and -2B, ATRC2 - - - -
SLC7A3 CAT-3, ATRC3 CHOv3_005547 0.65 0.42 -0.63
SLC7A5 LAT1 CHOv3_013995 30.85 91.26 1.56
FPKM
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SLC7A6 y+LAT2 CHOv3_017011 23.25 20.53 -0.18
SLC7A7 y+LAT1 CHOv3_014453 11.77 13.70 0.22
SLC7A8 LAT2 CHOv3_013127 0.06 0.07 0.21
SLC7A9 b0,+AT - - - -
SLC7A10 Asc-1 - - - -
SLC7A11 xCT CHOv3_014733 0.73 8.26 3.51
CHOv3_014734 5.26 41.60 2.98
Total: 5.99 49.86 3.06
SLC7A12 Asc-2 - - - -
SLC7A13 AGT-1, XAT2 - - - -
SLC7A15 ArpAT CHOv3_011147 12.76 14.12 0.15
SLC16A10 TAT1, MCT10 CHOv3_014950 0.00 0.02 0.00
SLC36A1 PAT1 CHOv3_008024 5.70 10.30 0.85
SLC36A2 PAT2 - - - -
SLC36A4 PAT4 CHOv3_011956 10.89 19.91 0.87
SLC38A1 SNAT1 - - - -
SLC38A2 SNAT2 CHOv3_000065 17.27 42.06 1.28
CHOv3_000066 75.92 87.34 0.20
Total: 93.19 129.40 0.47
SLC38A3 SNAT3 CHOv3_006952 0.03 0.06 0.73
SLC38A4 SNAT4 CHOv3_000064 7.68 7.57 -0.02
SLC38A5 SNAT5 CHOv3_006268 0.05 0.20 2.14
SLC38A7 SNAT7 CHOv3_017260 19.62 22.06 0.17
SLC43A1 LAT3 - - - -
SLC43A2 LAT4 CHOv3_013395 18.87 19.74 0.07
Orphan transporters:
SLC7A4 CAT-4 - - - -
SLC7A14 CHOv3_013091 0.00 0.00 0.00
SLC36A3 PAT3 - - - -
SLC38A6 SNAT6 CHOv3_017371 20.65 17.19 -0.26
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All FPKM values are the average of two independently sequenced samples. Significant 
fold changes are in bold (Q-value < 0.05). Transporters with multiple gene entries had 
their FPKM values summed to calculate total fold change, which was designated 
significant if at least one gene entry exhibited a significant fold change. Dash entries 
indicate that no transcriptomic data exists. 
 
 
 
 
 
 
 
 
 
 
 
 
SLC38A8 CHOv3_013991 0.00 0.00 0.00
SLC38A9 CHOv3_015616 6.47 9.46 0.55
SLC38A10 CHOv3_013664 62.90 93.22 0.57
SLC38A11 CHOv3_000880 0.01 0.01 -0.13
SLC43A4 EEG1 - - - -
Di/Tripeptide transporters:
SLC15A1 PepT1 CHOv3_004436 0.01 0.04 2.46
SLC15A2 PepT2 CHOv3_014577 0.04 0.23 2.59
SLC15A3 PhT2 CHOv3_008787 44.34 26.97 -0.72
SLC15A4 PhT1 CHOv3_000890 12.04 14.36 0.25
Other amino acid transporters:
SLC6A1 GAT1 - - - -
SLC6A6 TauT CHOv3_017568 57.82 77.54 0.42
SLC6A11 GAT-B, GAT-3 CHOv3_016377 0.00 0.01 0.00
SLC6A12 BGT1 CHOv3_011902 0.00 0.02 0.00
SLC6A13 GAT2 - - - -
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Table A5 FPKM boundaries for low, medium and high gene expression in CAT-S, 
GS-Null and T127 cells at exponential and stationary growth phase 
 
 
 
 
 
  
Expression level Exponential Stationary
Low (bottom 25th percentile) FPKM ≤ 3.67 FPKM ≤ 2.99
Medium (middle 50th percentile) 3.67 < FPKM ≤ 41.03 2.99 < FPKM ≤ 39.16
High (top 25th percentile) FPKM > 41.03 FPKM > 39.16
CAT-S
Expression level Exponential Stationary
Low (bottom 25th percentile) FPKM ≤ 4.22 FPKM ≤ 3.07
Medium (middle 50th percentile) 4.22 < FPKM ≤ 41.49 3.07 < FPKM ≤ 38.16
High (top 25th percentile) FPKM > 41.49 FPKM > 38.16
GS-Null
Expression level Exponential Stationary
Low (bottom 25th percentile) FPKM ≤ 3.55 FPKM ≤ 3.25
Medium (middle 50th percentile) 3.55 < FPKM ≤ 40.70 3.25 < FPKM ≤ 39.06
High (top 25th percentile) FPKM > 40.70 FPKM > 39.06
T127
! 181 
 
 
 
0 2 4 6 8 10 12 14
0
200
400
600
800
1000
Asparagine
0 2 4 6 8 10 12 14
0
400
800
1200
1600
2000
Alanine
0 2 4 6 8 10 12 14
0
100
200
300
400
500
600
Histidine
0 2 4 6 8 10 12 14
0
200
400
600
800
1000
Glutamine
0 2 4 6 8 10 12 14
0
200
400
600
800
Threonine
0 2 4 6 8 10 12 14
0
100
200
300
400
500
600
Methionine
0 2 4 6 8 10 12 14
0
200
400
600
800
Serine
0 2 4 6 8 10 12 14
0
100
200
300
400
500
600
Proline
0 2 4 6 8 10 12 14
0
100
200
300
400
500
600
Glycine
Culture time (d)
Co
nc
en
tr
at
io
n 
(m
g/
L)
Small neutral amino acids
Culture time (d)
Co
nc
en
tr
at
io
n 
(m
g/
L)
0 2 4 6 8 10 12 14
0
400
800
1200
1600
2000
Leucine
0 2 4 6 8 10 12 14
0
400
800
1200
1600
2000
Isoleucine
0 2 4 6 8 10 12 14
0
400
800
1200
1600
2000
Valine
0 2 4 6 8 10 12 14
0
200
400
600
800
Tyrosine
0 2 4 6 8 10 12 14
0
200
400
600
800
Phenylalanine
0 2 4 6 8 10 12 14
0
200
400
600
800
Tryptophan
Branch-chained and aromatic amino acids
! 182 
 
Figure A1 Extracellular amino acid concentrations for CAT-S, GS-Null, and T127 
cells throughout fed-batch culture. CAT-S (blue) and GS-Null (green) concentrations 
are measured from parallel duplicate 1-L bioreactors (mean ± SEM, n = 2). T127 (red) 
concentrations are from a single bioreactor. Amino acids are grouped by charge and 
size. *Cystine is included with the anionic group due its transport dependence upon 
glutamate via the xCT transporter. 
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Appendix B 
Table B1 Design matrix for the two-level factorial experiment showing factor interactions, response variable data and calculated effects 
 
The factorial experiment was set up by following the randomised run order. The response variables show the average data taken from Figure 5.20. +, 
inhibitor applied at IC25 concentration; -, inhibitor applied at 0 mM; M, MeAIB (5 mM); B, BCH (10 mM); S, SAS (0.6 mM); G, GPNA (0.4 mM).!
Standard Run M B S G MB MS MG BS BG SG MBS MBG BSG MSG MBSG
11 1 - + - + - + - - + - + - - + + 59.4 97.3 106.6
16 2 + + + + + + + + + + + + + + + 18.7 68.7 71.9
10 3 + - - + - - + + - - + - + - + 65.4 95.1 94.1
2 4 + - - - - - - + + + + + - + - 73.3 98.7 88.1
15 5 - + + + - - - + + + - - + - - 27.5 68.6 68.0
1 6 - - - - + + + + + + - - - - + 100.0 100.0 100.0
8 7 + + + - + + - + - - + - - - - 44.5 82.6 79.8
13 8 - - + + + - - - - + + + - - + 34.0 73.7 69.7
9 9 - - - + + + - + - - - + + + - 72.8 95.4 91.9
7 10 - + + - - - + + - - - + - + + 46.0 81.5 70.0
12 11 + + - + + - + - + - - + - - - 42.3 95.5 86.9
14 12 + - + + - + + - - + - - - + - 28.6 71.2 73.6
3 13 - + - - - + + - - + + + + - - 84.5 99.3 117.0
4 14 + + - - + - - - - + - - + + + 50.0 98.1 99.7
6 15 + - + - - + + - + - - + + - + 60.5 92.7 63.0
5 16 - - + - + - - - + - + - + + - 76.1 89.4 82.5
-14.63 -17.23 -26.5 -23.29 -0.84 6.78 4.93 1.6 3.98 -6.3 3.54 -2.42 3.41 -4.22 -1.94
Viability effect: -0.33 -3.08 -18.87 -9.59 -0.13 0.81 -0.79 -3.33 1.74 -6.38 0.21 0.41 0.82 -0.93 0.79
-6.07 4.63 -25.73 -4.65 0.25 5.62 3.66 -4.39 -3.61 1.66 7.07 -5.74 1.67 0.72 -1.61
Growth rate effect:
Productivity effect:
Indvidual factors Factor combinations (interactions)
Growth rate
Culture 
viability
Specific 
productivity
Response variables                                   
(% of vehicle control)
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Figure B1 Half-normal probability plot of absolute effects for growth response. 
Factors identified as significant are labeled. 
 
 
 
Figure B2 Normal probability plot of residuals for growth rate. 
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Figure B3 Half-normal probability plot of absolute effects for culture viability. 
Factors identified as significant are labeled. 
 
 
 
Figure B4 Normal probability plot of residuals for culture viability. 
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Figure B5 Interactions between systems ASC, L, and XC- for culture viability. (A.) 
Interaction of systems XC- and ASC; (B.) Interaction of systems L and XC-; (C.) 
Interaction of systems L and ASC. 
 
 
 
Figure B6 Half-normal probability plot of absolute effects for specific productivity. 
SAS factor identified as significant is labeled. 
 
Design-Expert® Software
QmAb
Shapiro-Wilk test
W-value = 0.942
p-value = 0.441
A: MeAIB
B: BCH
C: SAS
D: GPNA
Positive Effects 
Negative Effects 
0.00 6.43 12.87 19.30 25.73
0
10
20
30
50
70
80
90
95
99
Half-Normal Plot
|Standardized Effect|
H
al
f-N
or
m
al
 %
 P
ro
ba
bi
lit
y
C-SAS
! 188 
 
Figure B7 Normal probability plot of residuals for specific productivity. 
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Appendix C 
 
0.0 0.2 0.4 0.6 0.8 1.0
0
20
40
60
Aspartate
ρ = -0.84
r = < 0.0001
0.0 0.2 0.4 0.6 0.8 1.0
-150
-100
-50
0
Asparagine
ρ = 0.77
r = < 0.0001
0.0 0.2 0.4 0.6 0.8 1.0
-8
-6
-4
-2
0
2
Histidine
ρ = -0.35
r = 0.005
0.0 0.2 0.4 0.6 0.8 1.0
0
20
40
60
80
Alanine
ρ = -0.79
r = < 0.0001
0.0 0.2 0.4 0.6 0.8 1.0
-8
-6
-4
-2
0
Cystine
ρ = 0.49
r = < 0.0001
0.0 0.2 0.4 0.6 0.8 1.0
-15
-10
-5
0
5
Isoleucine
ρ = -0.13
r = 0.33
0.0 0.2 0.4 0.6 0.8 1.0
-8
-6
-4
-2
0
2
Phenylalanine
ρ = -0.43
r = 0.0005
0.0 0.2 0.4 0.6 0.8 1.0
0
20
40
60
80
Glutamate
ρ = -0.71
r = < 0.0001
0.0 0.2 0.4 0.6 0.8 1.0
0
10
20
30
40
50
Glycine
ρ = -0.87
r = < 0.0001
0.0 0.2 0.4 0.6 0.8 1.0
-15
-10
-5
0
5
Threonine
ρ = -0.49
r = < 0.0001
0.0 0.2 0.4 0.6 0.8 1.0
-15
-10
-5
0
5
10
15
Proline
ρ = -0.49
r = < 0.0001
0.0 0.2 0.4 0.6 0.8 1.0
-15
-10
-5
0
5
Valine
ρ = -0.36
r = 0.004
0.0 0.2 0.4 0.6 0.8 1.0
-20
-15
-10
-5
0
Leucine
ρ = -0.13
r = 0.36
0.0 0.2 0.4 0.6 0.8 1.0
-3
-2
-1
0
1
2
Tryptophan
ρ = -0.45
r = 0.0002
0.0 0.2 0.4 0.6 0.8 1.0
-60
-40
-20
0
Serine
ρ = 0.62
r = < 0.0001
0.0 0.2 0.4 0.6 0.8 1.0
-200
-150
-100
-50
0
Glutamine
ρ = 0.72
r = < 0.0001
0.0 0.2 0.4 0.6 0.8 1.0
-15
-10
-5
0
5
Arginine
ρ = -0.36
r = 0.004
0.0 0.2 0.4 0.6 0.8 1.0
-10
-8
-6
-4
-2
0
2
Tyrosine
ρ = -0.42
r = 0.001
0.0 0.2 0.4 0.6 0.8 1.0
-6
-4
-2
0
2
Methionine
ρ = -0.42
r = 0.006
0.0 0.2 0.4 0.6 0.8 1.0
-20
-15
-10
-5
0
5
Lysine
ρ = -0.45
r = 0.0003
Growth rate (d-1)
Sp
ec
ifi
c 
tr
an
sp
or
t r
at
e 
(x
10
-5
 n
m
ol
.c
el
l-1
.d
-1
) 
CAT-S
! 190  
-0.2 0.0 0.2 0.4 0.6 0.8 1.0
0
10
20
30
40
50
Aspartate
ρ = -0.91
r = < 0.0001
-0.2 0.0 0.2 0.4 0.6 0.8 1.0
-150
-100
-50
0
Asparagine
ρ = 0.25
r = 0.05
-0.2 0.0 0.2 0.4 0.6 0.8 1.0
-10
-5
0
5
10
Histidine
ρ = -0.68
r = < 0.0001
-0.2 0.0 0.2 0.4 0.6 0.8 1.0
-10
0
10
20
30
Alanine
ρ = -0.58
r = < 0.0001
-0.2 0.0 0.2 0.4 0.6 0.8 1.0
-15
-10
-5
0
Cystine
ρ = 0.30
r = 0.01
-0.2 0.0 0.2 0.4 0.6 0.8 1.0
-20
-10
0
10
20
Isoleucine
ρ = -0.13
r = 0.30
-0.2 0.0 0.2 0.4 0.6 0.8 1.0
-10
-5
0
5
10
Phenylalanine
ρ = -0.70
r = < 0.0001
-0.2 0.0 0.2 0.4 0.6 0.8 1.0
-10
0
10
20
30
Glutamate
ρ = -0.73
r = < 0.0001
-0.2 0.0 0.2 0.4 0.6 0.8 1.0
0
20
40
60
80
100
Glycine
ρ = -0.68
r = < 0.0001
-0.2 0.0 0.2 0.4 0.6 0.8 1.0
-10
0
10
20
30
Threonine
ρ = -0.80
r = < 0.0001
-0.2 0.0 0.2 0.4 0.6 0.8 1.0
-20
-10
0
10
20
30
40
Proline
ρ = -0.78
r = < 0.0001
-0.2 0.0 0.2 0.4 0.6 0.8 1.0
-20
-10
0
10
20
Valine
ρ = -0.52
r = < 0.0001
-0.2 0.0 0.2 0.4 0.6 0.8 1.0
-25
-20
-15
-10
-5
0
Leucine
ρ = -0.02
r = 0.87
-0.2 0.0 0.2 0.4 0.6 0.8 1.0
-4
-2
0
2
4
6
Tryptophan
ρ = -0.66
r = < 0.0001
-0.2 0.0 0.2 0.4 0.6 0.8 1.0
-80
-60
-40
-20
0
Serine
ρ = 0.26
r = 0.04
-0.2 0.0 0.2 0.4 0.6 0.8 1.0
-5
0
5
10
15
20
Glutamine
ρ = -0.43
r = 0.0006
-0.2 0.0 0.2 0.4 0.6 0.8 1.0
-15
-10
-5
0
5
10
15
Arginine
ρ = -0.71
r = < 0.0001
-0.2 0.0 0.2 0.4 0.6 0.8 1.0
-10
-5
0
5
10
15
Tyrosine
ρ = -0.64
r = < 0.0001
-0.2 0.0 0.2 0.4 0.6 0.8 1.0
-6
-4
-2
0
2
4
6
Methionine
ρ = -0.58
r = < 0.0001
-0.2 0.0 0.2 0.4 0.6 0.8 1.0
-20
-10
0
10
20
30
Lysine
ρ = -0.71
r = < 0.0001
Growth rate (d-1)
Sp
ec
ifi
c 
tr
an
sp
or
t r
at
e 
(x
10
-5
 n
m
ol
.c
el
l-1
.d
-1
) 
GS-Null
! 191  
0.0 0.2 0.4 0.6 0.8
-5
0
5
10
15
Aspartate
ρ = -0.63
r = < 0.0001
0.0 0.2 0.4 0.6 0.8
-100
-80
-60
-40
-20
0
Asparagine
ρ = -0.20
r = 0.10
0.0 0.2 0.4 0.6 0.8
-5
0
5
10
Histidine
ρ = -0.50
r = < 0.0001
0.0 0.2 0.4 0.6 0.8
-5
0
5
10
15
20
Alanine
ρ = -0.42
r = 0.0003
0.0 0.2 0.4 0.6 0.8
-5
-4
-3
-2
-1
0
Cystine
ρ = 0.06
r = 0.60
0.0 0.2 0.4 0.6 0.8
-15
-10
-5
0
5
10
Isoleucine
ρ = -0.20
r = 0.10
0.0 0.2 0.4 0.6 0.8
-10
-5
0
5
Phenylalanine
ρ = -0.57
r = < 0.0001
0.0 0.2 0.4 0.6 0.8
-10
-5
0
5
Glutamate
ρ = -0.46
r = < 0.0001
0.0 0.2 0.4 0.6 0.8
0
20
40
60
Glycine
ρ = -0.52
r = < 0.0001
0.0 0.2 0.4 0.6 0.8
-10
-5
0
5
10
15
Threonine
ρ = -0.55
r = < 0.0001
0.0 0.2 0.4 0.6 0.8
-10
0
10
20
30
Proline
ρ = -0.53
r = < 0.0001
0.0 0.2 0.4 0.6 0.8
-20
-15
-10
-5
0
5
10
Valine
ρ = -0.46
r = < 0.0001
0.0 0.2 0.4 0.6 0.8
-25
-20
-15
-10
-5
0
Leucine
ρ = -0.13
r = 0.32
0.0 0.2 0.4 0.6 0.8
-4
-2
0
2
4
Tryptophan
ρ = -0.35
r = 0.003
0.0 0.2 0.4 0.6 0.8
-80
-60
-40
-20
0
Serine
ρ = 0.03
r = 0.80
0.0 0.2 0.4 0.6 0.8
0
10
20
30
40
Glutamine
ρ = -0.18
r = 0.10
0.0 0.2 0.4 0.6 0.8
-15
-10
-5
0
5
10
Arginine
ρ = -0.58
r = < 0.0001
0.0 0.2 0.4 0.6 0.8
-10
-5
0
5
Tyrosine
ρ = -0.55
r = < 0.0001
0.0 0.2 0.4 0.6 0.8
-4
-2
0
2
4
Methionine
ρ = -0.47
r = < 0.0001
0.0 0.2 0.4 0.6 0.8
-20
-10
0
10
20
Lysine
ρ = -0.57
r = < 0.0001
Growth rate (d-1)
Sp
ec
ifi
c 
tr
an
sp
or
t r
at
e 
(x
10
-5
 n
m
ol
.c
el
l-1
.d
-1
) 
T127
! 192 
Figure C1 Relationships between transport rates of individual amino acids and 
growth rates in CAT-S, GS-Null and T127 cells. For each of the 62, 64 and 71 
transport profiles for CAT-S, GS-Null and T127 cells respectively, the specific 
transport rate for an individual amino acid was plotted against growth rate. Spearman’s 
rank correlation was performed using GraphPad Prism v6.0 (GraphPad Software, San 
Diego, USA) to analyse these relationships. Blue and red data points indicate amino 
acids with significant (P < 0.05) increased and decreased transport rates respectively as 
a function of decreasing growth rates. 
 
 
Table C1 Spearman’s rank correlation coefficient values for CAT-S cells 
 
 
 
Table C2 Spearman’s rank correlation coefficient values for GS-Null cells 
 
 
Asp
Asp 1.00 Glu
Glu 0.95 1.00 Ser
Ser &0.77 &0.78 1.00 Asn
Asn &0.88 &0.78 0.82 1.00 Gly
Gly 0.94 0.89 &0.73 &0.78 1.00 Gln
Gln &0.90 &0.86 0.87 0.96 &0.80 1.00 His
His 0.31 0.31 0.11 0.02 0.47 &0.01 1.00 Thr
Thr 0.49 0.49 &0.05 &0.16 0.62 &0.21 0.96 1.00 Arg
Arg 0.30 0.31 0.06 0.05 0.48 0.00 0.97 0.93 1.00 Ala
Ala 0.85 0.72 &0.67 &0.92 0.80 &0.87 0.11 0.28 0.06 1.00 Pro
Pro 0.51 0.52 &0.06 &0.19 0.60 &0.24 0.93 0.97 0.87 0.33 1.00 Tyr
Tyr 0.45 0.45 &0.03 &0.13 0.57 &0.16 0.94 0.94 0.92 0.20 0.89 1.00 Cys2
Cys2 &0.66 &0.72 0.81 0.65 &0.64 0.71 &0.10 &0.22 &0.13 &0.51 &0.26 &0.21 1.00 Val
Val 0.30 0.29 0.09 0.05 0.47 0.01 0.99 0.94 0.99 0.08 0.90 0.93 &0.10 1.00 Met
Met 0.30 0.31 0.05 0.06 0.47 0.01 0.95 0.92 0.99 0.05 0.85 0.91 &0.10 0.98 1.00 lle
lle 0.01 0.01 0.33 0.30 0.21 0.29 0.92 0.81 0.90 &0.14 0.77 0.83 0.09 0.93 0.89 1.00 Leu
Leu 0.14 0.17 0.26 0.15 0.22 0.10 0.97 0.89 0.95 &0.14 0.86 0.88 &0.17 0.97 0.94 0.98 1.00 Lys
Lys 0.41 0.42 &0.03 &0.07 0.56 &0.12 0.97 0.97 0.99 0.15 0.91 0.94 &0.20 0.98 0.98 0.87 0.92 1.00 Phe
Phe 0.41 0.42 &0.01 &0.07 0.56 &0.11 0.97 0.97 0.98 0.18 0.91 0.94 &0.17 0.97 0.97 0.85 0.92 0.99 1.00 Trp
Trp 0.52 0.54 &0.06 &0.22 0.57 &0.27 0.85 0.89 0.76 0.38 0.95 0.80 &0.26 0.80 0.74 0.70 0.76 0.80 0.82 1.00
Asp
Asp 1.00 Glu
Glu 0.87 1.00 Ser
Ser &0.46 &0.37 1.00 Asn
Asn &0.39 &0.22 0.94 1.00 Gly
Gly 0.84 0.73 &0.78 &0.70 1.00 Gln
Gln 0.46 0.19 &0.54 &0.66 0.52 1.00 His
His 0.64 0.66 0.13 0.21 0.39 0.05 1.00 Thr
Thr 0.80 0.80 &0.07 0.03 0.58 0.22 0.93 1.00 Arg
Arg 0.68 0.73 0.15 0.24 0.37 0.02 0.97 0.94 1.00 Ala
Ala 0.77 0.56 &0.76 &0.80 0.86 0.67 0.30 0.46 0.28 1.00 Pro
Pro 0.76 0.76 &0.04 0.04 0.56 0.23 0.96 0.98 0.95 0.46 1.00 Tyr
Tyr 0.63 0.71 0.12 0.22 0.38 &0.03 0.95 0.90 0.95 0.25 0.91 1.00 Cys2
Cys2 &0.55 &0.54 0.89 0.79 &0.75 &0.42 0.04 &0.18 0.02 &0.68 &0.14 &0.01 1.00 Val
Val 0.44 0.51 0.37 0.43 0.14 &0.16 0.93 0.80 0.93 0.04 0.84 0.89 0.28 1.00 Met
Met 0.53 0.60 0.28 0.38 0.24 &0.13 0.96 0.85 0.96 0.12 0.88 0.93 0.17 0.97 1.00 lle
lle &0.01 0.12 0.73 0.75 &0.33 &0.46 0.64 0.43 0.64 &0.42 0.47 0.62 0.66 0.84 0.76 1.00 Leu
Leu &0.05 0.17 0.52 0.56 &0.33 &0.37 0.70 0.45 0.70 &0.33 0.51 0.67 0.40 0.89 0.81 0.98 1.00 Lys
Lys 0.67 0.73 0.12 0.23 0.39 0.02 0.97 0.94 0.99 0.28 0.95 0.95 0.01 0.93 0.96 0.63 0.68 1.00 Phe
Phe 0.66 0.72 0.14 0.24 0.38 0.01 0.96 0.94 0.99 0.28 0.95 0.95 0.03 0.93 0.96 0.65 0.69 1.00 1.00 Trp
Trp 0.65 0.59 &0.07 &0.04 0.54 0.28 0.90 0.85 0.81 0.50 0.91 0.82 &0.10 0.76 0.79 0.41 0.41 0.82 0.81 1.00
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Table C3 Spearman’s rank correlation coefficient values for T127 cells 
 
 
Asp
Asp 1.00 Glu
Glu 0.86 1.00 Ser
Ser &0.24 &0.22 1.00 Asn
Asn &0.02 0.27 0.53 1.00 Gly
Gly 0.71 0.75 &0.65 0.01 1.00 Gln
Gln 0.15 &0.17 &0.02 &0.43 &0.17 1.00 His
His 0.67 0.77 0.24 0.59 0.47 &0.16 1.00 Thr
Thr 0.68 0.81 0.18 0.60 0.53 &0.14 0.96 1.00 Arg
Arg 0.64 0.77 0.22 0.66 0.52 &0.25 0.97 0.97 1.00 Ala
Ala 0.51 0.26 &0.24 &0.40 0.41 0.29 0.15 0.14 0.11 1.00 Pro
Pro 0.67 0.77 0.23 0.60 0.48 &0.13 0.98 0.97 0.97 0.13 1.00 Tyr
Tyr 0.56 0.69 0.29 0.67 0.43 &0.32 0.91 0.90 0.94 0.10 0.91 1.00 Cys2
Cys2 &0.11 &0.28 0.59 &0.17 &0.52 0.34 0.00 &0.13 &0.11 0.20 &0.08 &0.06 1.00 Val
Val 0.52 0.60 0.43 0.60 0.30 &0.29 0.92 0.87 0.91 0.13 0.89 0.89 0.18 1.00 Met
Met 0.58 0.73 0.24 0.66 0.47 &0.33 0.97 0.92 0.97 0.07 0.93 0.94 &0.06 0.92 1.00 lle
lle 0.21 0.21 0.65 0.42 &0.07 &0.26 0.62 0.53 0.59 0.09 0.57 0.63 0.53 0.83 0.63 1.00 Leu
Leu 0.36 0.44 0.67 0.50 &0.12 &0.22 0.78 0.69 0.70 &0.01 0.72 0.68 0.42 0.90 0.72 0.99 1.00 Lys
Lys 0.64 0.77 0.24 0.65 0.50 &0.25 0.96 0.96 0.99 0.13 0.97 0.94 &0.09 0.91 0.96 0.59 0.71 1.00 Phe
Phe 0.63 0.76 0.23 0.67 0.50 &0.25 0.96 0.95 0.98 0.08 0.95 0.94 &0.11 0.90 0.97 0.58 0.70 0.98 1.00 Trp
Trp 0.70 0.76 0.15 0.39 0.45 &0.10 0.92 0.85 0.84 0.23 0.88 0.78 0.10 0.85 0.87 0.60 0.78 0.83 0.84 1.00
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